CA2226012A1 - Implantable sensor and system for measurement and control of blood constituent levels - Google Patents
Implantable sensor and system for measurement and control of blood constituent levels Download PDFInfo
- Publication number
- CA2226012A1 CA2226012A1 CA002226012A CA2226012A CA2226012A1 CA 2226012 A1 CA2226012 A1 CA 2226012A1 CA 002226012 A CA002226012 A CA 002226012A CA 2226012 A CA2226012 A CA 2226012A CA 2226012 A1 CA2226012 A1 CA 2226012A1
- Authority
- CA
- Canada
- Prior art keywords
- radiation
- blood
- tissue
- source
- detectors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0031—Implanted circuitry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
- A61B5/6876—Blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6879—Means for maintaining contact with the body
- A61B5/6884—Clamps or clips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
Abstract
This invention is an implantable sensor and system capable of measuring, controlling, monitoring and reporting blood constituent levels. The implantable sensor (14) for sensing in vivo the level of at least one blood constituent in mammalian vascular tissue (20, 24) having at least one source of radiation from infrared through visible light, arranged to direct the radiation at the tissue where it is affected by interaction with the tissue, and at least one detector. The invention also encompasses a device for measuring and controlling the level of a blood constituent, such as glucose or oxygen, and includes an implantable infrared source and sensor module for generating an output signal representative of the sensed infrared radiation.
The system includes a processor module responsive to the output signal which performs spectral analysis of the output signal and generates a control signal. The system further includes other devices for dispensing (16) doses of medications or controlling organ function in response to the control signal.
The system includes a processor module responsive to the output signal which performs spectral analysis of the output signal and generates a control signal. The system further includes other devices for dispensing (16) doses of medications or controlling organ function in response to the control signal.
Description
W O 97/01986 PCT~US96/11435 Il\~PLANTABLE SENSOR AND SYSTEM FOR MEASUREMENT
AND CONTROL OF BLOOD CONSTITUENT LEVELS
Field of the Invention The present invention relates to medical devices for sensing the 5 level of a conctit~lent in a body fluid such as blood, including but not limited to blood glucose, oxygen, antibiotics, enzymes, hormones, tumor markers, fatty acids, and amino acid levels. The present invention also relates to a system forcontrol, monitoring and reporting blood constituent levels in response to sensedlevels and to provide continuous monitoring and control of blood constituent 10 levels to permit aggressive therapy and concomitant clinical benefit of such therapy.
B~k~round of the Invention Metabolic processes in living org~nicmc proceed according to an exact :ltlminictration of chemical compounds that are m~m-f~çtl-red and released15 throughout the organism. These chemical compounds control the function as well as the condition of vital organs, tissues and processes that sustain or exist within the org~ni.cm In many inct~nl~es these cht--mir~l compounds can be found in the org~ni.cmc fluids including blood as in the case of m~mm~lc. These chemical compounds in the blood are generically referred to as blood constitu-20 ents.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 Blood Constituents Glucose A blood constituent such as Glucose is an important nutrient and indicator for human org~ni~m~. During periods of moderate to heavy exercise, S the muscles utilize large arnounts of glucose to release energy. In addition, large amounts of glucose are taken up by muscle cells in the few hours after a meal. This glucose is stored in the form of muscle glycogen, and can later be used by the muscles for short periods of extreme use and to provide spurts of energy for a few minutes at a time. Moreover, glucose is an essential nutrient for brain and spinal cord function. Glucose is the only nutrient that can normally be utilized by the brain, retina, and germinal epithelium of the gonadsin sufficient quantity to supply those organs with their required energy. Brain tissue has an obligate requirement for a steady supply of blood glucose. When blood glucose levels fall below 50 mg/dl, memory loss, agitation, confusion, irritability, sweating, tachycardia, and hypertension commonly occur. Brain failure occurs when blood glucose levels fall below 30 mg/dl, and is associated with coma, hypoventilation, and vascular instability. Death may occur. There-fore, it is important to m~in~in the blood glucose concentration at a high enough level to provide this n~cess~ry nutrition.
At the same time, however, it is also important that the blood glucose concentration not rise too high. Glucose exerts a large osmotic pressurein the extracellular fluid. If glucose concentration rises to excessive levels, this can draw water out of the cells and cause considerable cellular dehydration.
Blood sugars above 200 mg/dl often exceed renal threshold producing an osmotic diuresis by the kidneys, which can deplete the body of fluids and electrolytes.
The steady supply of blood glucose is tightly controlled by the pancreas and the liver. Following a meal, gastric digestion and intestinal absorption provide an increasing amount of carbohydrates, free fatty acids, and amino acids into the portal venous blood. Sixty percent of the glucose absorbed after a meal is imm~ tely stored in the liver in the form of glycogen. Be-W O 97/01986 PCTrUS96/11435 tween meals, when the glucose concentration begins to fall, liver glycogen is dephosphorolated, allowing large quantities of glucose to diffuse out of the liver cells and into the blood stream. The liver, a large organ, can store six percentof its mass as glycogen. In contrast, muscle tissue can store only two percent 5 of its mass as glycogen, barely enough to be used by the muscle as its own energy reserve.
Normally, blood glucose concentration is regulated by two hor-mones, insulin and glucagon, secreted by the pancreas. Insulin is released in a bimodal fashion from the pancreas in direct response to a rise in blood glucose 10 level and, to a lesser extent, to a rise in the blood level of free fatty acids and amino acids. Insulin promotes transport of these nutrients into the cells to be utilized for energy, to be stored as glycogen or triglycerides, or to be synthe-sized into more complex compounds such as proteins.
Some individuals develop diabetes mellitus, and do not secrete 15 insulin in sufficient quantities to properly regulate blood glucose. Lack of insulin inhibits the cell membrane transport of nutrients such as glucose, fattyacids, and amino acids into the cells, forcing the cells to use other compounds for energy and cell growth. Diabetics exhibit a decreased utilization of those nutrients by the cells, resulting in a marked increase in blood glucose concen-20 tration, an increase in triglyceride mobilization from the adipose tissue resllltin~in a marked increase in blood fatty acid and cholesterol concentrations, and a marked loss of protein on a cellular level. Many of the severe end-organ com-plications which result from diabetes are due to the cellular wasting which occurs secondary to abnormal amino acid uptake and protein wasting. Abnor-25 mal fatty acid metabolism results in elevated levels of blood concentrations oflow-density lipo~loL~hl (LDL), cholesterol, and free fatty acids, all leading to accelerated atherosclerosis and obstructive vascular disease. Those with diabe-tes are also prone to ketosis, and develop dehydration, acidosis, and electrolyte imbalance under stress. In some forms of the disease, insulin injections may 30 be required, and other long-term complications such as retinopathy, blindness and kidney disease commonly occur.
W O 97101986 PCT~US96/11435 The pancreas also secretes glucagon, a hormone which has cellular functions that are diametrically opposed to those of insulin. Glucagon stimn1~t~s the liver to release large amounts of glucose from glycogen when the blood glucose concentration falls below 90 mg/dl. This system of insulin 5 inhibition and glycogen release prevents glucose concentrations from falling dangerously low.
In short, glucose is regulated within a narrow range between 80 and 90 mg/dl during fasting, with a rise toward 140 mg/dl following a high carbohydrate meal. The liver functions as a reservoir and buffer, so that glu-10 cose is available to the brain during meals and during periods of prolonged fast.
Type I diabetics have an absolute deficiency in insulin synthesisby the beta cells of the pancreas, and have the most severe clinical course if not aggressively managed with nutrition and insulin therapy. These individuals are ketosis prone and may develop a severe metabolic acidosis. Wide swings in 15 blood glucose commonly occur with a high incidence of symptomatic hypogly-cemia following insulin therapy. End organ dysfunction is common due to accelerated atherosclerosis, cellular protein wasting, and small vessel disease.Type II diabetics release insulin from the pancreas in a blunted fashion following the intake of food. Blood insulin levels do not rise sufficient-20 ly to prevent hyperglycemia. However, in some forms of the disease, insulinlevels may be elevated. In addition, peripheral tissues of type II diabetics may possess a smaller number of membrane tissue receptors and possibly a down regulation of those receptors. Ketoacidosis is uncommon. However, hyperglycemia and hyperosmolar conditions may occur, leading to coma and 25 death. Insulin therapy may or may not be required to m~int~in normal glycemialevels. Other therapies include weight loss, diet, and oral hypoglycemic agents which stimnl~te the pancreas to release larger qn:~ntitiPs of insulin.
There is no doubt that long term tight glucose control is able to significantly reduce the incidence of end organ complications. Control of blood 30 glucose concentration in diabetic individuals by Q.I.D. insulin injections has, of course, been done for many years. This type of treatment does have a W O 97/01986 PCT~US96111435 number of serious drawbacks, however. One or more needle sticks of the finger must be performed on a daily basis to obtain blood for glucose assay.
Many patients suffer anxiety and discomfort when subjected to finger pricking.
After the blood sample is obtained, the sample must be exposed to a surface 5 coated with chemical agents and enzymes that produce a color change corre-sponding to glucose concentration. The patient or m~f~ical practitioner perform-ing the assay must hltel~et the color change accurately, and inject a dose of insulin based on the glucose level. Some patients use a hand held glucometer to measure glucose concentrations in their blood. Many individuals experience 10 anxiety and discomfort when facing injections, and resist them. Some individuals may have no one to ~lmini.~ter the required injections, but have difficulty injecting themselves. Dosage can also be problematic. Color change can be mi~hllel~l~ted, and it is not unusual for patients to miss an injection, or to be off schedule. In addition, patients even have difficulties when using 15 glucometers. Syringes, which these days tend to be disposable, contribute to the growing problem of hazardous medical waste.
Some of these problems have been partially dealt with in the past, but none of the past attempts at dealing with these problems has been entirely s~tisf~tory. Non-invasive optical techniques for measuring blood glucose have 20 been developed, but these techniques do not solve the problems associated with ~Aministering insulin injections where required. Non-invasive optical techniquesfor measuring blood glucose are prone to error because the interface between the sensor and the tissue changes constantly with manipulation and contact pressure. Skin and extremity blood flow also varies considerably with cardiac 25 output, body temperature and level of activity. These non-invasive optical tech-niques typically use a source of infrared (IR) radiation and a detector to measure absorption, reflection, or some other parameter to derive inforrnation about blood glucose levels. The effective optical distance from the IR source and the detector changes with subcutaneous body fat and the variability in placin~ the 30 sensor from day to day. In addition, non-invasive IR sensors measure blood glucose in a non-continuous manner, and are thereby limited to functioning as W O 97/01986 PCT~US96/1143S
a glucose measuring device and not as a therapeutic device for the treatment of diabetes.
Implantable pumps for ~imini~t~ring insulin as well as other chemical compounds are known. It has even been proposed to automatically S measure blood glucose and ~lmini.~ter insulin as may be required using an implantable sensor and insulin pump system. The latter systems are know to incorporate sensors to perform chrmiL~l analysis of blood samples which require the introduction of chemical reagents into the patient's body. Typically, these reagents periodically need to be replenished, which imposes the require-ment of access below the surface of the skin through which fresh reagents must be injected from time to time. No matter what sensor is used, insulin still mustbe injected approximately every 6 weeks into the pump reservoir by placing a thin needle through the skin. Moreover, commercially available implantable pumps have FDA approval only for the infusion of chemotherapy and Baclofen for the treatment of spastic leg disorders. Pumps implanted for the infusion of insulin have been successfully tested in hllm~n~ however, there is no clinical benefit to implantations without a sensor for closed-loop control.
Oxygen Cells require a continuous supply of oxygen and nutrients for basic metabolism. Oxygen must be efficiently absorbed through the lungs and combined with hemoglobin in the blood for proper transport to the tissues.
Oxygen delivery depends upon the pumping action of the heart (blood flow per minute) and the content of oxygen bound to hemoglobin and dissolved within the plasma.
Once in the tissues, oxygen is released from the hemoglobin molecule and diffuses through the hltel~Lilial fluid and into each cell. The workhorse of any m~mm~ n cell is the mitochondria. A series of surface bound enzymes within the mitochondria transfer electrons generated during the metabolism of glucose called the Krebs' (~ycle. Oxygen acts as the final electron acceptor generating ATP, NADH heat, and CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 carbon dioxide as a waste product. High energy phosphate compounds such as ATP and NADH are generated to provide energy for most cellular metabolic processes. Examples of processes requiring ATP for energy include:
m~int~ining ionic gradients, active membrane transport, intracellular synthesis,5 and cell reproduction. Highly metabolic tissues such as brain and heart muscletolerate an inadequate delivery of oxygen and other nutrients poorly.
Conditions that produce a low blood flow state include cardiac pump failure, hemorrhage, dehydration, and sepsis. The tissues attempt to compensate for this low blood flow state by extracting a greater portion of the delivered 10 nutrients.
When oxygen delivery is insufficient to supply the aerobic needs for ATP production, alternative metabolic pathways will dominate causing lactic acid to ~çcl-m~ te. Anaerobic metabolism produces an insufficient supply of high energy compounds and cellular functions quickly deteriorate. Ionic 15 gradients are lost and repair mech~nismc cease to function. Persistent low flow states lead to i.cch-omic damage to various end-organs including the kidneys, brain, and liver. Hypoxemia and metabolic acidosis proceeds organ failure followed by death of the m~mm~l.
Large multicellular org~nismc require a distribution system for 20 the delivery of oxygen and nutrients. The heart, blood vessels, and hemoglobin molecules efficiently transport oxygen and other nutrients to the peripheral tissues such that every cell is within diffusion distance of a nutrient capillary.
Typically, the heart provides pulsatile blood flow (cardiac output) exceeding 5.0 liters per minute. During periods of increased metabolic activity such as 25 exercise, infection, or following surgery, the cardiovascular system is required to increase the cardiac output several fold to meet the increased oxygen requirements. Many disease states colnlJrolllise the cardiovascular system such ~ that an inadequate supply of oxygen and nutrients reach the tissues. Chronic heart failure due to hypertension, ischemic heart disease, valve disease, or 30 alcohol is the most common cause of death in the U.S.
CA 022260l2 l997-l2-30 Fatigue, shortness of breath, and poor exercise tolerance are comrnon as the failing heart is unable to pump sufficient quantities of blood tosatisfy the metabolic needs of the tissues. In addition, cardiac arrhythmia may further compromising forward blood flow. To solve some of these problems, S physicians are can only intervene with medications and supplemental oxygen improving oxygenation and blood flow to the vital organs.
Devices and Implantable Sensors for Detectzon of Blood Constituent~
Devices for the detection of blood glucose incorporate an implantable sensor using a semipermeable membrane and an enzyme coated surface and an oxygen electrode have been studied for the continuous measurement of blood glucose. This sensor has signific~nt drift and quickly fails due to host reaction and cont~min~tion of the membrane and enzyme surface. Needle-type amperometric glucose sensors implanted within the sub-cutaneous tissues and having an enzyme coated surface and an electrical output to an external processor are known, but loss of sensitivity and sensor drift occur upon implantation. This type of sensor, which is in the form of a thin wire, must be inserted through a hollow needle into the subcutaneous tissue and must be changed every three to four days due to enzyme depletion and membrane cont~rnin~tion. In addition, glucose concentration within the subcutaneous tissues lags 20 minutes behind blood glucose and varies between 70-80% of blood values.
Devices for the detection of blood o~ygen such as a pulse oxime-ter are well known. The oximeter measures blood oxygen by measuring the amount of light absorbed by hemoglobin at two different frequencies. It was observed that oxygenated hemoglobin absorbs light differently from that of reduced hemoglobin at two certain frequencies. For example, at 660 nanometers, reduced hemoglobin is known to absorb as much as ten times the amount of light as oxygenated hemoglobin, whereas oxygenated hemoglobin absorbs a much greater amount of light at the infrared wavelength of 940 CA 022260l2 l997-l2-30 nanometers. In addition, the absorbed light has a pulsatile sinusoidal componentcaused by pulsing vol~,lmes of arterial blood from the heart.
The typical pulse oximeter has two light emitting diodes (L~Ds) and a ~letecting sensor arranged in a noninvasive manner to allow emitted light to pass through body tissue for detection by the sensor. As the light passes through the body tissue it is partially absorbed as described above and then detected to produce an estimate of blood oxygen in the human body.
Pulse oximeters have been developed for continuous measurement of in-vivo human blood oxygen saturation by transillllmin~tin~. tissue 10 noninvasively. However, these devices have several disadvantages. Because the pulse oximeter is external to the body and noninvasive, it can only measure red and infrared light tr~ncmitterl through blood in human tissue, typically theear or finger. As a consequence, several inaccuracies are introduced into the measurement of oxygenated hemoglobin by the absorption and dispersion of 15 light through intervening tissues such as skin, soft tissue, bone, venous blood and arterial blood. In addition, the sensors of a pulse oximeter are susceptibleto hltelr~ ce from ambient light, low perfusion, and body motion. Pulse oximetry is known in the art and further described in Kevin K. Tremper and Steven J. Barker, "Pulse Oximetry", Anesthesiology, Vol 70, pp 70-108 1989 20 which is incorporated herein by reference.
Therefore there is a need to control levels of blood constirlents, such as glucose concentration, oxygen, fatty acid concentration, and amino acid concentration without requiring blood sampling, chemical test reagents or re-agent injections, and with continuous monitoring of levels of blood constituents.
25 The present invention meets that need by providing a sensor which is fully implantable and can be used In-vivo, can be used continuously and over the long term, and which is reliable and safe.
- The present invention provides the ability to achieve close, continuous monitoring and control of blood constituents such as, but not limited30 to, glucose and oxygen, as well as tumor markers, antibiotics, enzymes, CA 022260l2 l99i-l2-30 W O 97/01986 PCT~US96/11435 hormones, fatty acids, and amino acid levels, thereby providing a clinical and therapeutic breakthrough.
Summary of the Invention The present invention is an implantable sensor and system capable 5 of measuring, controlling, monitoring, and reporting blood constituent levels.The invention includes an implantable device for sensing In-vivo the level of atleast one blood constituent in m~mm~ n vascular tissue. The internal device includes a commllnic~tion system and a calibration system.
In one aspect of the invention, the implantable device comprises 10 at least one source of radiation from infrared through visible light, arranged to direct the radiation at the tissue. The radiation is affected by interaction with the tissue and detected by a plurality of detectors. The detectors are located with respect to the tissue to receive radiation affected by said tissue. The detectors each have a filter transparent to a discrete narrow band of radiation.15 Each detector provides an output signal representative of detected radiation in said narrow band.
In another aspect of the invention, the implantable device com prises at least two sources of radiation from infrared through visible light, arranged to direct the radiation at the tissue. The radiation is affected by 20 interaction with the tissue and detected by at least one detector. The detectors being located with respect to the tissue to receive radiation affected by said tis-sue. Each source is adapted to emit radiation in a selected number of discrete bandwidths and each detector is adapted to detect the radiation being emitted inthe discrete bandwidth. Each detector provides an output signal representative 25 of detected radiation in said discrete bandwidth.
In another of its aspects, the present invention includes a device for both measuring and controlling the level of a blood constituent in a mam-mal, and comprises an implantable infrared source and sensor module for di-recting infrared radiation through vascular tissue such as, but not limited to, an 30 artery, a vein, a vascular membrane, or vascular tissue. The sensor module W O 97/01986 PCT~US96111435 senses the infrared radiation after it has passed through the tissue and generates an output signal representative of the sensed infrared radiation. A processor module, responsive to the output signal from the infrared source and sensor module, performs spectral analysis of the output signal and derives therefrom a control signal representative of the level of the blood constituent. The processor module or another device in cu~ llunication with the processor module is used to control, monitor, and report the level of the blood constituent.
In one aspect of the invention, an insulin pump is used to control the level of glucose by dispensing doses of insulin in response to the control signal. In another aspect of the invention, an implanted cardiac pacemaker as well as an int~rn~l cardiac defibrillator (ICD) is used to control the level of oxygenated hemoglobin in the blood in response to the control signal. In yet another aspect of the invention, an implanted dispensing device is used to control the level and ~lmini~tration of medications such as, but not limited to,cardiac drugs, antibiotics, or chemotherapies in response to the control signal.In still another aspect of the invention, the level of tumor markers is monitored and reported to other devices in response to the control signal. In all aspects of the invention, the system is capable of monitoring and reporting all blood conctitllentc that are sensed and measured.
In another aspect of the invention, an implantable oxygenation, hemoglobin, and perfusion sensor is provided to obtain frequent objective data on patients with chronic illnesses such as heart failure and respiratory failure.
Patients would be monitored for changes in hemoglobin oxygen saturation (pulse oximeter), hemoglobin concentration (infrared measurement), and changes in tissue perfusion (analysis of the photoplethsmograph waveform) for the purpose of cletecting cardiovascular decompensation early so that the physician can manage the problem as an outpatient. Visits to the emergency room and admissions to the ICU would significantly ~liminich. Data from the sensors will be stored within a memory chip and Physicians would be notified automatically if data changed significantly from data established for an individual patient's background.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 Typically, cardiovascular patients are not alerted to significant cardiovascular decompensation until overt symptoms have occurred resulting in the need for acute care in a n ICU following ~lmi~csion through an emergency room. With this implantable sensor of the present invention, physicians will be 5 able to detect early cardiovascular decompensation and in~ti~lt~ corrective therapy as required.
Data stored in a memory by the invention can provide the patient or clinician, either directly of remotely, with the natural history of the disease process. The physician will be able to ~lmini.~t~r me~ l therapy based on an 10 objective presentation of data and conclude from the data and immediately acquire information on the effects of the therapy applied. The invention provides the major determin~nt~ of oxygen delivery such as to the tissues which are measured by the sensor.
For example, after a patient is stabilized following a myocardial 15 infarction and the onset of heart failure and pulmonary edema, a sensor wouldbe implanted under local anesthesia. The sensor would immediately provide and collect data directly and co~ unicate data to an extracorporeal device for remote monitoring of the patient for changes in oxygenation, perfusion, hemoglobin concentration, and cardiac alll,yLlllllia. Once discharged from the 20 hospital, the sensor would continue to monitor the patient and provide data extracorporeally for significant changes in oxygenation, perfusion, hemoglobin concentration, and cardiac arrhythmia. Depending on the condition of the patient, data would be stored in a memory or reported directly to the patient ormedical personnel for interpretation as required. Therefore, the present 25 invention can facilitate the ~(lmini~tration of medications, ap~lupliately according to objective measured data thereby improving cardiac contractility andimproved tissue blood flow in advance of an acute event.
In another aspect of the invention, the implantable device comprises at least one radiation source consisting of at least two discrete 30 spectral bands Iying somewhere within the infrared through visible spectrum, arranged to direct the radiation at the tissue. The radiation is affected by CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 interation with the tissue and detected by at least one detector. The different spectral bands in each source are substantially collinear and interact with substantially identical tissue. The detectors being located with respect tO the tissue to receive radiation from source affected by said tissue.
Discrimination amongst different spectral bands is provided by each spectral band having a unique temporal or frequency modulation. Each detector provides an output signal representative of detected radiation from said source. A commllnic~tion means is provided to relay the output signal from detector to processor. A processor is used to determine level of blood constituent in blood.
Des~ ion of the D~ ~wi..gs For the purpose of illustrating the invention, there is shown in the drawings a form which is presently preferred; it being understood, however, that this invention is not limited to the precise arrangements and instrumentali-ties shown.
Figure 1 illustrates an implantable glucose sensor according to one embodiment of the invention as it might be implanted in a human patient, shown in conjunction with an implantable insulin pump, with the sensor array arranged to monitor blood flow through a blood vessel.
Figure 2 is an enlarged view of the sensor of Figure 1, showing the sensor in conjunction with an implantable insulin pump and processor mod-ule cont~ining associated processing and control electronics.
Figure 3 is a transverse sectional view through the sensor shown in Figure 2, taken along the lines 3-3 in Figure 2, showing the distribution of individual photocells.
Figure 4 is a longitl-(1in~1 sectional view through the sensor, taken - along the lines 4-4 in Figure 3.
Figure 5 illustrates an implantable glucose sensor according to an alternate embodiment of the invention as it might be implanted in a human W O 97/01986 PCT~US96111435 patient, with a sensor array arranged to monitor blood flow through a vascular membrane such as parietal peritoneum.
Figure 6 is an enlarged view of the embodiment of the sensor of Figure 5, showing the sensor in conjunction with an implantable insulin pump S and processor module cont~3ining associated processing and control electronics.
Figure 7 is a sectional view through the sensor shown in Figure 6? taken along the lines 7-7 in Figure 6.
Figure 8 is a top plan view of the sensor shown in Figure 6, showing the distribution of individual photocells.
Figure 9 illustrates a third embodiment of the invention, partially broken away, showing an arrangement of individual photocells in a rectangular array.
Figure 10 is a sectional view of the sensor shown in Figure 9, taken along the lines 10-10 in Figure 9.
Figure 11 is an enlarged plan view of an individual photocell from the array shown in Figure 9.
Figure 12 is a fourth embodiment of the invention, in cross-sectional view.
Figure 13a illustrates a functional block diagram of an implantable blood constituent sensor module with co~ unication means shown in conjunction with extracorporeal receiving, calibration, and communication modules.
Figure 13b illustrates a typical oxygen delivery process monitored according to a plc~f~ d embodiment of the present invention.
Figure 1 3c illustrates an implantable oxygen sensor module having at least one pair of detector and sensor elements according to a preferred embodiment of the present invention.
Figure 13d illustrates a plethysmograph of a plurality of pulse waves through a vascular membrane at a specific rate as would be measured by at least two pairs of the detector and sensor elements shown in Figure 13c.
CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 Figure 14 is a schematic representation of a device for controlling the blood oxygen according to a pl~fell~d embodiment of the present invention.
Figure lSa is a schematic representation of a device for controlling the level of blood oxygen according to another preferred 5 embodiment of the present invention.
Figure 15b is a schematic representation of vascular tissue plethysmography and ECG fibrillation according to a preferred embodiment of the present invention.
Figure 16a is a schematic representation of an infrared sensor 10 according to a preferred embodiment of the present invention.
Figure 16b is a schematic representation of the infrared sensor shown in Figure 16a used to measure and control a medicinal blood constituent such as an antibiotic.
Figure 17 is a schematic representation of an infrared sensor 15 according to another L~l~fell~d embodiment of the present invention.
Figure 18a is an illustration of an extracorporeal calibration and commllnil~tion module unit for use in connection with implantable blood constituent sensor modules according to the invention.
Figure 1 8b is an illustration of a extracorporeal calibration 20 handheld unit for use in connection with implantable blood constituent sensor modules according to the invention.
Figure 18c is a functional block diagram showing the operation of an implantable device according to the invention in commllni(~:~tion with theextracorporeal calibration and commlmic~tion module shown in Figure 18a.
Description of the Invention Referring now to the drawings, wherein like numerals indicate like elements, there is shown in Figure 1 a representation of an implantable blood constituent monitoring and control system 10.
Glucose Monitoring and Control System CA 02226012 l997-l2-30 W O 97/01986 PCT~US96/11435 Figure 1 shows a blood glucose monitoring and control system 10 comprising a sensor and an insulin pump, as it might be surgically implanted in a patient 12. It should be understood that Figure 1 is not intended to be anatomically accurate in every detail; rather, it is intended to represent generally 5 how the system 10 would be implanted. Moreover, it should also be understood that, while for convenience the present invention is illustrated and described in reference to monitoring and control of blood glucose, the invention is not so limited, and encompasses the monitoring and control of other blood constituents such as, by way of example and not by way of limitation, fatty acid or amino 10 acid concentration. Several plerell~d embodiments of the invention are presented below.
As best seen in Figure 2, system 10 comprises a sensor assembly 14 connPctPd to a processor/pump module 16 via a signal cable 18. Sensor assembly 14, described in greater detail below, has an opening which enables 15 it to be arranged to subst~nti~lly surround a blood vessel 20. Processor/pumpmodule 16 is illustrated as dispensing insulin via a tube 22 into a second bloodvessel such as a vein 24, which may be the portal vein for direct transport to the liver. Alternatively, processor/pump module dispenses insulin via a non-thrombogenic multilumen catheter including a one-way valve, directly into the 20 peritoneal space adjacent the hilum of the liver. Insulin will be rapidly ab-sorbed into the portal venous system and transported to the liver. While the processor/pump module 16 is illustrated as implanted within a patient's body, the pump portion of processor/pump module 16 may also be an external device, worn or otherwise carried by the patient, without departing from the present 25 invention. Where an external pump is used, insulin may be delivered percuta-neously into an infusaport implanted under the patient's skin for final transport to the peritoneal cavity or portal vein. Alternatively, insulin may also be delivered by an external device with a needle placed chronically within the patient's subcutaneous tissues. Moreover, when an external pump is used, the 30 processor portion of processor/pump module 16 requires a data telemetry portion in order to telemeter command signals to the external pump. Insulin CA 022260l2 l997-l2-30 W O 97/01986 . PCT~US96/11435 reservoirs and pumps, telemetry devices, and infusaports are all known per se, and therefore need not be described here in any great detail.
Processor/pump module 16 contains a conventional insulin reser-voir and pump. In addition to an insulin reservoir and pump, processor/pump 5 module 16 contains an electronic microprocessor and associated electronic circuitry for generating signals to and processing signals from sensor assembly 14 and for generating control signals to the insulin pump itself. Processor/pumpmodule 16 further includes a long-life battery to power the electronic circuitry, the sensor assembly 14 and the insulin pump.
Blood Constituent Sensor Sensor assembly 14 is illustrated in greater detail in Figures 3 and 4. Sensor assembly 14 has a body portion 26 which is generally C-shaped in transverse cross-section. Thus, body portion 26 has a longih--lin~l channel which runs through body portion 26, and a lon~ lin~l gap 28 which communi-lS cates with the longitudinal channel. Body portion 26 is preferably fabricatedfrom a semi-rigid material such as titanium or epoxy, which is easily worked and biocompatible for long-term implantation. The shape and semi-rigid materi-al of sensor assembly 14 enables it to be placed closely around vessel 20 and place optical sources and individual optical detectors in optimum position with 20 respect to vessel 20. The ~lis~nre between the optical sources and the optical detectors can thus be made small and as close to constant as possible, for optimum signal acquisition.
In the embodiment of sensor 14 illustrated in Figures 3 and 4, the optical sources and optical detectors may be infrared (IR) sources and IR detec-2~ tors, although radiation from infrared through the visible spectrum may beemployed without departing from the invention. In the figures, individual IR
sources and individual IR detectors are grouped together in three groups, or arrays, 30, 32, and 34. Each array comprises an IR source (30a, 32a, and 34a, respectively) and two IR detectors (30b~ 30c; 32b, 32c; and 34b, 34c, respec-tively). The individual IR sources 30a, 32a, and 34a may be mini~h~re infrared CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 diodes located, in the illustrated embodiment, on one side of vessel 20. IR
sources 30a, 32a, and 34a are driven by signals generated in the processor/pu-mp module 16 and transmitted to IR sources 30a, 32a, and 34a via conductors 36a, 38a, and 40a, respectively. Similarly, output signals from individual S detectors 30b, 30c; 32b, 32c; and 34b, 34c are tr~n~mitt~l to processor/pump module 16 via conductors 36b, 36c; 38b, 38c, and 40b, 40c, respectively. Con-ductors 36, 38, and 40 collectively are dressed together to form signal cable 18, which couples sensor array 14 to processor/pump module 16. Cable 18 exits body portion through an extension portion 42, which serves to support cable 18 and minimi7e the chance of breakage of conductors 36, 38, and 40 from flexing or being subjected to sharp bends. If desired, cable 18 may exit extension portion 42 through a strain relief sleeve 44, to further protect cable 18.
Each IR source 30a, 32a, and 34a has associated with it an optical filter 46a, 48a, and 50a, respectively. Each filter transmits a different discrete narrow band of radiation. In similar fashion, each detector 30b, 30c;
32b, 32c, and 34b, 34c has associated with it an optical filter 46b, 46c; 48b, 48c; and 50b, 50c, respectively. In this manner, each optical source and the detectors associated with it in a given array 30, 32, or 34 operates in only a discrete narrow band.
With this embodiment, detectors 30b, 32b, and 34b are arranged diametrically opposite IR sources 30a, 32s, and 34a, respectively, to detect light transmitted from the associated source through the blood vessel 20. The angle between the sources and the detectors is thus 180~. (These detectors could also be used to determine reflected light, since light that is not tr;~n~mitt~l may, for purposes of the invention, be assumed to have been reflected. By determining the amount of light transmitted, and subtracting it from the amount of light emitted from the source, the amount of light reflected can be calculated.) Detectors 30c, 32c, and 34c are arranged at an angle less than 180~ from the associate sources, and are located to detect IR radiation either reflected or scattered from vessel 20.
W O 97/01986 PCT~US96111435 It is important to note that, although this embodiment of the invention is described using three arrays of IR sources and associated detectors, that precise configuration is not crucial to the invention. The invention may beimplemented, for example, using a single IR source and multiple detectors for 5 det~ctin~ reflected, scattered, and tr~n~mitt~tl IR radiation. In such an embodi-ment, the IR source would not have a narrow band filter associated with it, but would emit broadband IR. Each detector, however, would have a narrow band filter associated with it, so that it would respond only to a preselected wave-length.
Conductors 36, collectively,38, collectively, and 40, collectively, can be either electrical conductors or optical fibers. That is, the IR sources and the IR detectors may be located either within sensor assembly 14 itself, in which case the conductors are electrical conductors and carry electrical signals between processor/pump module 16 and sensor assembly 14, or within processor/pump 15 module 16, in which case the conductors are optical fibers and carry infrared radiation between processor/pump module 16 and sensor assembly 14.
It will be appreciated that IR radiation generated by IR sources 30a, 32a, and 34a is directed through the walls of vessel 20, and thus the bloodflowing in the vessel, to detectors 30b, 30c; 32b, 32c; and 34b, 34c located 20 across from and at right angles to the IR sources. The IR radiation detected by the several detectors is, of course, affected by its interaction with vessel 20 and the blood flowing therethrough. Consequently, by analyzing the output signals from the several detectors, it is possible to derive information about the levels of glucose, fatty acids, and amino acids in the blood flowing through vessel 20.25 Preferably, although not necessarily, selected sensor/detector pairs are used for different measurement techniques. For example, pair 30a, 30b could be used to measure infrared tr~n~mitt~nre~ and pair 30a, 30c to measure infrared scat-tcring. That is, the output signals from the several detectors can be processed dir~lcllLly to obtain different characteristics of the blood being measured.
W O 97/01986 . PCTrUS96/11435 In contrast to prior electro-chemical glucose sensors, sensor array 14 does need require direct contact with blood, does not need to be replenished with test reagents, and can operate indefinitely.
Alternative Blood Constituent Sensor In another embodiment, source 30 a or 32 a, or 32 a) may consisl of multiple LEDs or multiple laser diodes, each of a different wavelength spaced identically collinear or spaced very closely so that each wavelength has substantially the identical optical path ad interacts with substantially identical tissue. The detector 30 b or c, 32 b or c, and 34 b or c detects light from eachindividual wavelength from source 30 a, 32 a, and 32 c, respectively. The processor discrimin~trs amongst the different wavelengths by having each wavelength pulse at a different frequency or at a different time. As the processor can discriminate amongst the different wavelengths by either differentfrequency or temporal information, narrow wavelength filters 46 a, 48 a, and 50 a are nnn~ce~ry in this embodiment. Multiple sources and multiple detectors provide reAIlntl:~nr.y or alternatively the ability to measure different chemical species, although in many cases a single source and detector is adequate. The operation of the sensor is otherwise the same as described in the previous embodiment.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 Vascular Membrane Sensor Inte~ face An alternative form of device 10' according to the present inven-tion is illustrated in Figures 5 through 8. In alternative form 10', the device monitors blood flowing through a highly vascular membrane, such as a portion of the parietal peritoneum 52. The parietal peritoneum is an ideal tissue for measurement due to its high vascularity, translucency, constant temperature. andbris~ blood flow. As best seen in Figures 6 and 7, a portion of a vascular membrane such as the parietal peritoneum 52 (shown in phantom in Figure 6) is sandwiched between two halves 54 and 56 of an alternate form 58 of sensor assembly. Halves 54 and 56 are essentially mirror images of each other~ and define a gap 60 between them, which receives the peritoneal tissue. Sensor assembly 58 is preferably molded from the same type of material as used to fabricate sensor assembly 14, as already described. The shape and semi-rigid material of sensor assembly 58 enable it to be clamped snugly around peritoneal tissue 52 and to place individual IR sources 62a though 62d and individual IR
detectors 64a through 64d, 66a through 66d, 68a through 68d, and 70, in opti-mum position with respect to tissue 52.
One half of sensor assembly 58, such as half 56 for example.
contains the individual IR sources 62a through 62e, while the other half. such as half 54, for example, contains the individual detectors 64 collectively, 66 collectively, 68 collectively, and 70. The detectors are grouped together in groups of three, for example, such as 64a, 66a, and 68a, and are located oppo-site a source, such as 62a. Only a single detector 70 is shown located opposite source 62e, although a group of detectors could also be located opposite source 62e.
IR sources 62, collectively, are driven by signals generated in the processor/pump module 16 and tr;~n~mitte~1 to IR sources 62a through 62e via ~ conductors 72a through 72e, respectively. Similarly, output signals ~rom individual detectors 64a through 64e, 66a through 66e, 68a through 68e, and 70 are tr~n~mitt.od to processor/pump module 16 via conductors 74a through 74e, 76a through 76e, 78a through 78e, and 80, respectively. Conductors 72. collec-W O 97/01986 PCT~US96111435 tively, are dressed together to ~orm a signal cable 82, while conductors 74 collectively, 76 collectively, 78 collectively, and 80 are dressed together to form a signal cable 84. Cables 82 and 84 are merged together into a single signal ca-ble 86 (see Figure 6), which connects sensor assembly 58 to processor/pump module 16.
As with conductors 36, 38, and 40, conductors 72, 74, 76, 78, collectively, and 80 can be either electrical conductors or optical fibers. Thatis, the IR sources 62, collectively, and the IR detectors 64, 66, 68, collectively, and 70 may be located either within sensor assembly 58 itself, in which case theconductors are electrical conductors and carry electrical signals between proces-sor/pump module 16 and sensor assembly 58, or within processor/pump module 16, in which case the conductors are optical fibers and carry infrared radiationbetween processor/pump module 16 and sensor assembly 58.
IR radiation generated by IR sources 62, collectively, is directed through peritoneal tissue 52, and thus the blood flowing through the tissue, to detectors 64, 66, 68, collectively, and 70 located across from the IR sources.
As in the previous embodiment, each source or detector may have associated with it a narrow band filter, so that each optical source and the detectors associ-ated with it in a given array operate in only a discrete narrow band of IR ra-diation. The IR radiation detect~-d by detectors 64, 66, 68, collectively, and 70 is, of course, affected by its interaction with tissue 52 and the blood flowing therethrough. Consequently, by analyzing the output signals from the detectors, it is possible to derive information about the blood flowing through tissue 52.
Preferably, although not necessarily, selected sensor/detector pairs are used for different measurement techniques, such as, for example, infrared tr:~nsmitt~nce,infrared reflectance, and infrared scattering. Thus, the output signals from theindividual detectors can be processed differently to obtain different characteris-tics of the blood being measured.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 Alternative ~ensor ConJ~i~guration A third embodiment 88 of sensor assembly is illustrated in Fig-ures 9 and 10. In those figures, sensor assémbly 88 comprises a generally rectangular array of source/detectors 90 disposed on opposite halves 92 and 94 of the sensor assembly~ with each half being on opposite sides of a vascular membrane 52. Source/detectors 90 are preferably, although not necessarily, arranged opposite one another on respective halves 92 and 94, so that the array on one half is substantially in ~ nment with the array on the other half.
An individual source/detector 90 is illustrated in more detail in Figure 11. Source/detector 90 is generally circular, and at its center portion contains a source segment 96, from which infrared radiation is emitted. An inactive buffer ring 98 surrounds source segment 96. A second inactive buffer ring 100 is radially spaced from and surrounds buffer ring 98. Buffer rings 98 and 100 are inactive in the sense that they neither emit nor respond to IR radia-tion. The portion of source/detector 90 between buffer rings 98 and 100 is divided into a plurality of detector segments 102, each of which is associated with a narrow band filter so that it responds to a selected band of radiation. Alinearly-variable filter can be used, for example. In this manner, each detectorsegment 102 operates in only a discrete narrow band. A second plurality of detector segments 104 is located radially outward of buffer ring 100, each of which is also associated with a narrow band filter so that it, too, responds to a selected band of radiation.
It will be appreciated that a single source/detector 90 can operate to measure both reflected and scattered IR, or a single pair of source/detectors90 can operate to measure reflected, scattered, and tr~n~mitt~-d light over a plurality of discrete radiation bands.
Figure 12 illustrates an embodiment 106 of a sensor assembly similar to those shown in Figures 7 and 10, except that the two halves 108 and 110 are not spaced apart by a fixed distance, as are the halves of the detectorsin Figures 7 and 10. Instead, the halves 108 and 110 are movable toward and away from each other, and the gap 112 may be adjusted by means of adjusting CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 screws 114. Preferably, the head portion of screw 114 iS made captive, but freely rotatable, in one half, such as half 108. The shank portion of the screw is received in a threaded bore 116 in the opposite half. Thus, by rotating screw114, the width of the gap 112 between halves 108 and 110 can be easily adjust-5 ed for optimum spacing of the individual sources and detectors relative to thevascular membrane 52.
Oxygenation and Tissue Perfusion Monitoring Figure 13b illustrates this concept can be summarized using the following equations:
A. Oxy~en delivery = cardiac output X oxygen saturation (%) x hemoglobin concentration (gm/dl) X 1.39 + partial pressure of oxygen (PaO2) x 0.0031 B. Cardiac output = heart rate x stroke volume Cardiac output is a measurement of blood flow (liters/minute) and can be defined as the heart rate times the stroke volume. The stroke volume is the amount of blood ejected with each beat of the heart and is influenced by th amount of blood returning to the heart, the state of contractility of the heart muscle, and degree of afterload or impedance to forward blood flow. (72 bts/min x 80 ml/bt = 5,760 ml/min). Heart rate can be measured by counting the plethysmograph pulse wave as shown in Figure 13b.
Stroke volume can be estimated by analyzing the plethysmograph pulse wave illustrated in Figure 13d including the maximum amplitude, the area under the curve, the rate of upstroke, and the velocity of wave propagation according to standard processing techniques. Current research is correlating pulse wave analysis with invasive monitoring such as Swan Ganz catheters and transesophageal echocardiography. Current pulse oximeter technology displays a pulse wave reflecting the volume of blood perfusing the tissue between the CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 source and detector. Pulse detection algorithms evaluate the changes in light attenuation across a vascular tissue (photoplethysmography). The optical path length of the diastolic tissue bed and the optical path length of the systolic tissue bed is measured. The difrt:lcllce between the two is the optical path length of light being affected only by arterial blood. The microprocessor continually calculates the ratio of light absorption associated with both wavelengths of light emitted by the two source diodes. With (limini~h~d blood flow, conventional pulse oximeters increase the gain on the signal with no attempt to measure bloodflow or pulse wave velocity. With sufficient gain on the signal and noise rejection algorithms, an accurate oxygen saturation measurement can be m~int~in~ despite a fall in tissue blood flow to less than 10% of baseline.
Some commercially available pulse oximeters display the signal gain required (2x, 4x, 8x, etc.) to m~int~in a normal amplitude plethysmograph waveform and an accurate hemoglobin oxygen saturation reading. Analysis of the raw signal that produces the pulse wave includes the maximum amplitude, the area under the curve, the rate of upstroke, and the velocity of wave propagation. This raw signal data can be used to estimate the stroke volume per beat of the heart (volume of blood ejected per beat). The velocity of wave propagation can be measured using two or more source/detector pairs in series such that the pulse wave is detected with a slight time delay at the second pair and an additional time delay at the third. Since the distance between the sensor pairs is known and fixed, a pulse wave velocity can be calculated. The total combined analysis of the pulse wave will be used to estimate stroke volume and therefore an on-line estimate of cardiac output.
The amount of radiation absorption and scattered is significantly limini~hed by using a thin translucent vascular membrane as the optical interface. A higher signal to noise ratio is found compared to non-invasive pulse oximetry techniques.
C. Oxy~en content within the blood = hemoglobin oxygen saturation (%) x hemoglobin concentration (gm/di ) X 1.39 + partial pressure of oxygen (PaO2) x 0.0031 W O 97/01986 PCTrUS96/11435 Hemoglobin oxygen saturation reflects the sigmoidal shaped dissociation curve in which hemoglobin is 98% saturated or greater when the partial pressure of oxygen exceeds 100 mm Hg. Saturation slowly falls such that hemoglobin is 95 % saturated at an oxygen partial pressure of 60 mm Hg.
5 Below this partial pressure, oxygen saturation falls dramatically. Commercially available pulse oximeter technology provides this information accurately and reliably.
Infrared spectroscopy is able to accurately measure blood hemoglobin concentration. Since 1.39 millilit~rs of oxygen can bind to each 10 gram of hemoglobin, the total oxygen content of the blood can therefore be measured using optical means. The amount of oxygen dissolved in the plasma is negligible (partial pressure of oxygen (PaO2) x 0.0031) and of little clinical significance.
The purpose of the implantable oxygenation, hemoglobin, and 15 perfusion sensor is to obtain frequent obiective data on patients with chronic illnt?sses such as heart failure and respiratory failure. Patients would be monitored for changes in hemoglobin oxygen saturation (pulse oximeter), hemoglobin concentration (infrared measurement), and changes in tissue perfusion (analysis of the photoplethsmograph waveform) for the purpose of 20 detecting cardiovascular decompensation early so that the physician can manage the problem as an outpatient. Visits to the emergency room and admissions to the ICU would significantly ~liminich Data from the sensors will be stored within a memory chip and reviewed by the physician during an office visit or over the phone. In one embodiment, the physician would be notified 25 automatically if data changed significantly from the individual patient's normal pattern. Typically, patients wait until significant cardiovascular decompensation has produced overt symptoms re~uiring admission through the emergency room to the ICU. With this implantable sensor, physicians will be able to detect early decompensation and in.ctitllte corrective therapy as an outpatient. Data stored 30 in the memory chip will provide the clinician with the natural history of thedisease process. The physician will be able to titrate medical therapy based on W O 97/01986 PCT~US96111435 objective numbers and conclude from the data the benefits incurred by this therapy. All of the major determin~ntc of oxygen delivery to the ~issues can be measured with this sensor. For example, a patient develops heart failure and pulmonary edema following a myocardial infarction. Once stabilized in the ICU
S a sensor would be implanted under local ~n~sth~sia and data collected on-line.Once discharged from the hospital, the sensor would monitor the patient for significant changes in oxygenation, perfusion, hemoglobin concentration, and cardiac arrhythmia. If no significant changes occur, data would be stored in a memory chip and downloaded for physician hlLel~l~talion during the patient's 10 routine office visit. Medications that improve cardiac contractility and improve tissue blood flow could be titrated to objective endpoints rather than to vague patient symptoms.
Alternate clinical uses for this optical technology include integration of the output signal with an internal cardiac defibrillator (ICD).
15 Patients are implanted the ICD following a near death experience due to a serious ventricular arrhythmia of the heart. Unfortunately, the electrocardiogram algorithms programmed into the ICD are unable to dirr~l~llLiate a life threatening allhyllllllia from noise in certain cases. It is estim~t~l that hlap~ )liate defibrillation occurs 30% of the time. Using the 20 implantable photoplethsmograph sensor (pulse oximeter), tissue blood flow data can be integrated with the algorithm for defibrillation. Both the ECG and tissueblood flow have to agree that a life threatening arrhythmia is present before defibrillation.
Closed-loop feedback with a programmable pacemaker provides 25 a means to increase/decrease the heart rate and fine tune the timing intervals of a pacemaker to more physiologically meet the oxygenation and perfusion needs of the tissues during various levels of physical activity. The sensor would be placed on around a central vein returning to the right heart.
Measurement of venous oxygen saturation reflects the adequacy 30 of cardiac output and oxygen delivery to the peripheral tissues. During exercise, blood flow increases several fold to the muscles and other tissues.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 When the heart is paced at a fixed low rate, the tissues extract a greater percentage of the oxygen delivered. Low venous saturation suggests the need to increase oxygen delivery by increasing the cardiac output and by increasing the oxygen carrying capacity of the blood ( transfusion red blood cells, iron therapy ). Decreasing venous oxygen saturation would signal the pacemaker to increase the heart rate and to optimize the timing intervals between atrial and ventricular contraction thus regulating the cardiac output of the heart. Once the oxygen debt was satisfied, the heart rate would slowly return to baseline values.
In this way, the pacemaker would compensate for an increased demand for oxygen in the peripheral tissues.
Figure 13a illustrates a functional block diagram of a blood oxygen and perfusion monitoring and control system 200 comprising an implanted sensor 330 (shown in Figure 13c) and an implanted control module 300 (not shown in detail) which is in communication with an extracorporeal monitor 210. The extracorporeal monitor 210 is in communication with a direct blood calibration module 400 (explained in detail below) and other communication systems such as, but not limited to, a cellular telephone 2'70, anemergency medical warning system (not shown), or a hand held monitoring device (shown in Figure 18b).
The blood oxygen perfusion monitoring and control module 200 is surgically implanted in a patient where it is employed to measure, control, monitor, and report measured hemoglobin oxygen saturation and tissue perfusion. As shown in Figure 13b, measured blood oxygen is represented as the amount of oxygen delivered to the blood on a pulse by pulse basis as the blood is pumped by the heart. The amount of blood oxygen delivered to the body can be represented according the following formula:
~2 (Delivered) = * Hb * SaO, * 1.39 + PaO2 * 0.0031, where, C.O. = Cardiac Output = Heart rate x stroke volume liters/mn, Hb = Hemoglobin concentration mg/dl, CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 SaO2 = Hemoglobin oxygen saturation %, 1.39 = a constant representing 1.39 ml of oxygen bound to one gram of Hemoglobin, PaO2 = partial pressure of oxygen dissolved in plasma, S and 0.0031 = a constant representing the amount of oxygen dissolved in plasma.
The blood oxygen is measured as an estimate of oxygen according to the pulsatile perfusion of the blood through a vascular interface. It is to be understood that the vascular interface can be, but is not limited to, an artery,a vein, a vascular membrane, or vascular tissue. The oxygen measurement is acquired according to standard pulse oximetry described above. In a plef~l~ed embodiment of the present invention, oxygen is measured by the implanted control module 300 and at least one paired sensor assembly 330 (shown in Figure 13c).
Figure 13c illustrates an embodiment of the sensor assembly 330 assembly similar to those shown in Figures 7, 10 and 12. However, the two halves 310 and 320 have linearly arrayed elements that are spaced apart by a distance defined by a vascular membrane 340. The linear arrays are paired together to form a plurality of paired arrays as may be required to acquire a plethysmographic representation of the pulsatile flow of oxygenated and reduced hemoglobin passing through the vascular membrane 340. A single paired array is required to produce a plethysmograph as shown in Figure 13b, and, multiple arrays, are required to measure a velocity of the pulse wave.
In the embodiment of sensor 330 illustrated in Figures 13c, the optical sources and optical detectors may be infrared (IR) sources and IR detec-tors, although radiation from infrared through the visible spectrum may be employed without departing from the invention. In the figures, individual IR
sources 310 a-d and individual IR detectors 320 a-d are grouped together in pairs forming the paired array 330. A plurality of paired arrays will also com-prise an plurality of IR sources and IR detectors respectively. The individual CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 IR sources 310 a-d may be mini~hlre infrared diodes located, in the illustrated embodiment, on one side of the vascular membrane 340. IR sources 310 a-d are driven by signals generated in the control module 300 and tr~n.cmitred to the IR sources 310 a-d via conductors (not shown). Similarly, output signals from S individual detectors 320 a-d are tr~ncmitted to the control module 300 via separate conductors (not shown).
Each IR source 310 and detector 320 may have associated with it an optical filter (not shown) or a time based or encoded discriminator (not shown) for selectively emitting and detecting the selected bands of radiation 10 emitted for detecting blood oxygen saturation.
With this embodiment, the IR sources 310 and detectors 320 are arranged diametrically opposite each other to detect light tr~n.cmits~d through the vascular membrane 340.
It is important to note that, although this embodiment of the 15 invention is described using a single array of paired IR sources and associated detectors, that precise configuration is not crucial to the invention. In fact, the invention may be implemented, for example, using a plurality of paired arrays for detecting reflected, scattered, and tr~ncmitted IR radiation.
Figure 13d shows a plethysmographic representation of pulsatile 20 blood oxygen perfusion when four paired arrays are employed.
The implanted control module 300 preferably incorporates a pulse oximeter module (not shown) for producing perfusion data (as shown in Figure 13d). Also incorporated in the control module 300 is a processor module ~not shown) for analyzing the perfusion data and for producing a control signal that 25 is commllnic~t~d by the control module 300 to a blood oxygen regulating device such as, but not limited to, a pacemaker or defibrillator.
Figure 14 is an illustration of a preferred aspect of the invention showing a control module 300 having a sensor 330 for measuring perfusion data to determine the level of blood oxygen. The sensor 330 as explained above 30 employs at least two selected bands of frequencies to produce detected signals W O 97/01986 PCTrUS96/11435 corresponding to oxygenated hemoglobin levels which are analyzed by the processor module (not shown~ of the control module 300.
The control module 300 also incorporates a co"""l"-ic~tion module (not shown) for commllnic~ting control information to an implanted pacemaker 360. The pacemaker 360, in response to the control information received from the control module 300, regulates the heart 1000 (shown for illustrative purposes) to pump blood as required to produce a desired blood oxygen level. The control module 300 controls blood oxygen by regulating the pacemaker to control heart rate and timing of atrial and ventricular contractionaccording to stored blood oxygen values programmed into the control module 300. Programmed blood oxygen values are stored in the control module 300 through its comml-nication module. An extracorporeal cul"",ll,-ic~tion device (shown in Figure 18a) is used to control and calibrate the control module 300 which is explained in detail below.
Figure 15a is an illustration of another preferred aspect of the invention showing a control module 300 having a sensor 330 for measuring perfusion data to estimate quantity of blood delivered per beat to the tissues.
The control module 300 incorporates a comml-nic~tion module (not shown) for communicating control information to an implanted defibrillator 380. The defibrillator 380, in response to the control information from the control module 300 and its own internal EKG system 381 (shown for illustrative purposes) will regulate the heart 1000 (shown for illustrative purposes) to prevent ina~ ol)liate in other words the discharge of the internal defribulator.
It is known that an internal defibrillator will at times hlapplopliately defibrillate irregular heart beat patterns. When this occurs thelevel of blood oxygen can be severally affected. To prevent this condition, the level of blood oxygen measured by the control module 300 is used to confirrn proper heart function. Because the control module 300 and sensor 330 use photo-plethysmography to measure pulsatile perfusion, actual defibrillation can be detected as an inst~nt~n,oous loss of blood oxygen.
;
CA 022260l2 l997-l2-30 W O97/01986 . PCT~US96/1143S
In Figure 1 Sa the electrical activity of the heart normal sinusrhythm with s~tisf~ctory tissue perfusion and oxygenation noted on the plethysmography waveform. As the trace pressures the cardiac rhythm degenerates into ventricular tachycardia and then ventricular fibrillation. The S tissue perfusion and oxygenation also deteriorates such that pulsatile flow is lost.
Figure lSb represents a contiml~tion of the ventricular fibrillation trace and lack of pulsatile tissue bound flow at timex. The internal defibrillation produces an electrical shock that converts the cardiac rhythm to normal with satisfactory pulsatile tissue blood flow.
Figure lSa illustrates vascular tissue plethysmography with a .simlllt~n~ous and EKG recording of the heart. Therefore, the use of perfusion data to control blood oxygen by preventing cardiac defibrillation is a very important feature of the invention. This feature provides increased assurance that blood oxygen will be m~int~inf~l consistently without disruptions caused by15 hla~L,r~ iate heart fibrillation.
Specific Blood Constituent Monitoring, Control and Reporting System Naturally, it should be understood that, although embodiments using different groupings of sources and detectors have been described for the measurement and control of blood glucose and blood oxygen, the invention is 20 not in any way limited to either a specific number of source/detector groupings or blood constituents, nor is it absolutely n~cess~ry that the sources and detectors be arranged in specific configurations.
Figures 16a is a schematic representation of an infrared sensor 330 and its control module 300 equipped with a commnnic~tion module (not 25 shown) according to a another preferred embodiment of the present invention.
The control module 300 and sensor 330 are implanted into the body subcutaneously just below the skin. The sensor 330 is placed about a vein, an artery or inserted into vascular tissue allowing it to measure and control selected blood constituents. The control module 300 through its co~ tion module 30 can communicate the measured level of blood constituent extracorporeally by W O 97/01986 PCT~US96/11435 means of its communication module to devices such as, but not limited ~o, an external monitoring and warning device, or a telecommunic~tion network.
Figure 16b is a schematic representation of the infrared sensor 330 shown in Figure 16a used to measure and control a medicinal blood constituent such as an antibiotic which is used to treat a localized infection 392 (shown for illustrative purposes). It is to be understood that this invention isnot limited to this embodiment, but may be used to deliver, measure and control any medicinal blood constituent such as, but not limited to, chemotherapy and cardiac medications. In addition, the measured level of medication in the blood can be monitored extracorporeally by a monitoring device or provide to a remote location by means of an external commnnir~tion system adapted to a telecommunication network.
In addition, to controlling blood constituents, the sensor 330 and control device 300 can be used to measure and report blood constituent levels extracorporeally to remote monitoring equipment. For example, blood constituents such as tumor markers including, but not limited to, prostate specific antigen (PSA) for detecting prostate cancer and colon embryonic antigen (CEA) for ~1ett~ctillg colon cancer, can be continuously monitored safely and conveniently without the need and inconvenience of constantly drawing blood and laboratory testing. By measuring these tumor markers on a daily basis, recurrence of tumor will be detected early prior to spread throughout thebody. This can be accomplished by selecting the applopliate optical sensors and detector and operating bandwidths for interaction with each specific blood constituent.
For example and as explained above, blood oxygen can be measured through oxygenated hemoglobin with two pairs of sensors and detectors operating at 660 nanometers and 940 nanometers for detecting oxygenated and reduced hemoglobin.
Implantable Optic Sensor Interface (IOSI) CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 Figure 17a is a schematic representation of an infrared sensor 1330 according to another preferred embodiment of the present invention. The sensor 1330 is shaped like a tuning fork and is implanted surgically into vascular tissue. The shape facilitates insertion and retention into vascular rich 5 tissue such as a muscle or vascular membrane as shown in Figures 17b and 17c.
The sensor has two parallel arms 1320 joined at one end and separated from each other by a fixed distance. Each arrn has a pointed tip 1332 at its other end for piercing the tissue. As the sensor is inserted into the tissue a vascular interface 1334 iS formed between the arms 1310,1320. The arms 1310,1320 10 have at least one electrom~gn~tically sensitive array comprising optical sources and detectors for illl-min~ting the vascular interface 1340 and detecting a desired blood constituent described above.
Figure 18a is an illustration of an extracorporeal calibration and communication module 410. Figure 18b is an illustration of a hand held 15 monitor, display and communication unit 450 for use in connection with implantable blood constituent sensors and control modules described above.
The calibration and control module 410 communicates with a commlmi~tion module (not shown) associated with the implanted control module 300, providing calibration data and extracorporeal display and reporting of the measured data produced by the control module 300.
The extracorporeal calibration and communication module 410 communicates calibration data directly to the implanted control module 300 allowing precise calibration of the measurements made by the control module 300 and its sensor 330. Calibration data is produced by the extracorporeal calibration and communication module 410 by commercially available methods such as glucose oxidase reagent strips 420.
The communication module 410 and the control module 300 are equipped with commercially available communic~tion means adapted for inter-corporeal communication.
W O 97/01986 PCTrUS96111435 Figure 18c is a functional block diagram showing the operation of an implantable device according to the invention in communication with the extracorporeal calibration and co,--",~ ic~tion module shown in Figure 18a.
Extraco~poreal Calibration and Communication Modules As already noted, processor/pump module 16 contains an elec-tronic microprocessor and associated electronic CileuiLl,y for generating signals to and processing signals from sensor assembly 14 and for generating control signals to the insulin pump itself. The microprocessor is preferably programm-ed to execute algoliL~ s to perform multispectral correlation, and matched digital b~n(lp~cs filtering to remove low frequency bias and high frequency noise. Such algolill..lls are well-known to those skilled in the art, and need not be described in detail. Moreover, the invention is not limited to any specific algorithm; rather, any algorithms suitable for performing the desired multispectral correlation and filtering functions may be used without departing 15 from the invention. It should also be noted that, while the present inventionprovides accurate glucose level measurements, accurate measurement is not crucial to the control of the insulin pump 16. In a manner similar to the way a house thermostat operates, the pump 16 can be controlled to release a fixed quantity of insulin until the glucose levels falls below a preselected level. Thus, 20 any algorithm capable of such control is within the scope of the invention. The algorithm may also control insulin pump 16 to release a glucagon bolus, (1 mg of glucagon, when blood glucose levels trend below 60 mg/dl will increase the blood glucose level above 150 mg/d~).
Processor/pump module 16 may also contain a telemetry transmit-25 ter to transmit sensor data to an external processor and external insulin pump.Insulin can be injected subcutaneously or into a subcutaneous infusaport for delivery into the peritoneal cavity or into a portal vein.
Processor/pump module 16 may also consist of a telemetry receiver for external calibration. If recalibration is necessary, the system 10 30 may be recalibrated externally by comparison to a weekly or monthly finger CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/1143'~
stick blood glucose measurement, such as, for example, using calorimetric assay of a glucose oxidase/hydrogen peroxide reaction using standard techniques. The absolute glucose amount from the external calibration measurement can then be telemetered to the processor for calibration.
S Alternatively, each source of radiation may consist of multiple discrete bands of light with a unique temporal or frequency modulation, allowing discrimination of the dirrelenl spectral bands.
Alternatively to providing a narrow band filter for each detector, the different spectral bands from the sources are each modulated in a unique temporal or frequency fashion, allowing for discrimination of the different spectral regions and obviating the need for narrow band filters.
In another embodiment, source 310 a (or 310 b, 310 C, or 310 d) may consist of multiple LEDs or multiple laser diodes, each of a different wavelength spaced identically collinear or spaced very closely so that each wavelength has substantially the identical optical path and interacts with substantially identical tissue. The detector 320 a, b, c, or d detects light from each individual wavelength from source 320 a, b, c, or d, respectively.
The processor discrimin~ s amongst the dirr~l~llt wavelengths by having each wavelength pulse at a different frequency or at a different time. Asthe processor can discriminate amongst the dirrelcl~t wavelengths by either different frequency or temporal information, narrow wavelength filters 46 a. 48 a, and 50 a are unnecessary in this embodiment. Multiple sources and multiple detectors provide re~ n-l~nry or alternatively the ability to measure different chemical species, although in many cases a single source and detector is adequate. The operation of the sensor is otherwise the same as described in the previous embodiment.
Fourier Transforrn Infrared Spectroscopy (FTIR) Analysis Using commercially available Fourier transform infrared spectroscopy (FTIR) analysis, it is possible to correlate the sensor output datawith blood glucose levels, blood fatty acid levels, and blood amino acid levels.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as inrlie.~ting the scope of the invention.
AND CONTROL OF BLOOD CONSTITUENT LEVELS
Field of the Invention The present invention relates to medical devices for sensing the 5 level of a conctit~lent in a body fluid such as blood, including but not limited to blood glucose, oxygen, antibiotics, enzymes, hormones, tumor markers, fatty acids, and amino acid levels. The present invention also relates to a system forcontrol, monitoring and reporting blood constituent levels in response to sensedlevels and to provide continuous monitoring and control of blood constituent 10 levels to permit aggressive therapy and concomitant clinical benefit of such therapy.
B~k~round of the Invention Metabolic processes in living org~nicmc proceed according to an exact :ltlminictration of chemical compounds that are m~m-f~çtl-red and released15 throughout the organism. These chemical compounds control the function as well as the condition of vital organs, tissues and processes that sustain or exist within the org~ni.cm In many inct~nl~es these cht--mir~l compounds can be found in the org~ni.cmc fluids including blood as in the case of m~mm~lc. These chemical compounds in the blood are generically referred to as blood constitu-20 ents.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 Blood Constituents Glucose A blood constituent such as Glucose is an important nutrient and indicator for human org~ni~m~. During periods of moderate to heavy exercise, S the muscles utilize large arnounts of glucose to release energy. In addition, large amounts of glucose are taken up by muscle cells in the few hours after a meal. This glucose is stored in the form of muscle glycogen, and can later be used by the muscles for short periods of extreme use and to provide spurts of energy for a few minutes at a time. Moreover, glucose is an essential nutrient for brain and spinal cord function. Glucose is the only nutrient that can normally be utilized by the brain, retina, and germinal epithelium of the gonadsin sufficient quantity to supply those organs with their required energy. Brain tissue has an obligate requirement for a steady supply of blood glucose. When blood glucose levels fall below 50 mg/dl, memory loss, agitation, confusion, irritability, sweating, tachycardia, and hypertension commonly occur. Brain failure occurs when blood glucose levels fall below 30 mg/dl, and is associated with coma, hypoventilation, and vascular instability. Death may occur. There-fore, it is important to m~in~in the blood glucose concentration at a high enough level to provide this n~cess~ry nutrition.
At the same time, however, it is also important that the blood glucose concentration not rise too high. Glucose exerts a large osmotic pressurein the extracellular fluid. If glucose concentration rises to excessive levels, this can draw water out of the cells and cause considerable cellular dehydration.
Blood sugars above 200 mg/dl often exceed renal threshold producing an osmotic diuresis by the kidneys, which can deplete the body of fluids and electrolytes.
The steady supply of blood glucose is tightly controlled by the pancreas and the liver. Following a meal, gastric digestion and intestinal absorption provide an increasing amount of carbohydrates, free fatty acids, and amino acids into the portal venous blood. Sixty percent of the glucose absorbed after a meal is imm~ tely stored in the liver in the form of glycogen. Be-W O 97/01986 PCTrUS96/11435 tween meals, when the glucose concentration begins to fall, liver glycogen is dephosphorolated, allowing large quantities of glucose to diffuse out of the liver cells and into the blood stream. The liver, a large organ, can store six percentof its mass as glycogen. In contrast, muscle tissue can store only two percent 5 of its mass as glycogen, barely enough to be used by the muscle as its own energy reserve.
Normally, blood glucose concentration is regulated by two hor-mones, insulin and glucagon, secreted by the pancreas. Insulin is released in a bimodal fashion from the pancreas in direct response to a rise in blood glucose 10 level and, to a lesser extent, to a rise in the blood level of free fatty acids and amino acids. Insulin promotes transport of these nutrients into the cells to be utilized for energy, to be stored as glycogen or triglycerides, or to be synthe-sized into more complex compounds such as proteins.
Some individuals develop diabetes mellitus, and do not secrete 15 insulin in sufficient quantities to properly regulate blood glucose. Lack of insulin inhibits the cell membrane transport of nutrients such as glucose, fattyacids, and amino acids into the cells, forcing the cells to use other compounds for energy and cell growth. Diabetics exhibit a decreased utilization of those nutrients by the cells, resulting in a marked increase in blood glucose concen-20 tration, an increase in triglyceride mobilization from the adipose tissue resllltin~in a marked increase in blood fatty acid and cholesterol concentrations, and a marked loss of protein on a cellular level. Many of the severe end-organ com-plications which result from diabetes are due to the cellular wasting which occurs secondary to abnormal amino acid uptake and protein wasting. Abnor-25 mal fatty acid metabolism results in elevated levels of blood concentrations oflow-density lipo~loL~hl (LDL), cholesterol, and free fatty acids, all leading to accelerated atherosclerosis and obstructive vascular disease. Those with diabe-tes are also prone to ketosis, and develop dehydration, acidosis, and electrolyte imbalance under stress. In some forms of the disease, insulin injections may 30 be required, and other long-term complications such as retinopathy, blindness and kidney disease commonly occur.
W O 97101986 PCT~US96/11435 The pancreas also secretes glucagon, a hormone which has cellular functions that are diametrically opposed to those of insulin. Glucagon stimn1~t~s the liver to release large amounts of glucose from glycogen when the blood glucose concentration falls below 90 mg/dl. This system of insulin 5 inhibition and glycogen release prevents glucose concentrations from falling dangerously low.
In short, glucose is regulated within a narrow range between 80 and 90 mg/dl during fasting, with a rise toward 140 mg/dl following a high carbohydrate meal. The liver functions as a reservoir and buffer, so that glu-10 cose is available to the brain during meals and during periods of prolonged fast.
Type I diabetics have an absolute deficiency in insulin synthesisby the beta cells of the pancreas, and have the most severe clinical course if not aggressively managed with nutrition and insulin therapy. These individuals are ketosis prone and may develop a severe metabolic acidosis. Wide swings in 15 blood glucose commonly occur with a high incidence of symptomatic hypogly-cemia following insulin therapy. End organ dysfunction is common due to accelerated atherosclerosis, cellular protein wasting, and small vessel disease.Type II diabetics release insulin from the pancreas in a blunted fashion following the intake of food. Blood insulin levels do not rise sufficient-20 ly to prevent hyperglycemia. However, in some forms of the disease, insulinlevels may be elevated. In addition, peripheral tissues of type II diabetics may possess a smaller number of membrane tissue receptors and possibly a down regulation of those receptors. Ketoacidosis is uncommon. However, hyperglycemia and hyperosmolar conditions may occur, leading to coma and 25 death. Insulin therapy may or may not be required to m~int~in normal glycemialevels. Other therapies include weight loss, diet, and oral hypoglycemic agents which stimnl~te the pancreas to release larger qn:~ntitiPs of insulin.
There is no doubt that long term tight glucose control is able to significantly reduce the incidence of end organ complications. Control of blood 30 glucose concentration in diabetic individuals by Q.I.D. insulin injections has, of course, been done for many years. This type of treatment does have a W O 97/01986 PCT~US96111435 number of serious drawbacks, however. One or more needle sticks of the finger must be performed on a daily basis to obtain blood for glucose assay.
Many patients suffer anxiety and discomfort when subjected to finger pricking.
After the blood sample is obtained, the sample must be exposed to a surface 5 coated with chemical agents and enzymes that produce a color change corre-sponding to glucose concentration. The patient or m~f~ical practitioner perform-ing the assay must hltel~et the color change accurately, and inject a dose of insulin based on the glucose level. Some patients use a hand held glucometer to measure glucose concentrations in their blood. Many individuals experience 10 anxiety and discomfort when facing injections, and resist them. Some individuals may have no one to ~lmini.~ter the required injections, but have difficulty injecting themselves. Dosage can also be problematic. Color change can be mi~hllel~l~ted, and it is not unusual for patients to miss an injection, or to be off schedule. In addition, patients even have difficulties when using 15 glucometers. Syringes, which these days tend to be disposable, contribute to the growing problem of hazardous medical waste.
Some of these problems have been partially dealt with in the past, but none of the past attempts at dealing with these problems has been entirely s~tisf~tory. Non-invasive optical techniques for measuring blood glucose have 20 been developed, but these techniques do not solve the problems associated with ~Aministering insulin injections where required. Non-invasive optical techniquesfor measuring blood glucose are prone to error because the interface between the sensor and the tissue changes constantly with manipulation and contact pressure. Skin and extremity blood flow also varies considerably with cardiac 25 output, body temperature and level of activity. These non-invasive optical tech-niques typically use a source of infrared (IR) radiation and a detector to measure absorption, reflection, or some other parameter to derive inforrnation about blood glucose levels. The effective optical distance from the IR source and the detector changes with subcutaneous body fat and the variability in placin~ the 30 sensor from day to day. In addition, non-invasive IR sensors measure blood glucose in a non-continuous manner, and are thereby limited to functioning as W O 97/01986 PCT~US96/1143S
a glucose measuring device and not as a therapeutic device for the treatment of diabetes.
Implantable pumps for ~imini~t~ring insulin as well as other chemical compounds are known. It has even been proposed to automatically S measure blood glucose and ~lmini.~ter insulin as may be required using an implantable sensor and insulin pump system. The latter systems are know to incorporate sensors to perform chrmiL~l analysis of blood samples which require the introduction of chemical reagents into the patient's body. Typically, these reagents periodically need to be replenished, which imposes the require-ment of access below the surface of the skin through which fresh reagents must be injected from time to time. No matter what sensor is used, insulin still mustbe injected approximately every 6 weeks into the pump reservoir by placing a thin needle through the skin. Moreover, commercially available implantable pumps have FDA approval only for the infusion of chemotherapy and Baclofen for the treatment of spastic leg disorders. Pumps implanted for the infusion of insulin have been successfully tested in hllm~n~ however, there is no clinical benefit to implantations without a sensor for closed-loop control.
Oxygen Cells require a continuous supply of oxygen and nutrients for basic metabolism. Oxygen must be efficiently absorbed through the lungs and combined with hemoglobin in the blood for proper transport to the tissues.
Oxygen delivery depends upon the pumping action of the heart (blood flow per minute) and the content of oxygen bound to hemoglobin and dissolved within the plasma.
Once in the tissues, oxygen is released from the hemoglobin molecule and diffuses through the hltel~Lilial fluid and into each cell. The workhorse of any m~mm~ n cell is the mitochondria. A series of surface bound enzymes within the mitochondria transfer electrons generated during the metabolism of glucose called the Krebs' (~ycle. Oxygen acts as the final electron acceptor generating ATP, NADH heat, and CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 carbon dioxide as a waste product. High energy phosphate compounds such as ATP and NADH are generated to provide energy for most cellular metabolic processes. Examples of processes requiring ATP for energy include:
m~int~ining ionic gradients, active membrane transport, intracellular synthesis,5 and cell reproduction. Highly metabolic tissues such as brain and heart muscletolerate an inadequate delivery of oxygen and other nutrients poorly.
Conditions that produce a low blood flow state include cardiac pump failure, hemorrhage, dehydration, and sepsis. The tissues attempt to compensate for this low blood flow state by extracting a greater portion of the delivered 10 nutrients.
When oxygen delivery is insufficient to supply the aerobic needs for ATP production, alternative metabolic pathways will dominate causing lactic acid to ~çcl-m~ te. Anaerobic metabolism produces an insufficient supply of high energy compounds and cellular functions quickly deteriorate. Ionic 15 gradients are lost and repair mech~nismc cease to function. Persistent low flow states lead to i.cch-omic damage to various end-organs including the kidneys, brain, and liver. Hypoxemia and metabolic acidosis proceeds organ failure followed by death of the m~mm~l.
Large multicellular org~nismc require a distribution system for 20 the delivery of oxygen and nutrients. The heart, blood vessels, and hemoglobin molecules efficiently transport oxygen and other nutrients to the peripheral tissues such that every cell is within diffusion distance of a nutrient capillary.
Typically, the heart provides pulsatile blood flow (cardiac output) exceeding 5.0 liters per minute. During periods of increased metabolic activity such as 25 exercise, infection, or following surgery, the cardiovascular system is required to increase the cardiac output several fold to meet the increased oxygen requirements. Many disease states colnlJrolllise the cardiovascular system such ~ that an inadequate supply of oxygen and nutrients reach the tissues. Chronic heart failure due to hypertension, ischemic heart disease, valve disease, or 30 alcohol is the most common cause of death in the U.S.
CA 022260l2 l997-l2-30 Fatigue, shortness of breath, and poor exercise tolerance are comrnon as the failing heart is unable to pump sufficient quantities of blood tosatisfy the metabolic needs of the tissues. In addition, cardiac arrhythmia may further compromising forward blood flow. To solve some of these problems, S physicians are can only intervene with medications and supplemental oxygen improving oxygenation and blood flow to the vital organs.
Devices and Implantable Sensors for Detectzon of Blood Constituent~
Devices for the detection of blood glucose incorporate an implantable sensor using a semipermeable membrane and an enzyme coated surface and an oxygen electrode have been studied for the continuous measurement of blood glucose. This sensor has signific~nt drift and quickly fails due to host reaction and cont~min~tion of the membrane and enzyme surface. Needle-type amperometric glucose sensors implanted within the sub-cutaneous tissues and having an enzyme coated surface and an electrical output to an external processor are known, but loss of sensitivity and sensor drift occur upon implantation. This type of sensor, which is in the form of a thin wire, must be inserted through a hollow needle into the subcutaneous tissue and must be changed every three to four days due to enzyme depletion and membrane cont~rnin~tion. In addition, glucose concentration within the subcutaneous tissues lags 20 minutes behind blood glucose and varies between 70-80% of blood values.
Devices for the detection of blood o~ygen such as a pulse oxime-ter are well known. The oximeter measures blood oxygen by measuring the amount of light absorbed by hemoglobin at two different frequencies. It was observed that oxygenated hemoglobin absorbs light differently from that of reduced hemoglobin at two certain frequencies. For example, at 660 nanometers, reduced hemoglobin is known to absorb as much as ten times the amount of light as oxygenated hemoglobin, whereas oxygenated hemoglobin absorbs a much greater amount of light at the infrared wavelength of 940 CA 022260l2 l997-l2-30 nanometers. In addition, the absorbed light has a pulsatile sinusoidal componentcaused by pulsing vol~,lmes of arterial blood from the heart.
The typical pulse oximeter has two light emitting diodes (L~Ds) and a ~letecting sensor arranged in a noninvasive manner to allow emitted light to pass through body tissue for detection by the sensor. As the light passes through the body tissue it is partially absorbed as described above and then detected to produce an estimate of blood oxygen in the human body.
Pulse oximeters have been developed for continuous measurement of in-vivo human blood oxygen saturation by transillllmin~tin~. tissue 10 noninvasively. However, these devices have several disadvantages. Because the pulse oximeter is external to the body and noninvasive, it can only measure red and infrared light tr~ncmitterl through blood in human tissue, typically theear or finger. As a consequence, several inaccuracies are introduced into the measurement of oxygenated hemoglobin by the absorption and dispersion of 15 light through intervening tissues such as skin, soft tissue, bone, venous blood and arterial blood. In addition, the sensors of a pulse oximeter are susceptibleto hltelr~ ce from ambient light, low perfusion, and body motion. Pulse oximetry is known in the art and further described in Kevin K. Tremper and Steven J. Barker, "Pulse Oximetry", Anesthesiology, Vol 70, pp 70-108 1989 20 which is incorporated herein by reference.
Therefore there is a need to control levels of blood constirlents, such as glucose concentration, oxygen, fatty acid concentration, and amino acid concentration without requiring blood sampling, chemical test reagents or re-agent injections, and with continuous monitoring of levels of blood constituents.
25 The present invention meets that need by providing a sensor which is fully implantable and can be used In-vivo, can be used continuously and over the long term, and which is reliable and safe.
- The present invention provides the ability to achieve close, continuous monitoring and control of blood constituents such as, but not limited30 to, glucose and oxygen, as well as tumor markers, antibiotics, enzymes, CA 022260l2 l99i-l2-30 W O 97/01986 PCT~US96/11435 hormones, fatty acids, and amino acid levels, thereby providing a clinical and therapeutic breakthrough.
Summary of the Invention The present invention is an implantable sensor and system capable 5 of measuring, controlling, monitoring, and reporting blood constituent levels.The invention includes an implantable device for sensing In-vivo the level of atleast one blood constituent in m~mm~ n vascular tissue. The internal device includes a commllnic~tion system and a calibration system.
In one aspect of the invention, the implantable device comprises 10 at least one source of radiation from infrared through visible light, arranged to direct the radiation at the tissue. The radiation is affected by interaction with the tissue and detected by a plurality of detectors. The detectors are located with respect to the tissue to receive radiation affected by said tissue. The detectors each have a filter transparent to a discrete narrow band of radiation.15 Each detector provides an output signal representative of detected radiation in said narrow band.
In another aspect of the invention, the implantable device com prises at least two sources of radiation from infrared through visible light, arranged to direct the radiation at the tissue. The radiation is affected by 20 interaction with the tissue and detected by at least one detector. The detectors being located with respect to the tissue to receive radiation affected by said tis-sue. Each source is adapted to emit radiation in a selected number of discrete bandwidths and each detector is adapted to detect the radiation being emitted inthe discrete bandwidth. Each detector provides an output signal representative 25 of detected radiation in said discrete bandwidth.
In another of its aspects, the present invention includes a device for both measuring and controlling the level of a blood constituent in a mam-mal, and comprises an implantable infrared source and sensor module for di-recting infrared radiation through vascular tissue such as, but not limited to, an 30 artery, a vein, a vascular membrane, or vascular tissue. The sensor module W O 97/01986 PCT~US96111435 senses the infrared radiation after it has passed through the tissue and generates an output signal representative of the sensed infrared radiation. A processor module, responsive to the output signal from the infrared source and sensor module, performs spectral analysis of the output signal and derives therefrom a control signal representative of the level of the blood constituent. The processor module or another device in cu~ llunication with the processor module is used to control, monitor, and report the level of the blood constituent.
In one aspect of the invention, an insulin pump is used to control the level of glucose by dispensing doses of insulin in response to the control signal. In another aspect of the invention, an implanted cardiac pacemaker as well as an int~rn~l cardiac defibrillator (ICD) is used to control the level of oxygenated hemoglobin in the blood in response to the control signal. In yet another aspect of the invention, an implanted dispensing device is used to control the level and ~lmini~tration of medications such as, but not limited to,cardiac drugs, antibiotics, or chemotherapies in response to the control signal.In still another aspect of the invention, the level of tumor markers is monitored and reported to other devices in response to the control signal. In all aspects of the invention, the system is capable of monitoring and reporting all blood conctitllentc that are sensed and measured.
In another aspect of the invention, an implantable oxygenation, hemoglobin, and perfusion sensor is provided to obtain frequent objective data on patients with chronic illnesses such as heart failure and respiratory failure.
Patients would be monitored for changes in hemoglobin oxygen saturation (pulse oximeter), hemoglobin concentration (infrared measurement), and changes in tissue perfusion (analysis of the photoplethsmograph waveform) for the purpose of cletecting cardiovascular decompensation early so that the physician can manage the problem as an outpatient. Visits to the emergency room and admissions to the ICU would significantly ~liminich. Data from the sensors will be stored within a memory chip and Physicians would be notified automatically if data changed significantly from data established for an individual patient's background.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 Typically, cardiovascular patients are not alerted to significant cardiovascular decompensation until overt symptoms have occurred resulting in the need for acute care in a n ICU following ~lmi~csion through an emergency room. With this implantable sensor of the present invention, physicians will be 5 able to detect early cardiovascular decompensation and in~ti~lt~ corrective therapy as required.
Data stored in a memory by the invention can provide the patient or clinician, either directly of remotely, with the natural history of the disease process. The physician will be able to ~lmini.~t~r me~ l therapy based on an 10 objective presentation of data and conclude from the data and immediately acquire information on the effects of the therapy applied. The invention provides the major determin~nt~ of oxygen delivery such as to the tissues which are measured by the sensor.
For example, after a patient is stabilized following a myocardial 15 infarction and the onset of heart failure and pulmonary edema, a sensor wouldbe implanted under local anesthesia. The sensor would immediately provide and collect data directly and co~ unicate data to an extracorporeal device for remote monitoring of the patient for changes in oxygenation, perfusion, hemoglobin concentration, and cardiac alll,yLlllllia. Once discharged from the 20 hospital, the sensor would continue to monitor the patient and provide data extracorporeally for significant changes in oxygenation, perfusion, hemoglobin concentration, and cardiac arrhythmia. Depending on the condition of the patient, data would be stored in a memory or reported directly to the patient ormedical personnel for interpretation as required. Therefore, the present 25 invention can facilitate the ~(lmini~tration of medications, ap~lupliately according to objective measured data thereby improving cardiac contractility andimproved tissue blood flow in advance of an acute event.
In another aspect of the invention, the implantable device comprises at least one radiation source consisting of at least two discrete 30 spectral bands Iying somewhere within the infrared through visible spectrum, arranged to direct the radiation at the tissue. The radiation is affected by CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 interation with the tissue and detected by at least one detector. The different spectral bands in each source are substantially collinear and interact with substantially identical tissue. The detectors being located with respect tO the tissue to receive radiation from source affected by said tissue.
Discrimination amongst different spectral bands is provided by each spectral band having a unique temporal or frequency modulation. Each detector provides an output signal representative of detected radiation from said source. A commllnic~tion means is provided to relay the output signal from detector to processor. A processor is used to determine level of blood constituent in blood.
Des~ ion of the D~ ~wi..gs For the purpose of illustrating the invention, there is shown in the drawings a form which is presently preferred; it being understood, however, that this invention is not limited to the precise arrangements and instrumentali-ties shown.
Figure 1 illustrates an implantable glucose sensor according to one embodiment of the invention as it might be implanted in a human patient, shown in conjunction with an implantable insulin pump, with the sensor array arranged to monitor blood flow through a blood vessel.
Figure 2 is an enlarged view of the sensor of Figure 1, showing the sensor in conjunction with an implantable insulin pump and processor mod-ule cont~ining associated processing and control electronics.
Figure 3 is a transverse sectional view through the sensor shown in Figure 2, taken along the lines 3-3 in Figure 2, showing the distribution of individual photocells.
Figure 4 is a longitl-(1in~1 sectional view through the sensor, taken - along the lines 4-4 in Figure 3.
Figure 5 illustrates an implantable glucose sensor according to an alternate embodiment of the invention as it might be implanted in a human W O 97/01986 PCT~US96111435 patient, with a sensor array arranged to monitor blood flow through a vascular membrane such as parietal peritoneum.
Figure 6 is an enlarged view of the embodiment of the sensor of Figure 5, showing the sensor in conjunction with an implantable insulin pump S and processor module cont~3ining associated processing and control electronics.
Figure 7 is a sectional view through the sensor shown in Figure 6? taken along the lines 7-7 in Figure 6.
Figure 8 is a top plan view of the sensor shown in Figure 6, showing the distribution of individual photocells.
Figure 9 illustrates a third embodiment of the invention, partially broken away, showing an arrangement of individual photocells in a rectangular array.
Figure 10 is a sectional view of the sensor shown in Figure 9, taken along the lines 10-10 in Figure 9.
Figure 11 is an enlarged plan view of an individual photocell from the array shown in Figure 9.
Figure 12 is a fourth embodiment of the invention, in cross-sectional view.
Figure 13a illustrates a functional block diagram of an implantable blood constituent sensor module with co~ unication means shown in conjunction with extracorporeal receiving, calibration, and communication modules.
Figure 13b illustrates a typical oxygen delivery process monitored according to a plc~f~ d embodiment of the present invention.
Figure 1 3c illustrates an implantable oxygen sensor module having at least one pair of detector and sensor elements according to a preferred embodiment of the present invention.
Figure 13d illustrates a plethysmograph of a plurality of pulse waves through a vascular membrane at a specific rate as would be measured by at least two pairs of the detector and sensor elements shown in Figure 13c.
CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 Figure 14 is a schematic representation of a device for controlling the blood oxygen according to a pl~fell~d embodiment of the present invention.
Figure lSa is a schematic representation of a device for controlling the level of blood oxygen according to another preferred 5 embodiment of the present invention.
Figure 15b is a schematic representation of vascular tissue plethysmography and ECG fibrillation according to a preferred embodiment of the present invention.
Figure 16a is a schematic representation of an infrared sensor 10 according to a preferred embodiment of the present invention.
Figure 16b is a schematic representation of the infrared sensor shown in Figure 16a used to measure and control a medicinal blood constituent such as an antibiotic.
Figure 17 is a schematic representation of an infrared sensor 15 according to another L~l~fell~d embodiment of the present invention.
Figure 18a is an illustration of an extracorporeal calibration and commllnil~tion module unit for use in connection with implantable blood constituent sensor modules according to the invention.
Figure 1 8b is an illustration of a extracorporeal calibration 20 handheld unit for use in connection with implantable blood constituent sensor modules according to the invention.
Figure 18c is a functional block diagram showing the operation of an implantable device according to the invention in commllni(~:~tion with theextracorporeal calibration and commlmic~tion module shown in Figure 18a.
Description of the Invention Referring now to the drawings, wherein like numerals indicate like elements, there is shown in Figure 1 a representation of an implantable blood constituent monitoring and control system 10.
Glucose Monitoring and Control System CA 02226012 l997-l2-30 W O 97/01986 PCT~US96/11435 Figure 1 shows a blood glucose monitoring and control system 10 comprising a sensor and an insulin pump, as it might be surgically implanted in a patient 12. It should be understood that Figure 1 is not intended to be anatomically accurate in every detail; rather, it is intended to represent generally 5 how the system 10 would be implanted. Moreover, it should also be understood that, while for convenience the present invention is illustrated and described in reference to monitoring and control of blood glucose, the invention is not so limited, and encompasses the monitoring and control of other blood constituents such as, by way of example and not by way of limitation, fatty acid or amino 10 acid concentration. Several plerell~d embodiments of the invention are presented below.
As best seen in Figure 2, system 10 comprises a sensor assembly 14 connPctPd to a processor/pump module 16 via a signal cable 18. Sensor assembly 14, described in greater detail below, has an opening which enables 15 it to be arranged to subst~nti~lly surround a blood vessel 20. Processor/pumpmodule 16 is illustrated as dispensing insulin via a tube 22 into a second bloodvessel such as a vein 24, which may be the portal vein for direct transport to the liver. Alternatively, processor/pump module dispenses insulin via a non-thrombogenic multilumen catheter including a one-way valve, directly into the 20 peritoneal space adjacent the hilum of the liver. Insulin will be rapidly ab-sorbed into the portal venous system and transported to the liver. While the processor/pump module 16 is illustrated as implanted within a patient's body, the pump portion of processor/pump module 16 may also be an external device, worn or otherwise carried by the patient, without departing from the present 25 invention. Where an external pump is used, insulin may be delivered percuta-neously into an infusaport implanted under the patient's skin for final transport to the peritoneal cavity or portal vein. Alternatively, insulin may also be delivered by an external device with a needle placed chronically within the patient's subcutaneous tissues. Moreover, when an external pump is used, the 30 processor portion of processor/pump module 16 requires a data telemetry portion in order to telemeter command signals to the external pump. Insulin CA 022260l2 l997-l2-30 W O 97/01986 . PCT~US96/11435 reservoirs and pumps, telemetry devices, and infusaports are all known per se, and therefore need not be described here in any great detail.
Processor/pump module 16 contains a conventional insulin reser-voir and pump. In addition to an insulin reservoir and pump, processor/pump 5 module 16 contains an electronic microprocessor and associated electronic circuitry for generating signals to and processing signals from sensor assembly 14 and for generating control signals to the insulin pump itself. Processor/pumpmodule 16 further includes a long-life battery to power the electronic circuitry, the sensor assembly 14 and the insulin pump.
Blood Constituent Sensor Sensor assembly 14 is illustrated in greater detail in Figures 3 and 4. Sensor assembly 14 has a body portion 26 which is generally C-shaped in transverse cross-section. Thus, body portion 26 has a longih--lin~l channel which runs through body portion 26, and a lon~ lin~l gap 28 which communi-lS cates with the longitudinal channel. Body portion 26 is preferably fabricatedfrom a semi-rigid material such as titanium or epoxy, which is easily worked and biocompatible for long-term implantation. The shape and semi-rigid materi-al of sensor assembly 14 enables it to be placed closely around vessel 20 and place optical sources and individual optical detectors in optimum position with 20 respect to vessel 20. The ~lis~nre between the optical sources and the optical detectors can thus be made small and as close to constant as possible, for optimum signal acquisition.
In the embodiment of sensor 14 illustrated in Figures 3 and 4, the optical sources and optical detectors may be infrared (IR) sources and IR detec-2~ tors, although radiation from infrared through the visible spectrum may beemployed without departing from the invention. In the figures, individual IR
sources and individual IR detectors are grouped together in three groups, or arrays, 30, 32, and 34. Each array comprises an IR source (30a, 32a, and 34a, respectively) and two IR detectors (30b~ 30c; 32b, 32c; and 34b, 34c, respec-tively). The individual IR sources 30a, 32a, and 34a may be mini~h~re infrared CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 diodes located, in the illustrated embodiment, on one side of vessel 20. IR
sources 30a, 32a, and 34a are driven by signals generated in the processor/pu-mp module 16 and transmitted to IR sources 30a, 32a, and 34a via conductors 36a, 38a, and 40a, respectively. Similarly, output signals from individual S detectors 30b, 30c; 32b, 32c; and 34b, 34c are tr~n~mitt~l to processor/pump module 16 via conductors 36b, 36c; 38b, 38c, and 40b, 40c, respectively. Con-ductors 36, 38, and 40 collectively are dressed together to form signal cable 18, which couples sensor array 14 to processor/pump module 16. Cable 18 exits body portion through an extension portion 42, which serves to support cable 18 and minimi7e the chance of breakage of conductors 36, 38, and 40 from flexing or being subjected to sharp bends. If desired, cable 18 may exit extension portion 42 through a strain relief sleeve 44, to further protect cable 18.
Each IR source 30a, 32a, and 34a has associated with it an optical filter 46a, 48a, and 50a, respectively. Each filter transmits a different discrete narrow band of radiation. In similar fashion, each detector 30b, 30c;
32b, 32c, and 34b, 34c has associated with it an optical filter 46b, 46c; 48b, 48c; and 50b, 50c, respectively. In this manner, each optical source and the detectors associated with it in a given array 30, 32, or 34 operates in only a discrete narrow band.
With this embodiment, detectors 30b, 32b, and 34b are arranged diametrically opposite IR sources 30a, 32s, and 34a, respectively, to detect light transmitted from the associated source through the blood vessel 20. The angle between the sources and the detectors is thus 180~. (These detectors could also be used to determine reflected light, since light that is not tr;~n~mitt~l may, for purposes of the invention, be assumed to have been reflected. By determining the amount of light transmitted, and subtracting it from the amount of light emitted from the source, the amount of light reflected can be calculated.) Detectors 30c, 32c, and 34c are arranged at an angle less than 180~ from the associate sources, and are located to detect IR radiation either reflected or scattered from vessel 20.
W O 97/01986 PCT~US96111435 It is important to note that, although this embodiment of the invention is described using three arrays of IR sources and associated detectors, that precise configuration is not crucial to the invention. The invention may beimplemented, for example, using a single IR source and multiple detectors for 5 det~ctin~ reflected, scattered, and tr~n~mitt~tl IR radiation. In such an embodi-ment, the IR source would not have a narrow band filter associated with it, but would emit broadband IR. Each detector, however, would have a narrow band filter associated with it, so that it would respond only to a preselected wave-length.
Conductors 36, collectively,38, collectively, and 40, collectively, can be either electrical conductors or optical fibers. That is, the IR sources and the IR detectors may be located either within sensor assembly 14 itself, in which case the conductors are electrical conductors and carry electrical signals between processor/pump module 16 and sensor assembly 14, or within processor/pump 15 module 16, in which case the conductors are optical fibers and carry infrared radiation between processor/pump module 16 and sensor assembly 14.
It will be appreciated that IR radiation generated by IR sources 30a, 32a, and 34a is directed through the walls of vessel 20, and thus the bloodflowing in the vessel, to detectors 30b, 30c; 32b, 32c; and 34b, 34c located 20 across from and at right angles to the IR sources. The IR radiation detected by the several detectors is, of course, affected by its interaction with vessel 20 and the blood flowing therethrough. Consequently, by analyzing the output signals from the several detectors, it is possible to derive information about the levels of glucose, fatty acids, and amino acids in the blood flowing through vessel 20.25 Preferably, although not necessarily, selected sensor/detector pairs are used for different measurement techniques. For example, pair 30a, 30b could be used to measure infrared tr~n~mitt~nre~ and pair 30a, 30c to measure infrared scat-tcring. That is, the output signals from the several detectors can be processed dir~lcllLly to obtain different characteristics of the blood being measured.
W O 97/01986 . PCTrUS96/11435 In contrast to prior electro-chemical glucose sensors, sensor array 14 does need require direct contact with blood, does not need to be replenished with test reagents, and can operate indefinitely.
Alternative Blood Constituent Sensor In another embodiment, source 30 a or 32 a, or 32 a) may consisl of multiple LEDs or multiple laser diodes, each of a different wavelength spaced identically collinear or spaced very closely so that each wavelength has substantially the identical optical path ad interacts with substantially identical tissue. The detector 30 b or c, 32 b or c, and 34 b or c detects light from eachindividual wavelength from source 30 a, 32 a, and 32 c, respectively. The processor discrimin~trs amongst the different wavelengths by having each wavelength pulse at a different frequency or at a different time. As the processor can discriminate amongst the different wavelengths by either differentfrequency or temporal information, narrow wavelength filters 46 a, 48 a, and 50 a are nnn~ce~ry in this embodiment. Multiple sources and multiple detectors provide reAIlntl:~nr.y or alternatively the ability to measure different chemical species, although in many cases a single source and detector is adequate. The operation of the sensor is otherwise the same as described in the previous embodiment.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 Vascular Membrane Sensor Inte~ face An alternative form of device 10' according to the present inven-tion is illustrated in Figures 5 through 8. In alternative form 10', the device monitors blood flowing through a highly vascular membrane, such as a portion of the parietal peritoneum 52. The parietal peritoneum is an ideal tissue for measurement due to its high vascularity, translucency, constant temperature. andbris~ blood flow. As best seen in Figures 6 and 7, a portion of a vascular membrane such as the parietal peritoneum 52 (shown in phantom in Figure 6) is sandwiched between two halves 54 and 56 of an alternate form 58 of sensor assembly. Halves 54 and 56 are essentially mirror images of each other~ and define a gap 60 between them, which receives the peritoneal tissue. Sensor assembly 58 is preferably molded from the same type of material as used to fabricate sensor assembly 14, as already described. The shape and semi-rigid material of sensor assembly 58 enable it to be clamped snugly around peritoneal tissue 52 and to place individual IR sources 62a though 62d and individual IR
detectors 64a through 64d, 66a through 66d, 68a through 68d, and 70, in opti-mum position with respect to tissue 52.
One half of sensor assembly 58, such as half 56 for example.
contains the individual IR sources 62a through 62e, while the other half. such as half 54, for example, contains the individual detectors 64 collectively, 66 collectively, 68 collectively, and 70. The detectors are grouped together in groups of three, for example, such as 64a, 66a, and 68a, and are located oppo-site a source, such as 62a. Only a single detector 70 is shown located opposite source 62e, although a group of detectors could also be located opposite source 62e.
IR sources 62, collectively, are driven by signals generated in the processor/pump module 16 and tr;~n~mitte~1 to IR sources 62a through 62e via ~ conductors 72a through 72e, respectively. Similarly, output signals ~rom individual detectors 64a through 64e, 66a through 66e, 68a through 68e, and 70 are tr~n~mitt.od to processor/pump module 16 via conductors 74a through 74e, 76a through 76e, 78a through 78e, and 80, respectively. Conductors 72. collec-W O 97/01986 PCT~US96111435 tively, are dressed together to ~orm a signal cable 82, while conductors 74 collectively, 76 collectively, 78 collectively, and 80 are dressed together to form a signal cable 84. Cables 82 and 84 are merged together into a single signal ca-ble 86 (see Figure 6), which connects sensor assembly 58 to processor/pump module 16.
As with conductors 36, 38, and 40, conductors 72, 74, 76, 78, collectively, and 80 can be either electrical conductors or optical fibers. Thatis, the IR sources 62, collectively, and the IR detectors 64, 66, 68, collectively, and 70 may be located either within sensor assembly 58 itself, in which case theconductors are electrical conductors and carry electrical signals between proces-sor/pump module 16 and sensor assembly 58, or within processor/pump module 16, in which case the conductors are optical fibers and carry infrared radiationbetween processor/pump module 16 and sensor assembly 58.
IR radiation generated by IR sources 62, collectively, is directed through peritoneal tissue 52, and thus the blood flowing through the tissue, to detectors 64, 66, 68, collectively, and 70 located across from the IR sources.
As in the previous embodiment, each source or detector may have associated with it a narrow band filter, so that each optical source and the detectors associ-ated with it in a given array operate in only a discrete narrow band of IR ra-diation. The IR radiation detect~-d by detectors 64, 66, 68, collectively, and 70 is, of course, affected by its interaction with tissue 52 and the blood flowing therethrough. Consequently, by analyzing the output signals from the detectors, it is possible to derive information about the blood flowing through tissue 52.
Preferably, although not necessarily, selected sensor/detector pairs are used for different measurement techniques, such as, for example, infrared tr:~nsmitt~nce,infrared reflectance, and infrared scattering. Thus, the output signals from theindividual detectors can be processed differently to obtain different characteris-tics of the blood being measured.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 Alternative ~ensor ConJ~i~guration A third embodiment 88 of sensor assembly is illustrated in Fig-ures 9 and 10. In those figures, sensor assémbly 88 comprises a generally rectangular array of source/detectors 90 disposed on opposite halves 92 and 94 of the sensor assembly~ with each half being on opposite sides of a vascular membrane 52. Source/detectors 90 are preferably, although not necessarily, arranged opposite one another on respective halves 92 and 94, so that the array on one half is substantially in ~ nment with the array on the other half.
An individual source/detector 90 is illustrated in more detail in Figure 11. Source/detector 90 is generally circular, and at its center portion contains a source segment 96, from which infrared radiation is emitted. An inactive buffer ring 98 surrounds source segment 96. A second inactive buffer ring 100 is radially spaced from and surrounds buffer ring 98. Buffer rings 98 and 100 are inactive in the sense that they neither emit nor respond to IR radia-tion. The portion of source/detector 90 between buffer rings 98 and 100 is divided into a plurality of detector segments 102, each of which is associated with a narrow band filter so that it responds to a selected band of radiation. Alinearly-variable filter can be used, for example. In this manner, each detectorsegment 102 operates in only a discrete narrow band. A second plurality of detector segments 104 is located radially outward of buffer ring 100, each of which is also associated with a narrow band filter so that it, too, responds to a selected band of radiation.
It will be appreciated that a single source/detector 90 can operate to measure both reflected and scattered IR, or a single pair of source/detectors90 can operate to measure reflected, scattered, and tr~n~mitt~-d light over a plurality of discrete radiation bands.
Figure 12 illustrates an embodiment 106 of a sensor assembly similar to those shown in Figures 7 and 10, except that the two halves 108 and 110 are not spaced apart by a fixed distance, as are the halves of the detectorsin Figures 7 and 10. Instead, the halves 108 and 110 are movable toward and away from each other, and the gap 112 may be adjusted by means of adjusting CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 screws 114. Preferably, the head portion of screw 114 iS made captive, but freely rotatable, in one half, such as half 108. The shank portion of the screw is received in a threaded bore 116 in the opposite half. Thus, by rotating screw114, the width of the gap 112 between halves 108 and 110 can be easily adjust-5 ed for optimum spacing of the individual sources and detectors relative to thevascular membrane 52.
Oxygenation and Tissue Perfusion Monitoring Figure 13b illustrates this concept can be summarized using the following equations:
A. Oxy~en delivery = cardiac output X oxygen saturation (%) x hemoglobin concentration (gm/dl) X 1.39 + partial pressure of oxygen (PaO2) x 0.0031 B. Cardiac output = heart rate x stroke volume Cardiac output is a measurement of blood flow (liters/minute) and can be defined as the heart rate times the stroke volume. The stroke volume is the amount of blood ejected with each beat of the heart and is influenced by th amount of blood returning to the heart, the state of contractility of the heart muscle, and degree of afterload or impedance to forward blood flow. (72 bts/min x 80 ml/bt = 5,760 ml/min). Heart rate can be measured by counting the plethysmograph pulse wave as shown in Figure 13b.
Stroke volume can be estimated by analyzing the plethysmograph pulse wave illustrated in Figure 13d including the maximum amplitude, the area under the curve, the rate of upstroke, and the velocity of wave propagation according to standard processing techniques. Current research is correlating pulse wave analysis with invasive monitoring such as Swan Ganz catheters and transesophageal echocardiography. Current pulse oximeter technology displays a pulse wave reflecting the volume of blood perfusing the tissue between the CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 source and detector. Pulse detection algorithms evaluate the changes in light attenuation across a vascular tissue (photoplethysmography). The optical path length of the diastolic tissue bed and the optical path length of the systolic tissue bed is measured. The difrt:lcllce between the two is the optical path length of light being affected only by arterial blood. The microprocessor continually calculates the ratio of light absorption associated with both wavelengths of light emitted by the two source diodes. With (limini~h~d blood flow, conventional pulse oximeters increase the gain on the signal with no attempt to measure bloodflow or pulse wave velocity. With sufficient gain on the signal and noise rejection algorithms, an accurate oxygen saturation measurement can be m~int~in~ despite a fall in tissue blood flow to less than 10% of baseline.
Some commercially available pulse oximeters display the signal gain required (2x, 4x, 8x, etc.) to m~int~in a normal amplitude plethysmograph waveform and an accurate hemoglobin oxygen saturation reading. Analysis of the raw signal that produces the pulse wave includes the maximum amplitude, the area under the curve, the rate of upstroke, and the velocity of wave propagation. This raw signal data can be used to estimate the stroke volume per beat of the heart (volume of blood ejected per beat). The velocity of wave propagation can be measured using two or more source/detector pairs in series such that the pulse wave is detected with a slight time delay at the second pair and an additional time delay at the third. Since the distance between the sensor pairs is known and fixed, a pulse wave velocity can be calculated. The total combined analysis of the pulse wave will be used to estimate stroke volume and therefore an on-line estimate of cardiac output.
The amount of radiation absorption and scattered is significantly limini~hed by using a thin translucent vascular membrane as the optical interface. A higher signal to noise ratio is found compared to non-invasive pulse oximetry techniques.
C. Oxy~en content within the blood = hemoglobin oxygen saturation (%) x hemoglobin concentration (gm/di ) X 1.39 + partial pressure of oxygen (PaO2) x 0.0031 W O 97/01986 PCTrUS96/11435 Hemoglobin oxygen saturation reflects the sigmoidal shaped dissociation curve in which hemoglobin is 98% saturated or greater when the partial pressure of oxygen exceeds 100 mm Hg. Saturation slowly falls such that hemoglobin is 95 % saturated at an oxygen partial pressure of 60 mm Hg.
5 Below this partial pressure, oxygen saturation falls dramatically. Commercially available pulse oximeter technology provides this information accurately and reliably.
Infrared spectroscopy is able to accurately measure blood hemoglobin concentration. Since 1.39 millilit~rs of oxygen can bind to each 10 gram of hemoglobin, the total oxygen content of the blood can therefore be measured using optical means. The amount of oxygen dissolved in the plasma is negligible (partial pressure of oxygen (PaO2) x 0.0031) and of little clinical significance.
The purpose of the implantable oxygenation, hemoglobin, and 15 perfusion sensor is to obtain frequent obiective data on patients with chronic illnt?sses such as heart failure and respiratory failure. Patients would be monitored for changes in hemoglobin oxygen saturation (pulse oximeter), hemoglobin concentration (infrared measurement), and changes in tissue perfusion (analysis of the photoplethsmograph waveform) for the purpose of 20 detecting cardiovascular decompensation early so that the physician can manage the problem as an outpatient. Visits to the emergency room and admissions to the ICU would significantly ~liminich Data from the sensors will be stored within a memory chip and reviewed by the physician during an office visit or over the phone. In one embodiment, the physician would be notified 25 automatically if data changed significantly from the individual patient's normal pattern. Typically, patients wait until significant cardiovascular decompensation has produced overt symptoms re~uiring admission through the emergency room to the ICU. With this implantable sensor, physicians will be able to detect early decompensation and in.ctitllte corrective therapy as an outpatient. Data stored 30 in the memory chip will provide the clinician with the natural history of thedisease process. The physician will be able to titrate medical therapy based on W O 97/01986 PCT~US96111435 objective numbers and conclude from the data the benefits incurred by this therapy. All of the major determin~ntc of oxygen delivery to the ~issues can be measured with this sensor. For example, a patient develops heart failure and pulmonary edema following a myocardial infarction. Once stabilized in the ICU
S a sensor would be implanted under local ~n~sth~sia and data collected on-line.Once discharged from the hospital, the sensor would monitor the patient for significant changes in oxygenation, perfusion, hemoglobin concentration, and cardiac arrhythmia. If no significant changes occur, data would be stored in a memory chip and downloaded for physician hlLel~l~talion during the patient's 10 routine office visit. Medications that improve cardiac contractility and improve tissue blood flow could be titrated to objective endpoints rather than to vague patient symptoms.
Alternate clinical uses for this optical technology include integration of the output signal with an internal cardiac defibrillator (ICD).
15 Patients are implanted the ICD following a near death experience due to a serious ventricular arrhythmia of the heart. Unfortunately, the electrocardiogram algorithms programmed into the ICD are unable to dirr~l~llLiate a life threatening allhyllllllia from noise in certain cases. It is estim~t~l that hlap~ )liate defibrillation occurs 30% of the time. Using the 20 implantable photoplethsmograph sensor (pulse oximeter), tissue blood flow data can be integrated with the algorithm for defibrillation. Both the ECG and tissueblood flow have to agree that a life threatening arrhythmia is present before defibrillation.
Closed-loop feedback with a programmable pacemaker provides 25 a means to increase/decrease the heart rate and fine tune the timing intervals of a pacemaker to more physiologically meet the oxygenation and perfusion needs of the tissues during various levels of physical activity. The sensor would be placed on around a central vein returning to the right heart.
Measurement of venous oxygen saturation reflects the adequacy 30 of cardiac output and oxygen delivery to the peripheral tissues. During exercise, blood flow increases several fold to the muscles and other tissues.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 When the heart is paced at a fixed low rate, the tissues extract a greater percentage of the oxygen delivered. Low venous saturation suggests the need to increase oxygen delivery by increasing the cardiac output and by increasing the oxygen carrying capacity of the blood ( transfusion red blood cells, iron therapy ). Decreasing venous oxygen saturation would signal the pacemaker to increase the heart rate and to optimize the timing intervals between atrial and ventricular contraction thus regulating the cardiac output of the heart. Once the oxygen debt was satisfied, the heart rate would slowly return to baseline values.
In this way, the pacemaker would compensate for an increased demand for oxygen in the peripheral tissues.
Figure 13a illustrates a functional block diagram of a blood oxygen and perfusion monitoring and control system 200 comprising an implanted sensor 330 (shown in Figure 13c) and an implanted control module 300 (not shown in detail) which is in communication with an extracorporeal monitor 210. The extracorporeal monitor 210 is in communication with a direct blood calibration module 400 (explained in detail below) and other communication systems such as, but not limited to, a cellular telephone 2'70, anemergency medical warning system (not shown), or a hand held monitoring device (shown in Figure 18b).
The blood oxygen perfusion monitoring and control module 200 is surgically implanted in a patient where it is employed to measure, control, monitor, and report measured hemoglobin oxygen saturation and tissue perfusion. As shown in Figure 13b, measured blood oxygen is represented as the amount of oxygen delivered to the blood on a pulse by pulse basis as the blood is pumped by the heart. The amount of blood oxygen delivered to the body can be represented according the following formula:
~2 (Delivered) = * Hb * SaO, * 1.39 + PaO2 * 0.0031, where, C.O. = Cardiac Output = Heart rate x stroke volume liters/mn, Hb = Hemoglobin concentration mg/dl, CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 SaO2 = Hemoglobin oxygen saturation %, 1.39 = a constant representing 1.39 ml of oxygen bound to one gram of Hemoglobin, PaO2 = partial pressure of oxygen dissolved in plasma, S and 0.0031 = a constant representing the amount of oxygen dissolved in plasma.
The blood oxygen is measured as an estimate of oxygen according to the pulsatile perfusion of the blood through a vascular interface. It is to be understood that the vascular interface can be, but is not limited to, an artery,a vein, a vascular membrane, or vascular tissue. The oxygen measurement is acquired according to standard pulse oximetry described above. In a plef~l~ed embodiment of the present invention, oxygen is measured by the implanted control module 300 and at least one paired sensor assembly 330 (shown in Figure 13c).
Figure 13c illustrates an embodiment of the sensor assembly 330 assembly similar to those shown in Figures 7, 10 and 12. However, the two halves 310 and 320 have linearly arrayed elements that are spaced apart by a distance defined by a vascular membrane 340. The linear arrays are paired together to form a plurality of paired arrays as may be required to acquire a plethysmographic representation of the pulsatile flow of oxygenated and reduced hemoglobin passing through the vascular membrane 340. A single paired array is required to produce a plethysmograph as shown in Figure 13b, and, multiple arrays, are required to measure a velocity of the pulse wave.
In the embodiment of sensor 330 illustrated in Figures 13c, the optical sources and optical detectors may be infrared (IR) sources and IR detec-tors, although radiation from infrared through the visible spectrum may be employed without departing from the invention. In the figures, individual IR
sources 310 a-d and individual IR detectors 320 a-d are grouped together in pairs forming the paired array 330. A plurality of paired arrays will also com-prise an plurality of IR sources and IR detectors respectively. The individual CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 IR sources 310 a-d may be mini~hlre infrared diodes located, in the illustrated embodiment, on one side of the vascular membrane 340. IR sources 310 a-d are driven by signals generated in the control module 300 and tr~n.cmitred to the IR sources 310 a-d via conductors (not shown). Similarly, output signals from S individual detectors 320 a-d are tr~ncmitted to the control module 300 via separate conductors (not shown).
Each IR source 310 and detector 320 may have associated with it an optical filter (not shown) or a time based or encoded discriminator (not shown) for selectively emitting and detecting the selected bands of radiation 10 emitted for detecting blood oxygen saturation.
With this embodiment, the IR sources 310 and detectors 320 are arranged diametrically opposite each other to detect light tr~n.cmits~d through the vascular membrane 340.
It is important to note that, although this embodiment of the 15 invention is described using a single array of paired IR sources and associated detectors, that precise configuration is not crucial to the invention. In fact, the invention may be implemented, for example, using a plurality of paired arrays for detecting reflected, scattered, and tr~ncmitted IR radiation.
Figure 13d shows a plethysmographic representation of pulsatile 20 blood oxygen perfusion when four paired arrays are employed.
The implanted control module 300 preferably incorporates a pulse oximeter module (not shown) for producing perfusion data (as shown in Figure 13d). Also incorporated in the control module 300 is a processor module ~not shown) for analyzing the perfusion data and for producing a control signal that 25 is commllnic~t~d by the control module 300 to a blood oxygen regulating device such as, but not limited to, a pacemaker or defibrillator.
Figure 14 is an illustration of a preferred aspect of the invention showing a control module 300 having a sensor 330 for measuring perfusion data to determine the level of blood oxygen. The sensor 330 as explained above 30 employs at least two selected bands of frequencies to produce detected signals W O 97/01986 PCTrUS96/11435 corresponding to oxygenated hemoglobin levels which are analyzed by the processor module (not shown~ of the control module 300.
The control module 300 also incorporates a co"""l"-ic~tion module (not shown) for commllnic~ting control information to an implanted pacemaker 360. The pacemaker 360, in response to the control information received from the control module 300, regulates the heart 1000 (shown for illustrative purposes) to pump blood as required to produce a desired blood oxygen level. The control module 300 controls blood oxygen by regulating the pacemaker to control heart rate and timing of atrial and ventricular contractionaccording to stored blood oxygen values programmed into the control module 300. Programmed blood oxygen values are stored in the control module 300 through its comml-nication module. An extracorporeal cul"",ll,-ic~tion device (shown in Figure 18a) is used to control and calibrate the control module 300 which is explained in detail below.
Figure 15a is an illustration of another preferred aspect of the invention showing a control module 300 having a sensor 330 for measuring perfusion data to estimate quantity of blood delivered per beat to the tissues.
The control module 300 incorporates a comml-nic~tion module (not shown) for communicating control information to an implanted defibrillator 380. The defibrillator 380, in response to the control information from the control module 300 and its own internal EKG system 381 (shown for illustrative purposes) will regulate the heart 1000 (shown for illustrative purposes) to prevent ina~ ol)liate in other words the discharge of the internal defribulator.
It is known that an internal defibrillator will at times hlapplopliately defibrillate irregular heart beat patterns. When this occurs thelevel of blood oxygen can be severally affected. To prevent this condition, the level of blood oxygen measured by the control module 300 is used to confirrn proper heart function. Because the control module 300 and sensor 330 use photo-plethysmography to measure pulsatile perfusion, actual defibrillation can be detected as an inst~nt~n,oous loss of blood oxygen.
;
CA 022260l2 l997-l2-30 W O97/01986 . PCT~US96/1143S
In Figure 1 Sa the electrical activity of the heart normal sinusrhythm with s~tisf~ctory tissue perfusion and oxygenation noted on the plethysmography waveform. As the trace pressures the cardiac rhythm degenerates into ventricular tachycardia and then ventricular fibrillation. The S tissue perfusion and oxygenation also deteriorates such that pulsatile flow is lost.
Figure lSb represents a contiml~tion of the ventricular fibrillation trace and lack of pulsatile tissue bound flow at timex. The internal defibrillation produces an electrical shock that converts the cardiac rhythm to normal with satisfactory pulsatile tissue blood flow.
Figure lSa illustrates vascular tissue plethysmography with a .simlllt~n~ous and EKG recording of the heart. Therefore, the use of perfusion data to control blood oxygen by preventing cardiac defibrillation is a very important feature of the invention. This feature provides increased assurance that blood oxygen will be m~int~inf~l consistently without disruptions caused by15 hla~L,r~ iate heart fibrillation.
Specific Blood Constituent Monitoring, Control and Reporting System Naturally, it should be understood that, although embodiments using different groupings of sources and detectors have been described for the measurement and control of blood glucose and blood oxygen, the invention is 20 not in any way limited to either a specific number of source/detector groupings or blood constituents, nor is it absolutely n~cess~ry that the sources and detectors be arranged in specific configurations.
Figures 16a is a schematic representation of an infrared sensor 330 and its control module 300 equipped with a commnnic~tion module (not 25 shown) according to a another preferred embodiment of the present invention.
The control module 300 and sensor 330 are implanted into the body subcutaneously just below the skin. The sensor 330 is placed about a vein, an artery or inserted into vascular tissue allowing it to measure and control selected blood constituents. The control module 300 through its co~ tion module 30 can communicate the measured level of blood constituent extracorporeally by W O 97/01986 PCT~US96/11435 means of its communication module to devices such as, but not limited ~o, an external monitoring and warning device, or a telecommunic~tion network.
Figure 16b is a schematic representation of the infrared sensor 330 shown in Figure 16a used to measure and control a medicinal blood constituent such as an antibiotic which is used to treat a localized infection 392 (shown for illustrative purposes). It is to be understood that this invention isnot limited to this embodiment, but may be used to deliver, measure and control any medicinal blood constituent such as, but not limited to, chemotherapy and cardiac medications. In addition, the measured level of medication in the blood can be monitored extracorporeally by a monitoring device or provide to a remote location by means of an external commnnir~tion system adapted to a telecommunication network.
In addition, to controlling blood constituents, the sensor 330 and control device 300 can be used to measure and report blood constituent levels extracorporeally to remote monitoring equipment. For example, blood constituents such as tumor markers including, but not limited to, prostate specific antigen (PSA) for detecting prostate cancer and colon embryonic antigen (CEA) for ~1ett~ctillg colon cancer, can be continuously monitored safely and conveniently without the need and inconvenience of constantly drawing blood and laboratory testing. By measuring these tumor markers on a daily basis, recurrence of tumor will be detected early prior to spread throughout thebody. This can be accomplished by selecting the applopliate optical sensors and detector and operating bandwidths for interaction with each specific blood constituent.
For example and as explained above, blood oxygen can be measured through oxygenated hemoglobin with two pairs of sensors and detectors operating at 660 nanometers and 940 nanometers for detecting oxygenated and reduced hemoglobin.
Implantable Optic Sensor Interface (IOSI) CA 022260l2 l997-l2-30 W O 97/01986 PCTrUS96/11435 Figure 17a is a schematic representation of an infrared sensor 1330 according to another preferred embodiment of the present invention. The sensor 1330 is shaped like a tuning fork and is implanted surgically into vascular tissue. The shape facilitates insertion and retention into vascular rich 5 tissue such as a muscle or vascular membrane as shown in Figures 17b and 17c.
The sensor has two parallel arms 1320 joined at one end and separated from each other by a fixed distance. Each arrn has a pointed tip 1332 at its other end for piercing the tissue. As the sensor is inserted into the tissue a vascular interface 1334 iS formed between the arms 1310,1320. The arms 1310,1320 10 have at least one electrom~gn~tically sensitive array comprising optical sources and detectors for illl-min~ting the vascular interface 1340 and detecting a desired blood constituent described above.
Figure 18a is an illustration of an extracorporeal calibration and communication module 410. Figure 18b is an illustration of a hand held 15 monitor, display and communication unit 450 for use in connection with implantable blood constituent sensors and control modules described above.
The calibration and control module 410 communicates with a commlmi~tion module (not shown) associated with the implanted control module 300, providing calibration data and extracorporeal display and reporting of the measured data produced by the control module 300.
The extracorporeal calibration and communication module 410 communicates calibration data directly to the implanted control module 300 allowing precise calibration of the measurements made by the control module 300 and its sensor 330. Calibration data is produced by the extracorporeal calibration and communication module 410 by commercially available methods such as glucose oxidase reagent strips 420.
The communication module 410 and the control module 300 are equipped with commercially available communic~tion means adapted for inter-corporeal communication.
W O 97/01986 PCTrUS96111435 Figure 18c is a functional block diagram showing the operation of an implantable device according to the invention in communication with the extracorporeal calibration and co,--",~ ic~tion module shown in Figure 18a.
Extraco~poreal Calibration and Communication Modules As already noted, processor/pump module 16 contains an elec-tronic microprocessor and associated electronic CileuiLl,y for generating signals to and processing signals from sensor assembly 14 and for generating control signals to the insulin pump itself. The microprocessor is preferably programm-ed to execute algoliL~ s to perform multispectral correlation, and matched digital b~n(lp~cs filtering to remove low frequency bias and high frequency noise. Such algolill..lls are well-known to those skilled in the art, and need not be described in detail. Moreover, the invention is not limited to any specific algorithm; rather, any algorithms suitable for performing the desired multispectral correlation and filtering functions may be used without departing 15 from the invention. It should also be noted that, while the present inventionprovides accurate glucose level measurements, accurate measurement is not crucial to the control of the insulin pump 16. In a manner similar to the way a house thermostat operates, the pump 16 can be controlled to release a fixed quantity of insulin until the glucose levels falls below a preselected level. Thus, 20 any algorithm capable of such control is within the scope of the invention. The algorithm may also control insulin pump 16 to release a glucagon bolus, (1 mg of glucagon, when blood glucose levels trend below 60 mg/dl will increase the blood glucose level above 150 mg/d~).
Processor/pump module 16 may also contain a telemetry transmit-25 ter to transmit sensor data to an external processor and external insulin pump.Insulin can be injected subcutaneously or into a subcutaneous infusaport for delivery into the peritoneal cavity or into a portal vein.
Processor/pump module 16 may also consist of a telemetry receiver for external calibration. If recalibration is necessary, the system 10 30 may be recalibrated externally by comparison to a weekly or monthly finger CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/1143'~
stick blood glucose measurement, such as, for example, using calorimetric assay of a glucose oxidase/hydrogen peroxide reaction using standard techniques. The absolute glucose amount from the external calibration measurement can then be telemetered to the processor for calibration.
S Alternatively, each source of radiation may consist of multiple discrete bands of light with a unique temporal or frequency modulation, allowing discrimination of the dirrelenl spectral bands.
Alternatively to providing a narrow band filter for each detector, the different spectral bands from the sources are each modulated in a unique temporal or frequency fashion, allowing for discrimination of the different spectral regions and obviating the need for narrow band filters.
In another embodiment, source 310 a (or 310 b, 310 C, or 310 d) may consist of multiple LEDs or multiple laser diodes, each of a different wavelength spaced identically collinear or spaced very closely so that each wavelength has substantially the identical optical path and interacts with substantially identical tissue. The detector 320 a, b, c, or d detects light from each individual wavelength from source 320 a, b, c, or d, respectively.
The processor discrimin~ s amongst the dirr~l~llt wavelengths by having each wavelength pulse at a different frequency or at a different time. Asthe processor can discriminate amongst the dirrelcl~t wavelengths by either different frequency or temporal information, narrow wavelength filters 46 a. 48 a, and 50 a are unnecessary in this embodiment. Multiple sources and multiple detectors provide re~ n-l~nry or alternatively the ability to measure different chemical species, although in many cases a single source and detector is adequate. The operation of the sensor is otherwise the same as described in the previous embodiment.
Fourier Transforrn Infrared Spectroscopy (FTIR) Analysis Using commercially available Fourier transform infrared spectroscopy (FTIR) analysis, it is possible to correlate the sensor output datawith blood glucose levels, blood fatty acid levels, and blood amino acid levels.
CA 022260l2 l997-l2-30 W O 97/01986 PCT~US96/11435 The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as inrlie.~ting the scope of the invention.
Claims (89)
1. An implantable device for sensing in vivo the level of at least one blood constituent in mammalian vascular tissue, comprising:
at least one implantable source of radiation from infrared through visible light, arranged to direct said radiation at said tissue, said radiation being affected directly by interaction with said tissue, and a plurality of implantable detectors, each having associated with it a filter transparent to a discrete narrow band of radiation, each detector providing an output signal representative of detected radiation in said narrow band, the detectors being located with respect to the tissue to receive said radiation affected directly by interaction with said tissue.
at least one implantable source of radiation from infrared through visible light, arranged to direct said radiation at said tissue, said radiation being affected directly by interaction with said tissue, and a plurality of implantable detectors, each having associated with it a filter transparent to a discrete narrow band of radiation, each detector providing an output signal representative of detected radiation in said narrow band, the detectors being located with respect to the tissue to receive said radiation affected directly by interaction with said tissue.
2. An implantable device for sensing in vivo the level of at least one blood constituent in mammalian vascular tissue according to claim 1, further comprising a channel having an internal circumference around which are arranged said source and said detectors, said channel being dimensioned to receive a blood vessel therein and to locate said vessel in proximity to said source and detectors.
3. The implantable device according to claim 1, further comprising a first half and a second half, one half supporting said at least one source and the other half supporting at least one of said plurality of detectors, said halves being spaced apart and defining a gap therebetween for receiving said vascular tissue therein and locating said tissue in proximity to said source and detectors.
4. The implantable device according to claim 3, further comprising said halves being separate from one another and moving reciprocally toward and away from each other for varying the size of said gap.
5. An implantable device for sensing in vivo the level of at least one blood constituent in mammalian vascular tissue according to claim 4, further comprising an adjustable fastener for adjustably fastening said halves together and for adjustably varying the size of said gap.
6. The implantable device according to claim 5, wherein the adjustable fastener comprises a rotatable screw in one of said halves and a threaded bore receiving said screw in the other of said halves.
7. The implantable device according to claim 1, wherein said at least one source and said plurality of detectors are arranged in a linear array, at least one of said plurality of detectors being located opposite said source and spaced therefrom by a distance sufficient to receive said tissue between said source and said detector.
8. The implantable device according to claim 1, wherein said at least one source and said plurality of detectors are arranged in a planar array, at least one of said plurality of detectors being located opposite said source and spaced therefrom by a distance sufficient to receive said tissue between said source and said detector.
9. An implantable device for sensing in vivo the level of at least one blood constituent in mammalian vascular tissue according to claim 1, wherein at least one detector of said plurality of detectors is located opposite said source and at least one detector of said plurality of detectors is located next to said source.
10. The implantable device according to claim 1, wherein at least one of said plurality of detectors is located to detect radiation scattered by said tissue.
11. The implantable device according to claim 1, wherein at least one of said plurality of detectors is located to detect radiation transmitted through said tissue.
12. The implantable device according to claim 1, wherein at least one of said plurality of detectors is located to detect radiation reflected by said tissue.
13. The implantable device according to claim 1, wherein at least one of said plurality of detectors is located to detect radiation scattered by said tissue and at least one of said plurality of detectors is located to detect radiation transmitted through said tissue.
14. The implantable device according to claim 1, wherein at least one of said plurality of detectors is located to detect radiation scattered by said tissue, at least one of said plurality of detectors is located to detect radiation transmitted by said tissue, and at least one of said plurality of detectors is arranged to detect radiation reflected by said tissue.
15. An implantable device for sensing in vivo the level of at least one blood constituent in mammalian vascular tissue according to claim 1, wherein at least one optical fiber is used in conjunction with at least a selected one of said source and detectors for conveying said radiation between said selected one of said source and detectors and said tissue.
16. The implantable device according to claim 1, further comprising a communication means responsive to said processor module for communicating said control signal representative of the level of said blood constituent to a receiving device.
17. The implantable device according to claim 16, wherein said blood constituent is selected from a group consisting of glucose, oxygen, hemoglobin medicinal therapies, and tumor markers.
18. A device for measuring and controlling the level of blood glucose in a mammal, comprising:
an implantable infrared source and sensor module for directing infrared radiation through vascular tissue and for sensing the infrared radiation after it has interacted directly with the tissue and generating an output signal representative of the direct interaction of infrared radiation with the tissue, a processor module responsive to the output signal from the infrared source and sensor module for performing spectral analysis of the output signal and deriving therefrom a control signal representative of the level of said blood constituent, and an insulin pump for dispensing doses of insulin in response to the control signal.
an implantable infrared source and sensor module for directing infrared radiation through vascular tissue and for sensing the infrared radiation after it has interacted directly with the tissue and generating an output signal representative of the direct interaction of infrared radiation with the tissue, a processor module responsive to the output signal from the infrared source and sensor module for performing spectral analysis of the output signal and deriving therefrom a control signal representative of the level of said blood constituent, and an insulin pump for dispensing doses of insulin in response to the control signal.
19. The device for measuring and controlling the level of blood glucose in a mammal according to claim 18, wherein the insulin pump is external to the body of the mammal.
20. The device for measuring and controlling the level of blood glucose in a mammal according to claim 18, wherein the insulin pump is implantable within the body of the mammal.
21. The device for measuring and controlling the level of blood glucose in a mammal according to claim 18, wherein the source and sensor module comprises at least one source of radiation from infrared through visible light, arranged to direct said radiation at said tissue, said radiation being affected by interaction with said tissue, and a plurality of detectors, each having associated with it a filter transparent to a discrete narrow band of radiation, each detector providing an output signal representative of detected radiation in said narrow band, the detectors being located with respect to the tissue to receive radiation from said source affected by said tissue.
22. The device for measuring and controlling the level of blood glucose in a mammal according to claim 18, wherein the source and sensor module comprises at least one source of radiation for emitting at least one selected band of radiation from infrared through visible light at said blood in said tissue, said radiation being affected by interaction with said tissue, and at least one detector adapted to receive said at least one selected band of affected radiation, each detector providing an output signal representative of said affected radiation.
23. The device for measuring and controlling the level of blood glucose in a mammal according to claim 18, further comprising a communication means responsible to said processor module for communicating said control signal representative of the level of said blood glucose to a receiving device.
24. The device for measuring and controlling the level of blood glucose in a mammal according to claim 23, further comprising a calibration system responsive to said communication means and said processor module for receiving calibration signals from another device for calibrating said signal representative of the level of said blood glucose.
25. A device for sensing In-vivo the level of at least one constituent of blood within mammalian vascular tissue, comprising at least one implantable source of radiation from infrared through visible light, arranged to direct said radiation at blood within said tissue and being located out of direct contact with said blood, said radiation being affected by interaction with said blood, at least one implantable detector located out of direct contact with said blood and being located with respect to the tissue to receive radiation affected by interaction with said blood, means associated with said source and said detector for deriving from said detector at least one output signal containing information within selected bands of frequencies from infrared through visible light, and a processor for processing said signal to derive information about the level of said blood constituent.
26. The device according to claim 25, wherein said means associated with said source and said detector comprises a filter transparent to at least two discrete narrow bands of radiation.
27. The device according to claim 25, further comprising a channel having an internal circumference around which are arranged said source and said detector, said channel being dimensioned to receive a blood vessel therein and to locate said vessel in proximity to said source and detectors.
28. The device according to claim 25, further comprising a first half and a second half, one half supporting said at least one source and the other half supporting said at least one detector, said halves being spaced apart and defining a gap therebetween for receiving said vascular tissue therein and locating said tissue in proximity to said source and detectors.
29. The device according to claim 27, further comprising said halves being separate from one another and movable reciprocally toward and away from each other for varying the size of said gap.
30. The device according to claim 29, further comprising an adjustable fastener for adjustably fastening said halves together for adjustably varying the size of said gap.
31. The device according to claim 30, wherein the adjustable fastener comprises a rotatable screw in one of said halves and a threaded bore receiving said screw in the other of said halves.
32. The device according to claim 25, wherein said at least one detector is located opposite said source and spaced therefrom by a distance sufficient to receive said tissue between said source and said detector.
33. The device according to claim 25, further comprising a plurality of detectors wherein at least one of said detectors is located opposite said source and at least one of said detectors is located next to said source.
34. The device according to claim 33, wherein at least one of said plurality of detectors is located to detect radiation scattered by said blood.
35. The device according to claim 33, wherein at least one of said plurality of detectors is located to detect radiation transmitted through said blood.
36. The device according to claim 33, wherein at least one of said plurality of detectors is located to detect radiation reflected by said blood.
37. The device according to claim 33, wherein at least one of said plurality of detectors is located to detect radiation scattered by said blood and at least one of said plurality of detectors is located to detect radiation transmitted through said blood.
38. The device according to claim 33, wherein at least one of said plurality of detectors is located to detect radiation scattered by said blood, at least one of said plurality of detectors is located to detect radiation transmitted by said blood, and at least one of said plurality of detectors is arranged to detect radiation reflected by said blood.
39. The device according to claim 25, wherein at least one optical fiber is used in conjunction with at least a selected one of said source ant detector for conveying said radiation between said selected one of said source and detector and said tissue.
40. The device according to claim 25, further comprising a telemetry transmitter for transmitting said information about the level of said blood constituent to an external device.
41. The device according to claim 25, further comprising a telemetry receiver for receiving signals from an external device.
42. The device according to claim 41, wherein said signals from an external device are calibration signals.
43. The device according to claim 25, further comprising a telemetry transmitter for transmitting said information about the level of said blood constituent to an external device and a telemetry receiver for receiving signals from said external device.
44. A device for measuring and controlling the level of blood glucose in a mammal, comprising an implantable infrared source and sensor module for directing infrared radiation through vascular tissue and for sensing the infrared radiation after it has passed through the tissue and through blood in said tissue and generating an output signal representative of the sensed infrared radiation, a processor module responsive to the output signal from the infrared source and sensor module for performing spectral analysis of the output signal and deriving therefrom a control signal representative of the level of said blood glucose, and an insulin pump for dispensing doses of insulin in response to the control signal.
45. The device according to claim 44, wherein the insulin pump is external to the body of the mammal.
46. The device according to claim 44, wherein the insulin pump is implantable within the body of the mammal.
47. The device according to claim 44, wherein the source and sensor module comprises at least one implantable source of radiation from infrared through visible light, arranged to direct said radiation at blood within said tissue and being located out of direct contact with said blood, said radiation being affected by interaction with said blood, at least one implantable detector located out of direct contact with said blood and being located with respect to the tissue to receive radiation affected by interaction with said blood, means associated with said source and said detector for deriving from said detector at least one output signal containing information within selected bands of frequencies from infrared through visible light, and a processor for processing said signal to derive information about the level of said blood glucose.
48. A method of performing In-vivo optical spectroscopy analysis of blood in a mammal, comprising the steps of implanting in vascular tissue and out of direct contact with blood to be analyzed a source of radiation having wavelengths within a preselected range of wavelengths and positioning said source to direct said radiation at said blood, said radiation being affected by interaction with said blood, implanting a detector responsive to said radiation out of direct contact with said blood and positioning said detector to receive radiation affected by said blood, obtaining from said detector an information-containing output signal, and analyzing the information contained in said output signal and deriving therefrom information about levels of at least one blood constituent within said blood.
49. The method according to claim 48, wherein the step of analyzing the information contained in said output signal includes Fourier transform infrared spectroscopy.
50. The method according to claim 49, further comprising performing said Fourier transform infrared spectroscopy on portions of said radiation affected by said blood within two separate narrow bands of wavelengths within said preselected range.
51. The method according to claim 48, further comprising the step of limiting radiation directed at said blood to two separate narrow bands of wavelengths within said preselected range.
52. The method according to claim 51, wherein said step of limiting radiation directed at said blood comprises optically filtering said radiation.
53. The method according to claim 49, further comprising the step of limiting radiation received by said detector to two separate narrow bands of wavelengths within said preselected range.
54. The method according to claim 53, wherein said step of limiting radiation received by said detector comprises optically filtering said radiation.
55. A device for measuring and controlling the level of blood oxygen in a mammal, comprising an implantable infrared source and sensor module for directing infrared radiation through vascular tissue and for sensing the infrared radiation after it has passed through the tissue and generating an output signal representative of the sensed infrared radiation, a processor module responsive to the output signal from the infrared source and sensor module for performing spectral analysis of the output signal and deriving therefrom a control signal representative of the level of said blood oxygen, anda control device for controlling the level of said blood oxygen in response to said control signal.
56. The device for measuring and controlling the level of blood oxygen in a mammal according to claim 55, wherein the control device is a pacemaker.
57. The device for measuring and controlling the level of blood oxygen in a mammal according to claim 55, wherein the control device is a defibrillator.
58. The device for measuring and controlling the level of blood oxygen in a mammal according to claim 55, wherein the source and sensor module comprises at least one source of radiation from infrared through visible light, arranged to direct said radiation at said tissue, said radiation being affected by interaction with said tissue, and a plurality of detectors, each having associated with it a filter transparent to a discrete narrow band of radiation, each detector providing an output signal representative of detected radiation in said narrow band, the detectors being located with respect to the tissue to receive radiation from said source affected by said tissue.
59. The device for measuring and controlling the level of blood oxygen in a mammal according to claim 55, wherein the source and sensor module comprises at least one source of radiation for emitting at least one selected band of radiation from infrared through visible light at said blood in said tissue, said radiation being affected by interaction with said tissue, and at least one detector adapted to receive said at least one selected band of affected radiation, each detector providing an output signal representative of said affected radiation.
60. The device for measuring and controlling the level of blood oxygen in a mammal according to claim 55, further comprising a communication means responsive to said processor module for communicating said control signal representative of the level of said blood oxygen to a receiving device.
61. The device for measuring and controlling the level of blood oxygen in a mammal according to claim 60, wherein said receiving device is an extracorporeal calibration module responsive to said control signal received from said communication means for communicating calibration signals to said processor module for calibrating said signal representative of the level of said blood oxygen.
62. The device for measuring and controlling the level of blood oxygen in a mammal according to claim 55, wherein the implanted source, sensor, and processor module comprises a pulse oximeter.
63. A device for measuring and controlling the level of medicinal blood constituent in a mammal, comprising an implantable infrared source and sensor module for directing infrared radiation through vascular tissue and for sensing the infrared after it has passed through the tissue and generating all output signal representative of the sensed infrared radiation, a processor module responsive to the output signal from the infrared source and sensor module for performing spectral analysis of the output signal and deriving therefrom a control signal representative of the level of said medicinal blood constituent, and a control device for controlling said medicinal blood constituent in response tosaid control signal.
64. The device according to claim 63, wherein said control device is a pump for dispensing doses of said medicinal blood constituent in response to the control signal.
65. The device according to claim 64, wherein the pump is external to the body of the mammal.
66. The device according to claim 63, wherein the pump is implantable within the body of the mammal.
67. The device according to claim 64, wherein the source and sensor module comprises at least one source of radiation from infrared through visible light arranged to direct said radiation at said tissue, said radiation being affected by interaction with said tissue, and a plurality of detectors, each having associated with it a filter transparent to a discrete narrow band of radiation, each detector providing an output signal representative of detected radiation in said narrow band, the detectors being located with respect to the tissue to receive radiation from said source affected by said tissue.
68. The device according to claim 63, wherein the source and sensor module comprises at least one source of radiation for emitting at least one selected band of radiation from infrared through visible light at said blood in said tissue, said radiation being affected by interaction with said tissue, and at least one detector adapted to receive said at least one selected band of affected radiation, each detector providing an output signal representative of said affected radiation.
69. The device according to claim 64, further comprising a communication means responsive to said processor module for communicating said control signal representative of the level of said medicinal blood constituent to a receiving device.
70. The device according to claim 69, wherein said receiving device is an extracorporeal calibration module responsive to said control signal from said communication means for communicating calibration signals for calibrating said signal representative of the level of said medicinal blood constituent.
71. A device for sensing In-vivo the level of at least one constituent of blood within mammalian vascular tissue, comprising:
an implantable source of radiation emitting radiation in at least two selected bands between infrared and visible light, said source arranged to direct emitted radiation at blood within said tissue and being located out of direct contact with said blood, said emitted radiation being affected by interaction with said blood, an implantable detector located out of direct contact with said blood and being located with respect to said tissue to receive radiation affected by interaction with said blood and generate an output signal in response to said affected radiation, a communication means responsive to said detector output signal for communicating information in said output signal associated with said affected radiation, and a processor in communication with said communication means for processing information communicated to the processor by said communication means to derive therefrom information about the level of said blood constituent.
an implantable source of radiation emitting radiation in at least two selected bands between infrared and visible light, said source arranged to direct emitted radiation at blood within said tissue and being located out of direct contact with said blood, said emitted radiation being affected by interaction with said blood, an implantable detector located out of direct contact with said blood and being located with respect to said tissue to receive radiation affected by interaction with said blood and generate an output signal in response to said affected radiation, a communication means responsive to said detector output signal for communicating information in said output signal associated with said affected radiation, and a processor in communication with said communication means for processing information communicated to the processor by said communication means to derive therefrom information about the level of said blood constituent.
72. The implantable device according to claim 71, further comprising a channel having a circular circumference around which is arranged said source and detector, said channel being dimensioned to receive a blood vessel therein and located such that said vessel is in proximity to said source and detectors, and the means for discriminating said signal by use of different spectral bands.
73. The implantable device according to claim 71, wherein said vascular tissue is a membrane and said emitted radiation from said source interacts with said membrane, said radiation being gathered by said detector.
74. The implantable device according to claim 71, wherein said vascular tissue is a muscle and said emitted radiation from said source interacts with said muscle, said radiation being gathered by the detector.
75. The implantable device according to claim 71, wherein said bands of radiation comprise a spectra and means to discriminate said spectra, said means to discriminate spectra comprising modulation of said radiation as a selected function of time, and said processor having knowledge of said modulation.
76. The implantable device according to claim 71, wherein said bands of radiation comprise a spectra and means to discriminate said spectra, said means to discriminate spectra comprising modulation of said radiation at selected frequencies, and said processor having knowledge of said modulation.
77. The implantable device according to claim 71, which measures degrees of oxygen saturation in hemoglobin.
78. An implantable device according to claim 71, wherein said source comprises at least one LED of selected wavelengths.
79. The device according to claim 77, wherein said output signal is communicated to a pacemaker to regulate heart rate and time of atrial and ventricular contractions in accordance with a predetermined level blood oxygen saturation.
80. A device according to claim 77, wherein said output signal is communicated to an implantable defibrillator to include tissue perfusion and oxygenation in the algorithm prior to defibrillation.
81. The implantable device according to claim 71, wherein said processor is located extracaporeally.
82. The implantable device according to claim 71, wherein said output signal is periodically calibrated according to a extracorporeal data acquired by measurement of a blood constituent by other known technique.
83. The implantable device according to claim 71, wherein said radiation source consists of at least two laser diodes.
84. The implantable sensor according to claim 82, wherein said blood constituent is at least blood glucose.
85. The implantable sensor according to claim 82, further comprising an audible alarm when a blood glucose level is determined by said processor to be in the hypoglycemic range.
86. The device according to claim 71, further comprising an insulin pump.
87. The device according to claim 86, wherein said insulin pump is located extracaporeally.
88. The device according to claim 86, wherein said insulin pump is implanted internally.
89. The device according to claim 71, wherein said selected bands of radiation are substantially colinear to one another and interacts with substantially the same vascular tissue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/500,388 US5995860A (en) | 1995-07-06 | 1995-07-06 | Implantable sensor and system for measurement and control of blood constituent levels |
US08/500,388 | 1995-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2226012A1 true CA2226012A1 (en) | 1997-01-23 |
Family
ID=23989201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002226012A Abandoned CA2226012A1 (en) | 1995-07-06 | 1996-07-08 | Implantable sensor and system for measurement and control of blood constituent levels |
Country Status (7)
Country | Link |
---|---|
US (2) | US5995860A (en) |
EP (1) | EP0840567A4 (en) |
JP (1) | JPH11508792A (en) |
AU (1) | AU6455696A (en) |
CA (1) | CA2226012A1 (en) |
IL (1) | IL122747A (en) |
WO (1) | WO1997001986A1 (en) |
Families Citing this family (711)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593852A (en) * | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
JPH04278450A (en) * | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US7167748B2 (en) | 1996-01-08 | 2007-01-23 | Impulse Dynamics Nv | Electrical muscle controller |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
JP4175662B2 (en) | 1996-01-08 | 2008-11-05 | インパルス ダイナミクス エヌ.ヴイ. | Electric muscle control device |
US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US6790178B1 (en) | 1999-09-24 | 2004-09-14 | Healthetech, Inc. | Physiological monitor and associated computation, display and communication unit |
US6106475A (en) * | 1996-06-26 | 2000-08-22 | Tobo, Llc | Device for use in temporary insertion of a sensor within a patient's body |
JP2000515778A (en) * | 1996-07-08 | 2000-11-28 | アニマス コーポレーシヨン | Implantable sensors and systems for in vivo measurement and control of body fluid component levels |
US6544193B2 (en) * | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US7885697B2 (en) | 2004-07-13 | 2011-02-08 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7657297B2 (en) * | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US6558321B1 (en) | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US6093167A (en) * | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
EP1029229A1 (en) | 1997-09-30 | 2000-08-23 | M- Biotech, Inc. | Biosensor |
FI107080B (en) * | 1997-10-27 | 2001-05-31 | Nokia Mobile Phones Ltd | measuring device |
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6140740A (en) | 1997-12-30 | 2000-10-31 | Remon Medical Technologies, Ltd. | Piezoelectric transducer |
US6486588B2 (en) | 1997-12-30 | 2002-11-26 | Remon Medical Technologies Ltd | Acoustic biosensor for monitoring physiological conditions in a body implantation site |
US6475170B1 (en) | 1997-12-30 | 2002-11-05 | Remon Medical Technologies Ltd | Acoustic biosensor for monitoring physiological conditions in a body implantation site |
US6431175B1 (en) | 1997-12-30 | 2002-08-13 | Remon Medical Technologies Ltd. | System and method for directing and monitoring radiation |
US6289229B1 (en) * | 1998-01-20 | 2001-09-11 | Scimed Life Systems, Inc. | Readable probe array for in vivo use |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
PT1077636E (en) * | 1998-05-13 | 2004-06-30 | Cygnus Therapeutic Systems | SIGNAL PROCESSING FOR PHYSIOLOGICAL ANALYZES MEDICATION |
US6554798B1 (en) * | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6330464B1 (en) | 1998-08-26 | 2001-12-11 | Sensors For Medicine & Science | Optical-based sensing devices |
US6949081B1 (en) * | 1998-08-26 | 2005-09-27 | Non-Invasive Technology, Inc. | Sensing and interactive drug delivery |
US6415188B1 (en) * | 1998-12-23 | 2002-07-02 | Dennis Sunga Fernandez | Method and apparatus for multi-sensor processing |
US6106477A (en) * | 1998-12-28 | 2000-08-22 | Medtronic, Inc. | Chronically implantable blood vessel cuff with sensor |
US6561978B1 (en) | 1999-02-12 | 2003-05-13 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
US9101765B2 (en) * | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US8346363B2 (en) * | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
US8103325B2 (en) * | 1999-03-08 | 2012-01-24 | Tyco Healthcare Group Lp | Method and circuit for storing and providing historical physiological data |
US6514689B2 (en) | 1999-05-11 | 2003-02-04 | M-Biotech, Inc. | Hydrogel biosensor |
US6475750B1 (en) | 1999-05-11 | 2002-11-05 | M-Biotech, Inc. | Glucose biosensor |
US6721594B2 (en) * | 1999-08-24 | 2004-04-13 | Cardiac Pacemakers, Inc. | Arrythmia display |
KR100771711B1 (en) * | 1999-08-27 | 2007-10-30 | 엠-바이오테크, 인코포레이티드 | Glucose biosensor |
US20030109790A1 (en) * | 2001-12-06 | 2003-06-12 | Medtronic Physio-Control Manufacturing Corp. | Pulse detection method and apparatus using patient impedance |
US20040039419A1 (en) * | 1999-09-30 | 2004-02-26 | Stickney Ronald E. | Apparatus, software, and methods for cardiac pulse detection using a piezoelectric sensor |
US9248306B2 (en) | 1999-09-30 | 2016-02-02 | Physio-Control, Inc. | Pulse detection apparatus, software, and methods using patient physiological signals |
US6440082B1 (en) * | 1999-09-30 | 2002-08-27 | Medtronic Physio-Control Manufacturing Corp. | Method and apparatus for using heart sounds to determine the presence of a pulse |
US6738661B1 (en) | 1999-10-22 | 2004-05-18 | Biosynergetics, Inc. | Apparatus and methods for the controllable modification of compound concentration in a tube |
US6438397B1 (en) * | 1999-10-28 | 2002-08-20 | Gerald G. Bosquet | Method and apparatus for analyte detection using intradermally implanted skin port |
US6409663B1 (en) * | 1999-11-12 | 2002-06-25 | Steven F. Mercereau | Apparatus and method for monitoring the vital status of biological materials |
US6277078B1 (en) | 1999-11-19 | 2001-08-21 | Remon Medical Technologies, Ltd. | System and method for monitoring a parameter associated with the performance of a heart |
DE10011284B4 (en) * | 2000-03-08 | 2007-06-28 | Disetronic Licensing Ag | Apparatus for in vivo measurement of the concentration of an ingredient of a body fluid |
US6592519B1 (en) * | 2000-04-28 | 2003-07-15 | Medtronic, Inc. | Smart microfluidic device with universal coating |
US6599281B1 (en) * | 2000-05-03 | 2003-07-29 | Aspect Medical Systems, Inc. | System and method for adaptive drug delivery |
WO2001088534A2 (en) * | 2000-05-16 | 2001-11-22 | Cygnus, Inc. | Methods for improving performance and reliability of biosensors |
US6482158B2 (en) | 2000-05-19 | 2002-11-19 | Healthetech, Inc. | System and method of ultrasonic mammography |
US6459917B1 (en) * | 2000-05-22 | 2002-10-01 | Ashok Gowda | Apparatus for access to interstitial fluid, blood, or blood plasma components |
US7978329B2 (en) * | 2000-08-02 | 2011-07-12 | Honeywell International Inc. | Portable scattering and fluorescence cytometer |
US7630063B2 (en) * | 2000-08-02 | 2009-12-08 | Honeywell International Inc. | Miniaturized cytometer for detecting multiple species in a sample |
US7553280B2 (en) * | 2000-06-29 | 2009-06-30 | Sensors For Medicine And Science, Inc. | Implanted sensor processing system and method |
US6606510B2 (en) * | 2000-08-31 | 2003-08-12 | Mallinckrodt Inc. | Oximeter sensor with digital memory encoding patient data |
US6591123B2 (en) * | 2000-08-31 | 2003-07-08 | Mallinckrodt Inc. | Oximeter sensor with digital memory recording sensor data |
US6628975B1 (en) | 2000-08-31 | 2003-09-30 | Mallinckrodt Inc. | Oximeter sensor with digital memory storing data |
US6600940B1 (en) | 2000-08-31 | 2003-07-29 | Mallinckrodt Inc. | Oximeter sensor with digital memory |
WO2002024065A1 (en) * | 2000-09-22 | 2002-03-28 | Knobbe, Lim & Buckingham | Method and apparatus for real-time estimation and control of pysiological parameters |
US6819950B2 (en) * | 2000-10-06 | 2004-11-16 | Alexander K. Mills | Method for noninvasive continuous determination of physiologic characteristics |
US6607387B2 (en) | 2000-10-30 | 2003-08-19 | Healthetech, Inc. | Sensor system for diagnosing dental conditions |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
DE10057832C1 (en) | 2000-11-21 | 2002-02-21 | Hartmann Paul Ag | Blood analysis device has syringe mounted in casing, annular mounting carrying needles mounted behind test strip and being swiveled so that needle can be pushed through strip and aperture in casing to take blood sample |
EP1339456A2 (en) | 2000-12-06 | 2003-09-03 | Resuscitek, Inc. | A medical device to restore functions of a fibrillating heart by cardiac therapies remotely directed by a physician via two-way communication |
US8548576B2 (en) | 2000-12-15 | 2013-10-01 | Cardiac Pacemakers, Inc. | System and method for correlation of patient health information and implant device data |
US6665558B2 (en) | 2000-12-15 | 2003-12-16 | Cardiac Pacemakers, Inc. | System and method for correlation of patient health information and implant device data |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US20030060695A1 (en) * | 2001-03-07 | 2003-03-27 | Connelly Patrick R. | Implantable artificial organ devices |
US7244232B2 (en) * | 2001-03-07 | 2007-07-17 | Biomed Solutions, Llc | Process for identifying cancerous and/or metastatic cells of a living organism |
US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
US7521019B2 (en) * | 2001-04-11 | 2009-04-21 | Lifescan, Inc. | Sensor device and methods for manufacture |
US6454710B1 (en) | 2001-04-11 | 2002-09-24 | Motorola, Inc. | Devices and methods for monitoring an analyte |
US6694158B2 (en) | 2001-04-11 | 2004-02-17 | Motorola, Inc. | System using a portable detection device for detection of an analyte through body tissue |
US6379622B1 (en) | 2001-04-11 | 2002-04-30 | Motorola, Inc. | Sensor incorporating a quantum dot as a reference |
MXPA03010064A (en) * | 2001-05-04 | 2004-03-09 | Sensors For Med & Science Inc | Electro-optical sensing device with reference channel. |
US6468263B1 (en) * | 2001-05-21 | 2002-10-22 | Angel Medical Systems, Inc. | Implantable responsive system for sensing and treating acute myocardial infarction and for treating stroke |
US6731984B2 (en) | 2001-06-07 | 2004-05-04 | Medtronic, Inc. | Method for providing a therapy to a patient involving modifying the therapy after detecting an onset of sleep in the patient, and implantable medical device embodying same |
US7206635B2 (en) * | 2001-06-07 | 2007-04-17 | Medtronic, Inc. | Method and apparatus for modifying delivery of a therapy in response to onset of sleep |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
EP1404233B1 (en) | 2001-06-12 | 2009-12-02 | Pelikan Technologies Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US7682318B2 (en) | 2001-06-12 | 2010-03-23 | Pelikan Technologies, Inc. | Blood sampling apparatus and method |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
EP1404235A4 (en) | 2001-06-12 | 2008-08-20 | Pelikan Technologies Inc | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
JP4149911B2 (en) | 2001-06-12 | 2008-09-17 | ペリカン テクノロジーズ インコーポレイテッド | Electric lancet actuator |
ATE497731T1 (en) | 2001-06-12 | 2011-02-15 | Pelikan Technologies Inc | DEVICE FOR INCREASING THE SUCCESS RATE OF BLOOD YIELD OBTAINED BY A FINGER PICK |
WO2003000127A2 (en) | 2001-06-22 | 2003-01-03 | Cygnus, Inc. | Method for improving the performance of an analyte monitoring system |
DE10132612A1 (en) * | 2001-07-04 | 2003-01-16 | Biotronik Mess & Therapieg | Electrical therapy device for regulating cardiovascular capacity, has electrostimulation device that delivers signals suitable for defibrillation of heart based on peripheral hemodynamic undersupply |
US20030208113A1 (en) * | 2001-07-18 | 2003-11-06 | Mault James R | Closed loop glycemic index system |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
DE10142019A1 (en) * | 2001-08-28 | 2003-03-20 | Philips Corp Intellectual Pty | Circuit arrangement for demodulating signals |
US8506550B2 (en) * | 2001-09-07 | 2013-08-13 | Medtronic Minimed, Inc. | Method and system for non-vascular sensor implantation |
US6671554B2 (en) | 2001-09-07 | 2003-12-30 | Medtronic Minimed, Inc. | Electronic lead for a medical implant device, method of making same, and method and apparatus for inserting same |
US7323142B2 (en) * | 2001-09-07 | 2008-01-29 | Medtronic Minimed, Inc. | Sensor substrate and method of fabricating same |
US6740072B2 (en) * | 2001-09-07 | 2004-05-25 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
US7025760B2 (en) * | 2001-09-07 | 2006-04-11 | Medtronic Minimed, Inc. | Method and system for non-vascular sensor implantation |
US8152789B2 (en) * | 2001-10-23 | 2012-04-10 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
US6915147B2 (en) | 2001-09-07 | 2005-07-05 | Medtronic Minimed, Inc. | Sensing apparatus and process |
US6827702B2 (en) | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
US6970741B1 (en) | 2001-09-18 | 2005-11-29 | Advanced Bionics Corporation | Monitoring, preventing, and treating rejection of transplanted organs |
GB2379978B (en) * | 2001-09-21 | 2005-03-23 | Soo Bong Choi | Portable automatic insulin syringe device with blood sugar measuring function |
US6939310B2 (en) * | 2001-10-10 | 2005-09-06 | Lifescan, Inc. | Devices for physiological fluid sampling and methods of using the same |
US6575912B1 (en) * | 2001-10-16 | 2003-06-10 | Pacesetter, Inc. | Assessing heart failure status using morphology of a signal representative of arterial pulse pressure |
US6809507B2 (en) | 2001-10-23 | 2004-10-26 | Medtronic Minimed, Inc. | Implantable sensor electrodes and electronic circuitry |
EP1438029A4 (en) * | 2001-10-23 | 2009-01-14 | Medtronic Minimed Inc | Method and system for non-vascular sensor implantation |
US7192766B2 (en) * | 2001-10-23 | 2007-03-20 | Medtronic Minimed, Inc. | Sensor containing molded solidified protein |
US8465466B2 (en) | 2001-10-23 | 2013-06-18 | Medtronic Minimed, Inc | Method and system for non-vascular sensor implantation |
US7308303B2 (en) | 2001-11-01 | 2007-12-11 | Advanced Bionics Corporation | Thrombolysis and chronic anticoagulation therapy |
WO2003047426A1 (en) * | 2001-12-03 | 2003-06-12 | Eli Lilly And Company | Medication delivery device having communication capability with glucose monitor |
EP1455641B1 (en) * | 2001-12-17 | 2008-09-03 | Danfoss A/S | Method and device for monitoring analyte concentration by optical detection |
US20040137547A1 (en) * | 2001-12-28 | 2004-07-15 | Medtronic Minimed, Inc. | Method for formulating a glucose oxidase enzyme with a desired property or properties and a glucose oxidase enzyme with the desired property |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US10022078B2 (en) | 2004-07-13 | 2018-07-17 | Dexcom, Inc. | Analyte sensor |
US7613491B2 (en) | 2002-05-22 | 2009-11-03 | Dexcom, Inc. | Silicone based membranes for use in implantable glucose sensors |
US8364229B2 (en) | 2003-07-25 | 2013-01-29 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US7108680B2 (en) * | 2002-03-06 | 2006-09-19 | Codman & Shurtleff, Inc. | Closed-loop drug delivery system |
US20030235817A1 (en) | 2002-03-22 | 2003-12-25 | Miroslaw Bartkowiak | Microprocessors, devices, and methods for use in analyte monitoring systems |
US7232429B2 (en) * | 2002-04-08 | 2007-06-19 | Boston Scientific Corporation | Medical devices |
US20070015981A1 (en) * | 2003-08-29 | 2007-01-18 | Benaron David A | Device and methods for the detection of locally-weighted tissue ischemia |
US20080009689A1 (en) * | 2002-04-09 | 2008-01-10 | Benaron David A | Difference-weighted somatic spectroscopy |
US6711426B2 (en) * | 2002-04-09 | 2004-03-23 | Spectros Corporation | Spectroscopy illuminator with improved delivery efficiency for high optical density and reduced thermal load |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7226461B2 (en) | 2002-04-19 | 2007-06-05 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with sterility barrier release |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7481776B2 (en) | 2002-04-19 | 2009-01-27 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7491178B2 (en) | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7076292B2 (en) * | 2002-04-25 | 2006-07-11 | Medtronic, Inc. | Optical communication of neurostimulation-system information |
US6847899B2 (en) | 2002-04-26 | 2005-01-25 | Dean Allgeyer, M.D., Inc. | Device and method for qualitative and quantitative determination of intravenous fluid components |
US7226978B2 (en) | 2002-05-22 | 2007-06-05 | Dexcom, Inc. | Techniques to improve polyurethane membranes for implantable glucose sensors |
US7738935B1 (en) | 2002-07-09 | 2010-06-15 | Pacesetter, Inc. | Methods and devices for reduction of motion-induced noise in pulse oximetry |
US6997879B1 (en) | 2002-07-09 | 2006-02-14 | Pacesetter, Inc. | Methods and devices for reduction of motion-induced noise in optical vascular plethysmography |
US20040014052A1 (en) * | 2002-07-22 | 2004-01-22 | Kurtz Warren H. | Process for regulating gene expression |
CA2493120A1 (en) * | 2002-08-07 | 2004-02-19 | Memry Corporation | Implantable artifical pancreas |
US20040039420A1 (en) * | 2002-08-26 | 2004-02-26 | Medtronic Physio-Control Manufacturing Corp. | Apparatus, software, and methods for cardiac pulse detection using accelerometer data |
US20040116969A1 (en) * | 2002-08-26 | 2004-06-17 | Owen James M. | Pulse detection using patient physiological signals |
US6962580B2 (en) * | 2002-09-17 | 2005-11-08 | Transoma Medical, Inc. | Vascular access port with needle detector |
US7070591B2 (en) * | 2002-09-17 | 2006-07-04 | Transoma Medical, Inc. | Vascular access port with physiological sensor |
US7801596B2 (en) * | 2002-09-20 | 2010-09-21 | Angel Medical Systems, Inc. | Physician's programmer for implantable devices having cardiac diagnostic and patient alerting capabilities |
US7736309B2 (en) | 2002-09-27 | 2010-06-15 | Medtronic Minimed, Inc. | Implantable sensor method and system |
US9740817B1 (en) | 2002-10-18 | 2017-08-22 | Dennis Sunga Fernandez | Apparatus for biological sensing and alerting of pharmaco-genomic mutation |
US7010337B2 (en) * | 2002-10-24 | 2006-03-07 | Furnary Anthony P | Method and apparatus for monitoring blood condition and cardiopulmonary function |
US20030126593A1 (en) * | 2002-11-04 | 2003-07-03 | Mault James R. | Interactive physiological monitoring system |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US7025791B2 (en) * | 2002-12-02 | 2006-04-11 | Gi Dynamics, Inc. | Bariatric sleeve |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
EP1578262A4 (en) | 2002-12-31 | 2007-12-05 | Therasense Inc | Continuous glucose monitoring system and methods of use |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US20040132167A1 (en) * | 2003-01-06 | 2004-07-08 | Peter Rule | Cartridge lance |
US7534207B2 (en) * | 2003-02-07 | 2009-05-19 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Implantable device with sensors for differential monitoring of internal condition |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
WO2004080533A1 (en) | 2003-03-10 | 2004-09-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
EP1615692A2 (en) * | 2003-04-11 | 2006-01-18 | Cardiac Pacemakers, Inc. | Multi-parameter arrhythmia discrimination |
US7218966B2 (en) | 2003-04-11 | 2007-05-15 | Cardiac Pacemakers, Inc. | Multi-parameter arrhythmia discrimination |
US7555335B2 (en) * | 2003-04-11 | 2009-06-30 | Cardiac Pacemakers, Inc. | Biopotential signal source separation using source impedances |
US7117035B2 (en) * | 2003-04-11 | 2006-10-03 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac stimulation system with patient activity sensing |
US7302294B2 (en) | 2003-04-11 | 2007-11-27 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac sensing and stimulation system employing blood sensor |
US7865233B2 (en) * | 2003-04-11 | 2011-01-04 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac signal discrimination employing non-electrophysiologic signal |
EP1618768B1 (en) * | 2003-04-15 | 2013-06-12 | Senseonics, Incorporated | Implantable sensor processing system with integrated printed circuit board antenna |
ES2737835T3 (en) | 2003-04-23 | 2020-01-16 | Valeritas Inc | Hydraulically driven pump for long-term medication administration |
US7463562B2 (en) * | 2003-04-30 | 2008-12-09 | Samsung Electronics Co., Ltd. | Method of recording temporary defect list on write-once recording medium, method of reproducing the temporary defect list, recording and/or reproducing apparatus, and the write-once recording medium |
US6944488B2 (en) * | 2003-04-30 | 2005-09-13 | Medtronic, Inc. | Normalization method for a chronically implanted optical sensor |
US6975892B2 (en) * | 2003-10-21 | 2005-12-13 | Oculir, Inc. | Methods for non-invasive analyte measurement from the conjunctiva |
US6968222B2 (en) * | 2003-05-02 | 2005-11-22 | Oculir, Inc. | Methods and device for non-invasive analyte measurement |
US6958039B2 (en) | 2003-05-02 | 2005-10-25 | Oculir, Inc. | Method and instruments for non-invasive analyte measurement |
US7875293B2 (en) * | 2003-05-21 | 2011-01-25 | Dexcom, Inc. | Biointerface membranes incorporating bioactive agents |
EP1481633B1 (en) * | 2003-05-30 | 2007-05-02 | Siemens Aktiengesellschaft | Apparatus for detecting a substance of metabolism of a living body |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
US7133718B2 (en) * | 2003-06-19 | 2006-11-07 | Medtronic, Inc. | Method and apparatus for temporarily varying a parameter in an implantable medical device |
US20040259270A1 (en) * | 2003-06-19 | 2004-12-23 | Wolf David E. | System, device and method for exciting a sensor and detecting analyte |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
WO2005019795A2 (en) * | 2003-07-25 | 2005-03-03 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
JP4708342B2 (en) | 2003-07-25 | 2011-06-22 | デックスコム・インコーポレーテッド | Oxygen augmentation membrane system for use in implantable devices |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
EP1649260A4 (en) | 2003-07-25 | 2010-07-07 | Dexcom Inc | Electrode systems for electrochemical sensors |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US20100168657A1 (en) | 2003-08-01 | 2010-07-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8626257B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | Analyte sensor |
US7925321B2 (en) | 2003-08-01 | 2011-04-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US6931327B2 (en) | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7189341B2 (en) * | 2003-08-15 | 2007-03-13 | Animas Technologies, Llc | Electrochemical sensor ink compositions, electrodes, and uses thereof |
US8346482B2 (en) * | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US7447533B1 (en) | 2003-09-25 | 2008-11-04 | Pacesetter, Inc. | Implantable electronic medical device having an encapsulated optical transducer |
EP1671096A4 (en) | 2003-09-29 | 2009-09-16 | Pelikan Technologies Inc | Method and apparatus for an improved sample capture device |
US9123077B2 (en) | 2003-10-07 | 2015-09-01 | Hospira, Inc. | Medication management system |
US8065161B2 (en) | 2003-11-13 | 2011-11-22 | Hospira, Inc. | System for maintaining drug information and communicating with medication delivery devices |
WO2005037095A1 (en) | 2003-10-14 | 2005-04-28 | Pelikan Technologies, Inc. | Method and apparatus for a variable user interface |
US20060224057A1 (en) * | 2003-10-21 | 2006-10-05 | Oculir, Inc. | Methods for non-invasive analyte measurement |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
US20050096514A1 (en) * | 2003-11-01 | 2005-05-05 | Medtronic, Inc. | Gastric activity notification |
WO2005044088A2 (en) * | 2003-11-03 | 2005-05-19 | Children's Medical Center Corporation | Continuous analyte monitor and method of using same |
USD902408S1 (en) | 2003-11-05 | 2020-11-17 | Abbott Diabetes Care Inc. | Analyte sensor control unit |
EP1696790B1 (en) * | 2003-11-19 | 2011-11-02 | Entelos, Inc. | Methods for assessing metabolic substrate utilization and effectiveness of a therapy |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8774886B2 (en) | 2006-10-04 | 2014-07-08 | Dexcom, Inc. | Analyte sensor |
US8364230B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
US8425416B2 (en) | 2006-10-04 | 2013-04-23 | Dexcom, Inc. | Analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
EP2239566B1 (en) | 2003-12-05 | 2014-04-23 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8425417B2 (en) | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device |
WO2005057175A2 (en) | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US7286884B2 (en) | 2004-01-16 | 2007-10-23 | Medtronic, Inc. | Implantable lead including sensor |
US9757045B2 (en) * | 2004-01-27 | 2017-09-12 | Universiteit Gent | System and method for adaptive drug delivery |
US7699964B2 (en) * | 2004-02-09 | 2010-04-20 | Abbott Diabetes Care Inc. | Membrane suitable for use in an analyte sensor, analyte sensor, and associated method |
US8165651B2 (en) | 2004-02-09 | 2012-04-24 | Abbott Diabetes Care Inc. | Analyte sensor, and associated system and method employing a catalytic agent |
CA2556331A1 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
US20080009688A1 (en) * | 2004-04-14 | 2008-01-10 | Oculir, Inc. | Methods for non-invasive analyte measurement |
US20060258919A1 (en) * | 2004-04-14 | 2006-11-16 | Oculir, Inc. | Non-Invasive Analyte Measurement Device for Measuring Tears and Other Ocular Elements Using Electromagnetic Radiation and Method of Using the Same |
US7223237B2 (en) * | 2004-04-22 | 2007-05-29 | Pacesetter, Inc. | Implantable biosensor and methods for monitoring cardiac health |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
EP1751546A2 (en) | 2004-05-20 | 2007-02-14 | Albatros Technologies GmbH & Co. KG | Printable hydrogel for biosensors |
US20050261561A1 (en) * | 2004-05-24 | 2005-11-24 | Christopher W. Jones | Blood testing and therapeutic compound delivery system |
WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
EP1810185A4 (en) | 2004-06-04 | 2010-01-06 | Therasense Inc | Diabetes care host-client architecture and data management system |
WO2005120335A2 (en) * | 2004-06-07 | 2005-12-22 | Glucon Inc | Assay apparatus comprising an implanted light source |
US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7909768B1 (en) | 2004-07-19 | 2011-03-22 | Pacesetter, Inc. | Reducing data acquisition, power and processing for hemodynamic signal sampling |
US7324848B1 (en) | 2004-07-19 | 2008-01-29 | Pacesetter, Inc. | Reducing data acquisition, power and processing for photoplethysmography and other applications |
US7828711B2 (en) * | 2004-08-16 | 2010-11-09 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular growth and regeneration using ventricular assist device |
US7522786B2 (en) * | 2005-12-22 | 2009-04-21 | Palo Alto Research Center Incorporated | Transmitting light with photon energy information |
US9183705B2 (en) | 2004-09-10 | 2015-11-10 | Bally Gaming, Inc. | Methods of playing wagering games |
US20060064133A1 (en) | 2004-09-17 | 2006-03-23 | Cardiac Pacemakers, Inc. | System and method for deriving relative physiologic measurements using an external computing device |
US20060079786A1 (en) * | 2004-10-08 | 2006-04-13 | Transoma Medical, Inc. | Blood flow meter and flow probe therefor |
US7578793B2 (en) | 2004-11-22 | 2009-08-25 | Widemed Ltd. | Sleep staging based on cardio-respiratory signals |
EP1661509A1 (en) * | 2004-11-29 | 2006-05-31 | Perioperative Medicine Consultancy B.V. | Method, system and computer product for determining an oxygen related property of blood that follows a path in a living body |
EP1827571B1 (en) | 2004-12-09 | 2016-09-07 | Impulse Dynamics NV | Protein activity modification |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
US8571624B2 (en) | 2004-12-29 | 2013-10-29 | Abbott Diabetes Care Inc. | Method and apparatus for mounting a data transmission device in a communication system |
US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US9351669B2 (en) | 2009-09-30 | 2016-05-31 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US20090105569A1 (en) | 2006-04-28 | 2009-04-23 | Abbott Diabetes Care, Inc. | Introducer Assembly and Methods of Use |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US8333714B2 (en) | 2006-09-10 | 2012-12-18 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US8613703B2 (en) | 2007-05-31 | 2013-12-24 | Abbott Diabetes Care Inc. | Insertion devices and methods |
US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
US8788021B1 (en) | 2005-01-24 | 2014-07-22 | The Board Of Trustees Of The Leland Stanford Junior Univerity | Live being optical analysis system and approach |
US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
US20090076360A1 (en) | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
WO2006097934A2 (en) | 2005-03-18 | 2006-09-21 | Metacure Limited | Pancreas lead |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
US7308292B2 (en) | 2005-04-15 | 2007-12-11 | Sensors For Medicine And Science, Inc. | Optical-based sensing devices |
US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
US20060283465A1 (en) * | 2005-06-16 | 2006-12-21 | Nickel Janice H | Smart drug delivery system and a method of implementation thereof |
US20070016089A1 (en) * | 2005-07-15 | 2007-01-18 | Fischell David R | Implantable device for vital signs monitoring |
US7813778B2 (en) * | 2005-07-29 | 2010-10-12 | Spectros Corporation | Implantable tissue ischemia sensor |
CN101365374B (en) | 2005-08-31 | 2011-11-16 | 弗吉尼亚大学专利基金委员会 | Improving accuracy of continuous glucose sensors |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US8880138B2 (en) | 2005-09-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Device for channeling fluid and methods of use |
WO2007047279A1 (en) * | 2005-10-18 | 2007-04-26 | Richards Cynthia C | Dispenser having a first pump for insulin and a second pump for glucose or glucagon |
WO2007052255A2 (en) | 2005-11-02 | 2007-05-10 | Mark Fenster | A system and method for external continuous blood content measurement and injection of pharmaceuticals |
US7713232B2 (en) * | 2005-11-04 | 2010-05-11 | Medrad, Inc. | System for washing and processing of cells for delivery thereof to tissue |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
US8182444B2 (en) * | 2005-11-04 | 2012-05-22 | Medrad, Inc. | Delivery of agents such as cells to tissue |
US7699834B2 (en) | 2005-11-09 | 2010-04-20 | Searete Llc | Method and system for control of osmotic pump device |
US8083710B2 (en) | 2006-03-09 | 2011-12-27 | The Invention Science Fund I, Llc | Acoustically controlled substance delivery device |
US8998884B2 (en) | 2005-11-09 | 2015-04-07 | The Invention Science Fund I, Llc | Remote controlled in situ reaction method |
US8992511B2 (en) | 2005-11-09 | 2015-03-31 | The Invention Science Fund I, Llc | Acoustically controlled substance delivery device |
US7942867B2 (en) | 2005-11-09 | 2011-05-17 | The Invention Science Fund I, Llc | Remotely controlled substance delivery device |
US8273071B2 (en) | 2006-01-18 | 2012-09-25 | The Invention Science Fund I, Llc | Remote controller for substance delivery system |
US8936590B2 (en) | 2005-11-09 | 2015-01-20 | The Invention Science Fund I, Llc | Acoustically controlled reaction device |
US8437582B2 (en) | 2005-12-22 | 2013-05-07 | Palo Alto Research Center Incorporated | Transmitting light with lateral variation |
US7433552B2 (en) | 2005-12-22 | 2008-10-07 | Palo Alto Research Center Incorporated | Obtaining analyte information |
CA2636034A1 (en) | 2005-12-28 | 2007-10-25 | Abbott Diabetes Care Inc. | Medical device insertion |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US20070156085A1 (en) * | 2005-12-30 | 2007-07-05 | Schulhauser Randal C | Implantable perfusion sensor |
US8109879B2 (en) | 2006-01-10 | 2012-02-07 | Cardiac Pacemakers, Inc. | Assessing autonomic activity using baroreflex analysis |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
US8099146B1 (en) | 2006-03-23 | 2012-01-17 | Pacesetter, Inc. | System and method for calibrating a blood oxygen saturation sensor for use with an implantable medical device |
SG173319A1 (en) | 2006-03-30 | 2011-08-29 | Valeritas Inc | Multi-cartridge fluid delivery device |
US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US9326709B2 (en) | 2010-03-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
US7801582B2 (en) | 2006-03-31 | 2010-09-21 | Abbott Diabetes Care Inc. | Analyte monitoring and management system and methods therefor |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
WO2007120381A2 (en) | 2006-04-14 | 2007-10-25 | Dexcom, Inc. | Analyte sensor |
US7846106B2 (en) * | 2006-04-26 | 2010-12-07 | The General Electric Company | Atrial fibrillation detection using SPO2 |
US20070260174A1 (en) * | 2006-05-05 | 2007-11-08 | Searete Llc | Detecting a failure to maintain a regimen |
US7616980B2 (en) | 2006-05-08 | 2009-11-10 | Tyco Healthcare Group Lp | Radial electrode array |
US8126554B2 (en) | 2006-05-17 | 2012-02-28 | Cardiac Pacemakers, Inc. | Implantable medical device with chemical sensor and related methods |
WO2007143225A2 (en) | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
WO2008000634A1 (en) * | 2006-06-30 | 2008-01-03 | Novo Nordisk A/S | Perfusion device with compensation of medical infusion during wear-time |
US8326390B2 (en) * | 2006-07-25 | 2012-12-04 | Edward Belotserkovsky | Optical non-invasive blood monitoring system and method |
US7486976B1 (en) | 2006-07-25 | 2009-02-03 | Edward Belotserkovsky | Optical non-invasive blood monitoring system and method |
US20110054391A1 (en) * | 2006-07-28 | 2011-03-03 | Ward W Kenneth | Analyte sensing and response system |
US8114023B2 (en) * | 2006-07-28 | 2012-02-14 | Legacy Emanuel Hospital & Health Center | Analyte sensing and response system |
WO2008018025A2 (en) * | 2006-08-08 | 2008-02-14 | Koninklijke Philips Electronics N.V. | Apparatus to image blood vessel |
EP2063762A1 (en) * | 2006-09-06 | 2009-06-03 | Medingo Ltd. | Fluid delivery system with optical sensing of analyte concentration levels |
US8109883B2 (en) | 2006-09-28 | 2012-02-07 | Tyco Healthcare Group Lp | Cable monitoring apparatus |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8447376B2 (en) | 2006-10-04 | 2013-05-21 | Dexcom, Inc. | Analyte sensor |
US8275438B2 (en) | 2006-10-04 | 2012-09-25 | Dexcom, Inc. | Analyte sensor |
US8562528B2 (en) | 2006-10-04 | 2013-10-22 | Dexcom, Inc. | Analyte sensor |
US8298142B2 (en) | 2006-10-04 | 2012-10-30 | Dexcom, Inc. | Analyte sensor |
US8449464B2 (en) | 2006-10-04 | 2013-05-28 | Dexcom, Inc. | Analyte sensor |
US8478377B2 (en) | 2006-10-04 | 2013-07-02 | Dexcom, Inc. | Analyte sensor |
AU2007317669A1 (en) | 2006-10-16 | 2008-05-15 | Hospira, Inc. | System and method for comparing and utilizing activity information and configuration information from mulitple device management systems |
JP2010508091A (en) | 2006-10-26 | 2010-03-18 | アボット ダイアベティス ケア インコーポレイテッド | Method, system, and computer program product for detecting in real time a decrease in sensitivity of an analyte sensor |
US8180425B2 (en) * | 2006-12-05 | 2012-05-15 | Tyco Healthcare Group Lp | ECG lead wire organizer and dispenser |
US8238996B2 (en) | 2006-12-05 | 2012-08-07 | Tyco Healthcare Group Lp | Electrode array |
US8668651B2 (en) | 2006-12-05 | 2014-03-11 | Covidien Lp | ECG lead set and ECG adapter system |
US8092386B1 (en) * | 2006-12-22 | 2012-01-10 | Pacesetter, Inc. | Method and implantable system for blood-glucose concentration monitoring |
US20080172111A1 (en) * | 2007-01-16 | 2008-07-17 | The General Hospital Corporation | Method and apparatus for selective photothermolysis of veins |
US9164037B2 (en) | 2007-01-26 | 2015-10-20 | Palo Alto Research Center Incorporated | Method and system for evaluation of signals received from spatially modulated excitation and emission to accurately determine particle positions and distances |
US8821799B2 (en) | 2007-01-26 | 2014-09-02 | Palo Alto Research Center Incorporated | Method and system implementing spatially modulated excitation or emission for particle characterization with enhanced sensitivity |
US7936463B2 (en) * | 2007-02-05 | 2011-05-03 | Palo Alto Research Center Incorporated | Containing analyte in optical cavity structures |
US7852490B2 (en) * | 2007-02-05 | 2010-12-14 | Palo Alto Research Center Incorporated | Implanting optical cavity structures |
US7633629B2 (en) * | 2007-02-05 | 2009-12-15 | Palo Alto Research Center Incorporated | Tuning optical cavities |
US8121857B2 (en) | 2007-02-15 | 2012-02-21 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
US20080199894A1 (en) | 2007-02-15 | 2008-08-21 | Abbott Diabetes Care, Inc. | Device and method for automatic data acquisition and/or detection |
US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
US20080203307A1 (en) * | 2007-02-23 | 2008-08-28 | Determan Gary E | Encoded binary liveness detector |
US8065001B1 (en) * | 2007-03-01 | 2011-11-22 | Pacesetter, Inc. | Use of implantable body position and body movement sensors |
US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
JP5109125B2 (en) * | 2007-03-14 | 2012-12-26 | 国立大学法人浜松医科大学 | In vivo component analyzer |
CN104069567A (en) | 2007-03-19 | 2014-10-01 | 茵苏莱恩医药有限公司 | Drug delivery device |
US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
EP2129285B1 (en) | 2007-03-26 | 2014-07-23 | Dexcom, Inc. | Analyte sensor |
US8139503B2 (en) | 2007-03-30 | 2012-03-20 | Tektronix, Inc. | System and method for automatic detection of UTRAN topology |
CA2684807A1 (en) | 2007-04-05 | 2008-10-16 | Velomedix, Inc. | Automated therapy system and method |
CA2683930A1 (en) | 2007-04-14 | 2008-10-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
WO2008130898A1 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in medical communication system |
WO2008130895A2 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
ES2817503T3 (en) | 2007-04-14 | 2021-04-07 | Abbott Diabetes Care Inc | Procedure and apparatus for providing data processing and control in a medical communication system |
CA2683953C (en) | 2007-04-14 | 2016-08-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US9615780B2 (en) | 2007-04-14 | 2017-04-11 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US7806832B2 (en) * | 2007-04-30 | 2010-10-05 | The General Electric Company | False positive reduction in SPO2 atrial fibrillation detection using average heart rate and NIBP |
US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20200037875A1 (en) | 2007-05-18 | 2020-02-06 | Dexcom, Inc. | Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise |
US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
CA2688184A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
WO2008156981A2 (en) | 2007-06-14 | 2008-12-24 | Cardiac Pacemakers, Inc. | Multi-element acoustic recharging system |
JP2010531169A (en) | 2007-06-21 | 2010-09-24 | アボット ダイアベティス ケア インコーポレイテッド | Health monitoring device |
AU2008265541B2 (en) | 2007-06-21 | 2014-07-17 | Abbott Diabetes Care, Inc. | Health management devices and methods |
US8463344B2 (en) * | 2007-06-22 | 2013-06-11 | Marlon Williams | Antigen monitoring system |
US7920913B1 (en) | 2007-06-29 | 2011-04-05 | Pacesetter, Inc. | Systems and methods for increasing implantable sensor accuracy |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
EP2011495A1 (en) * | 2007-07-03 | 2009-01-07 | Sygnis Bioscience GmbH & Co. KG | Use of piperine and derivatives thereof for the therapy of neurological conditions |
US8834366B2 (en) | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
US7768386B2 (en) | 2007-07-31 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US20120046533A1 (en) | 2007-08-29 | 2012-02-23 | Medtronic Minimed, Inc. | Combined sensor and infusion sets |
US9968742B2 (en) | 2007-08-29 | 2018-05-15 | Medtronic Minimed, Inc. | Combined sensor and infusion set using separated sites |
US8147416B2 (en) * | 2007-08-31 | 2012-04-03 | Pacesetter, Inc. | Implantable systemic blood pressure measurement systems and methods |
US8162841B2 (en) * | 2007-08-31 | 2012-04-24 | Pacesetter, Inc. | Standalone systemic arterial blood pressure monitoring device |
US20090088651A1 (en) * | 2007-09-28 | 2009-04-02 | Allan Charles Shuros | Method and apparatus to perform transvascular hemodynamic sensing |
US20090088652A1 (en) * | 2007-09-28 | 2009-04-02 | Kathleen Tremblay | Physiological sensor placement and signal transmission device |
US9452258B2 (en) | 2007-10-09 | 2016-09-27 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
TWI338584B (en) * | 2007-10-16 | 2011-03-11 | Ind Tech Res Inst | Tissue mimicking phantom |
US8216138B1 (en) | 2007-10-23 | 2012-07-10 | Abbott Diabetes Care Inc. | Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
EP4250312A3 (en) | 2007-10-25 | 2023-11-01 | DexCom, Inc. | Systems and methods for processing sensor data |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
DE102007053752B4 (en) * | 2007-11-12 | 2019-04-04 | Fresenius Medical Care Deutschland Gmbh | A method for determining at least one index concerning the glucose metabolism of a patient and device therefor |
US8615281B2 (en) * | 2007-11-21 | 2013-12-24 | Medingo Ltd. | Hypodermic optical monitoring of bodily analyte |
GB2446247B (en) * | 2007-11-27 | 2008-12-17 | Robert Joseph Wagener | Homeostatic insulin pump |
CA2646037C (en) | 2007-12-11 | 2017-11-28 | Tyco Healthcare Group Lp | Ecg electrode connector |
US8320983B2 (en) | 2007-12-17 | 2012-11-27 | Palo Alto Research Center Incorporated | Controlling transfer of objects affecting optical characteristics |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
EP2231229A1 (en) | 2007-12-18 | 2010-09-29 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US9026370B2 (en) | 2007-12-18 | 2015-05-05 | Hospira, Inc. | User interface improvements for medical devices |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US8260415B2 (en) * | 2007-12-21 | 2012-09-04 | Medtronic, Inc. | Optical sensor and method for detecting a patient condition |
US8165676B2 (en) | 2007-12-21 | 2012-04-24 | Medtronic, Inc. | Optical sensor and method for detecting a patient condition |
US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8373860B2 (en) | 2008-02-01 | 2013-02-12 | Palo Alto Research Center Incorporated | Transmitting/reflecting emanating light with time variation |
US8629981B2 (en) | 2008-02-01 | 2014-01-14 | Palo Alto Research Center Incorporated | Analyzers with time variation based on color-coded spatial modulation |
CA2715628A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20090247856A1 (en) | 2008-03-28 | 2009-10-01 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US20110224656A1 (en) * | 2008-04-03 | 2011-09-15 | The General Hospital Corporation | Method and apparatus for selective photothermolysis of veins |
US8252229B2 (en) | 2008-04-10 | 2012-08-28 | Abbott Diabetes Care Inc. | Method and system for sterilizing an analyte sensor |
WO2009126900A1 (en) | 2008-04-11 | 2009-10-15 | Pelikan Technologies, Inc. | Method and apparatus for analyte detecting device |
CN102014986B (en) | 2008-04-24 | 2013-09-25 | 爱科来株式会社 | Blood sugar level control system |
JP2011519635A (en) * | 2008-05-02 | 2011-07-14 | エスアールアイ インターナショナル | Optical microneedle spectrometer |
WO2009138880A2 (en) * | 2008-05-12 | 2009-11-19 | Cardio Art Technologies, Ltd. | Optical sensor apparatus and method of using same |
CN104939806B (en) | 2008-05-20 | 2021-12-10 | 大学健康网络 | Apparatus and method for fluorescence-based imaging and monitoring |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US7826382B2 (en) | 2008-05-30 | 2010-11-02 | Abbott Diabetes Care Inc. | Close proximity communication device and methods |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US9326711B2 (en) * | 2008-06-30 | 2016-05-03 | Medtronic, Inc. | Optical perfusion sensor detector |
US8577431B2 (en) | 2008-07-03 | 2013-11-05 | Cercacor Laboratories, Inc. | Noise shielding for a noninvasive device |
US20100030040A1 (en) | 2008-08-04 | 2010-02-04 | Masimo Laboratories, Inc. | Multi-stream data collection system for noninvasive measurement of blood constituents |
US8876755B2 (en) | 2008-07-14 | 2014-11-04 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
US9603558B2 (en) | 2008-08-15 | 2017-03-28 | Theranova, Llc | Methods and devices for the diagnosis and treatment of diabetes |
US20100057040A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
US8734422B2 (en) | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US8622988B2 (en) | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
US9943644B2 (en) | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Solute concentration measurement device and related methods |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
EP2355758A2 (en) | 2008-11-07 | 2011-08-17 | Insuline Medical Ltd. | Device and method for drug delivery |
US9801575B2 (en) | 2011-04-15 | 2017-10-31 | Dexcom, Inc. | Advanced analyte sensor calibration and error detection |
US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
USD737979S1 (en) | 2008-12-09 | 2015-09-01 | Covidien Lp | ECG electrode connector |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US8630692B2 (en) | 2009-04-30 | 2014-01-14 | Pacesetter, Inc. | Method and implantable system for blood-glucose concentration monitoring using parallel methodologies |
US8497777B2 (en) | 2009-04-15 | 2013-07-30 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
EP2419015A4 (en) | 2009-04-16 | 2014-08-20 | Abbott Diabetes Care Inc | Analyte sensor calibration management |
US8271106B2 (en) | 2009-04-17 | 2012-09-18 | Hospira, Inc. | System and method for configuring a rule set for medical event management and responses |
US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
US8368556B2 (en) | 2009-04-29 | 2013-02-05 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
US8483967B2 (en) | 2009-04-29 | 2013-07-09 | Abbott Diabetes Care Inc. | Method and system for providing real time analyte sensor calibration with retrospective backfill |
US10071261B2 (en) * | 2009-05-01 | 2018-09-11 | Wayne State University | Light therapy treatment |
EP2251010A1 (en) | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
WO2010138856A1 (en) | 2009-05-29 | 2010-12-02 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
US20100312128A1 (en) * | 2009-06-09 | 2010-12-09 | Edward Karst | Systems and methods for monitoring blood partitioning and organ function |
US8613892B2 (en) | 2009-06-30 | 2013-12-24 | Abbott Diabetes Care Inc. | Analyte meter with a moveable head and methods of using the same |
US9131885B2 (en) | 2009-07-02 | 2015-09-15 | Dexcom, Inc. | Analyte sensors and methods of manufacturing same |
US8321017B2 (en) * | 2009-07-08 | 2012-11-27 | Pacesetter, Inc. | Electromechanical delay (EMD) monitoring devices, systems and methods |
EP4289355A3 (en) | 2009-07-23 | 2024-02-28 | Abbott Diabetes Care Inc. | Continuous analyte measurement system |
CA2921304C (en) | 2009-07-30 | 2018-06-05 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
WO2011014851A1 (en) | 2009-07-31 | 2011-02-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
AU2010286917B2 (en) | 2009-08-31 | 2016-03-10 | Abbott Diabetes Care Inc. | Medical devices and methods |
US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
EP2473099A4 (en) | 2009-08-31 | 2015-01-14 | Abbott Diabetes Care Inc | Analyte monitoring system and methods for managing power and noise |
EP4070728A1 (en) | 2009-08-31 | 2022-10-12 | Abbott Diabetes Care, Inc. | Displays for a medical device |
WO2011041469A1 (en) | 2009-09-29 | 2011-04-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
CN102724913A (en) | 2009-09-30 | 2012-10-10 | 德克斯康公司 | Transcutaneous analyte sensor |
US20110082356A1 (en) | 2009-10-01 | 2011-04-07 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having interference rejection membranes and methods for making and using them |
US8694080B2 (en) | 2009-10-21 | 2014-04-08 | Covidien Lp | ECG lead system |
EP2494323A4 (en) | 2009-10-30 | 2014-07-16 | Abbott Diabetes Care Inc | Method and apparatus for detecting false hypoglycemic conditions |
FR2952518B1 (en) * | 2009-11-13 | 2011-10-28 | Univ Paris 6 Pierre Et Marie Curie | DEVICE FOR MEASURING THE ACTIVITY OF THE SPINAL CORD OF A VERTEBRA |
US20110288388A1 (en) | 2009-11-20 | 2011-11-24 | Medtronic Minimed, Inc. | Multi-conductor lead configurations useful with medical device systems and methods for making and using them |
US8882701B2 (en) | 2009-12-04 | 2014-11-11 | Smiths Medical Asd, Inc. | Advanced step therapy delivery for an ambulatory infusion pump and system |
TWI402501B (en) * | 2009-12-09 | 2013-07-21 | Nat Univ Tsing Hua | Immunodetection probe and method of immunodection using the same |
US8771251B2 (en) * | 2009-12-17 | 2014-07-08 | Hospira, Inc. | Systems and methods for managing and delivering patient therapy through electronic drug delivery systems |
US8660628B2 (en) | 2009-12-21 | 2014-02-25 | Medtronic Minimed, Inc. | Analyte sensors comprising blended membrane compositions and methods for making and using them |
US8396563B2 (en) | 2010-01-29 | 2013-03-12 | Medtronic, Inc. | Clock synchronization in an implantable medical device system |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
US10448872B2 (en) | 2010-03-16 | 2019-10-22 | Medtronic Minimed, Inc. | Analyte sensor apparatuses having improved electrode configurations and methods for making and using them |
CA3096110C (en) | 2010-03-24 | 2023-11-14 | Abbott Diabetes Care Inc. | Medical device inserters and processes of inserting and using medical devices |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US8958860B2 (en) * | 2010-05-17 | 2015-02-17 | Covidien Lp | Optical sensors for intraoperative procedures |
US8636711B2 (en) | 2010-06-14 | 2014-01-28 | Legacy Emanuel Hospital & Health Center | Stabilized glucagon solutions and uses therefor |
US9215995B2 (en) | 2010-06-23 | 2015-12-22 | Medtronic Minimed, Inc. | Sensor systems having multiple probes and electrode arrays |
US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
WO2011163519A2 (en) | 2010-06-25 | 2011-12-29 | Dexcom, Inc. | Systems and methods for communicating sensor data between communication devices |
US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US9622670B2 (en) | 2010-07-09 | 2017-04-18 | Potrero Medical, Inc. | Method and apparatus for pressure measurement |
CA2746944C (en) | 2010-07-29 | 2018-09-25 | Tyco Healthcare Group Lp | Ecg adapter system and method |
EP2624745A4 (en) | 2010-10-07 | 2018-05-23 | Abbott Diabetes Care, Inc. | Analyte monitoring devices and methods |
EP2632334B1 (en) | 2010-10-27 | 2020-09-09 | Dexcom, Inc. | Continuous analyte monitor data recording device operable in a blinded mode |
EP2452624A1 (en) * | 2010-11-12 | 2012-05-16 | BIOTRONIK SE & Co. KG | Implantable theranostic article |
US8478403B2 (en) | 2011-02-23 | 2013-07-02 | Pacesetter, Inc. | Implantable systems and methods for use therewith for monitoring and modifying arterial blood pressure without requiring an intravascular pressure transducer |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
CA3177983A1 (en) | 2011-02-28 | 2012-11-15 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US9008744B2 (en) | 2011-05-06 | 2015-04-14 | Medtronic Minimed, Inc. | Method and apparatus for continuous analyte monitoring |
CA2841601C (en) | 2011-07-22 | 2017-11-28 | David Zhou | Ecg electrode connector |
US8723140B2 (en) | 2011-08-09 | 2014-05-13 | Palo Alto Research Center Incorporated | Particle analyzer with spatial modulation and long lifetime bioprobes |
US9029800B2 (en) | 2011-08-09 | 2015-05-12 | Palo Alto Research Center Incorporated | Compact analyzer with spatial modulation and multiple intensity modulated excitation sources |
AU2012299169B2 (en) | 2011-08-19 | 2017-08-24 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
US20130053666A1 (en) | 2011-08-26 | 2013-02-28 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
EP2769357B1 (en) | 2011-10-21 | 2023-08-30 | ICU Medical, Inc. | Medical device update system |
US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
WO2013066873A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
JP6443802B2 (en) | 2011-11-07 | 2018-12-26 | アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. | Analyte monitoring apparatus and method |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
WO2013078426A2 (en) | 2011-11-25 | 2013-05-30 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
FI3831283T3 (en) | 2011-12-11 | 2023-06-01 | Abbott Diabetes Care Inc | Analyte sensor devices, connections, and methods |
US10398379B2 (en) | 2011-12-15 | 2019-09-03 | Becton, Dickinson And Company | System for improved interpretation of physiological data and presentation of physiological condition management information |
WO2013090709A1 (en) | 2011-12-16 | 2013-06-20 | Hospira, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
WO2013148798A1 (en) | 2012-03-30 | 2013-10-03 | Hospira, Inc. | Air detection system and method for detecting air in a pump of an infusion system |
WO2013158271A1 (en) * | 2012-04-20 | 2013-10-24 | University Of Rochester | Implantable real-time oximeter to determine potential strokes and post-traumatic brain-injury complication |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9493807B2 (en) | 2012-05-25 | 2016-11-15 | Medtronic Minimed, Inc. | Foldover sensors and methods for making and using them |
US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
US20170135633A1 (en) * | 2013-05-23 | 2017-05-18 | Medibotics Llc | Integrated System for Managing Cardiac Rhythm Including Wearable and Implanted Devices |
US20140012115A1 (en) | 2012-07-03 | 2014-01-09 | Medtronic Minimed, Inc. | Plasma deposited adhesion promoter layers for use with analyte sensors |
CA3089257C (en) | 2012-07-31 | 2023-07-25 | Icu Medical, Inc. | Patient care system for critical medications |
EP3395252A1 (en) | 2012-08-30 | 2018-10-31 | Abbott Diabetes Care, Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
EP2901153A4 (en) | 2012-09-26 | 2016-04-27 | Abbott Diabetes Care Inc | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US9788765B2 (en) | 2012-09-28 | 2017-10-17 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US10194840B2 (en) | 2012-12-06 | 2019-02-05 | Medtronic Minimed, Inc. | Microarray electrodes useful with analyte sensors and methods for making and using them |
US10426383B2 (en) | 2013-01-22 | 2019-10-01 | Medtronic Minimed, Inc. | Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating |
JP6356152B2 (en) | 2013-01-24 | 2018-07-11 | グラフトウォークス, インコーポレイテッド | Device for measuring flow through a lumen |
AU2014225658B2 (en) | 2013-03-06 | 2018-05-31 | Icu Medical, Inc. | Medical device communication method |
US10357606B2 (en) | 2013-03-13 | 2019-07-23 | Tandem Diabetes Care, Inc. | System and method for integration of insulin pumps and continuous glucose monitoring |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
USD771818S1 (en) | 2013-03-15 | 2016-11-15 | Covidien Lp | ECG electrode connector |
CN105120742B (en) | 2013-03-15 | 2017-07-28 | 柯惠有限合伙公司 | Electrode connector with conductive component |
US9408546B2 (en) | 2013-03-15 | 2016-08-09 | Covidien Lp | Radiolucent ECG electrode system |
US10016561B2 (en) | 2013-03-15 | 2018-07-10 | Tandem Diabetes Care, Inc. | Clinical variable determination |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
US20210379388A1 (en) * | 2013-05-23 | 2021-12-09 | Medibotics Llc | Integrated System to Assist Cardiovascular Functioning with Implanted Cardiac Device and Sensor-Enabled Wearable Device |
AU2014268355B2 (en) | 2013-05-24 | 2018-06-14 | Icu Medical, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
ES2838450T3 (en) | 2013-05-29 | 2021-07-02 | Icu Medical Inc | Infusion set that uses one or more sensors and additional information to make an air determination relative to the infusion set |
AU2014274122A1 (en) | 2013-05-29 | 2016-01-21 | Icu Medical, Inc. | Infusion system and method of use which prevents over-saturation of an analog-to-digital converter |
EP3039596A4 (en) | 2013-08-30 | 2017-04-12 | Hospira, Inc. | System and method of monitoring and managing a remote infusion regimen |
US9662436B2 (en) | 2013-09-20 | 2017-05-30 | Icu Medical, Inc. | Fail-safe drug infusion therapy system |
US20150122647A1 (en) | 2013-11-07 | 2015-05-07 | Medtronic Minimed, Inc. | Enzyme matrices for use with ethylene oxide sterilization |
US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
AU2014353130B9 (en) | 2013-11-19 | 2019-09-05 | Icu Medical, Inc. | Infusion pump automation system and method |
US10379125B2 (en) * | 2013-12-27 | 2019-08-13 | Becton, Dickinson And Company | System and method for dynamically calibrating and measuring analyte concentration in diabetes management monitors |
WO2015102745A1 (en) | 2013-12-31 | 2015-07-09 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
US10342917B2 (en) | 2014-02-28 | 2019-07-09 | Icu Medical, Inc. | Infusion system and method which utilizes dual wavelength optical air-in-line detection |
US20170185748A1 (en) | 2014-03-30 | 2017-06-29 | Abbott Diabetes Care Inc. | Method and Apparatus for Determining Meal Start and Peak Events in Analyte Monitoring Systems |
CA2945647C (en) | 2014-04-30 | 2023-08-08 | Hospira, Inc. | Patient care system with conditional alarm forwarding |
JP2017517302A (en) | 2014-05-29 | 2017-06-29 | ホスピーラ インコーポレイテッド | Infusion system and pump with configurable closed loop delivery rate catchup |
US9724470B2 (en) | 2014-06-16 | 2017-08-08 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US9381292B2 (en) * | 2014-07-24 | 2016-07-05 | Kamal Ahmed ALJOHANI | Diabetes regulator |
WO2016014987A2 (en) | 2014-07-24 | 2016-01-28 | Thomas Jefferson University | Long-term implantable monitoring system & methods of use |
US10438356B2 (en) | 2014-07-24 | 2019-10-08 | University Health Network | Collection and analysis of data for diagnostic purposes |
WO2016019133A1 (en) | 2014-07-30 | 2016-02-04 | Tandem Diabetes Care, Inc. | Temporary suspension for closed-loop medicament therapy |
US9724026B2 (en) * | 2014-08-29 | 2017-08-08 | Verily Life Sciences Llc | Passive detection of pulse |
US9539383B2 (en) | 2014-09-15 | 2017-01-10 | Hospira, Inc. | System and method that matches delayed infusion auto-programs with manually entered infusion programs and analyzes differences therein |
US11344668B2 (en) | 2014-12-19 | 2022-05-31 | Icu Medical, Inc. | Infusion system with concurrent TPN/insulin infusion |
US9759651B2 (en) * | 2014-12-23 | 2017-09-12 | Magellan Diagnostics, Inc. | Combination optical hemoglobin and electrochemical lead assay |
WO2016109163A1 (en) | 2014-12-31 | 2016-07-07 | Theranova, Llc | Methods and devices for analyte sensing in potential spaces |
US10850024B2 (en) | 2015-03-02 | 2020-12-01 | Icu Medical, Inc. | Infusion system, device, and method having advanced infusion features |
US9924905B2 (en) | 2015-03-09 | 2018-03-27 | Graftworx, Inc. | Sensor position on a prosthesis for detection of a stenosis |
US9629560B2 (en) | 2015-04-06 | 2017-04-25 | Thomas Jefferson University | Implantable vital sign sensor |
US10335043B2 (en) | 2015-04-06 | 2019-07-02 | Thomas Jefferson University | Implantable vital sign sensor |
US11330987B2 (en) | 2015-04-06 | 2022-05-17 | Thomas Jefferson University | Implantable vital sign sensor |
US11000195B2 (en) | 2015-04-06 | 2021-05-11 | Thomas Jefferson University | Implantable vital sign sensor |
US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
AU2016260547B2 (en) | 2015-05-14 | 2020-09-03 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
CA2988094A1 (en) | 2015-05-26 | 2016-12-01 | Icu Medical, Inc. | Infusion pump system and method with multiple drug library editor source capability |
US10716500B2 (en) | 2015-06-29 | 2020-07-21 | Cardiac Pacemakers, Inc. | Systems and methods for normalization of chemical sensor data based on fluid state changes |
AU2016291569B2 (en) | 2015-07-10 | 2021-07-08 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
CA3206809A1 (en) | 2015-12-30 | 2017-07-06 | Dexcom, Inc. | Biointerface layer for analyte sensors |
CA3010914A1 (en) * | 2016-01-20 | 2017-07-27 | LifeBridge Health, Inc. | Apparatus for detecting cells in circulating bloodstream |
US10324058B2 (en) | 2016-04-28 | 2019-06-18 | Medtronic Minimed, Inc. | In-situ chemistry stack for continuous glucose sensors |
CA3023658C (en) | 2016-05-13 | 2023-03-07 | Icu Medical, Inc. | Infusion pump system and method with common line auto flush |
US11179078B2 (en) | 2016-06-06 | 2021-11-23 | Medtronic Minimed, Inc. | Polycarbonate urea/urethane polymers for use with analyte sensors |
AU2017277804B2 (en) | 2016-06-10 | 2022-05-26 | Icu Medical, Inc. | Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion |
CA3028089A1 (en) | 2016-06-17 | 2017-12-21 | Predictive Safety Srp, Inc. | Area access control system and method |
NZ750032A (en) | 2016-07-14 | 2020-05-29 | Icu Medical Inc | Multi-communication path selection and security system for a medical device |
US11406274B2 (en) | 2016-09-12 | 2022-08-09 | Alio, Inc. | Wearable device with multimodal diagnostics |
US11071478B2 (en) | 2017-01-23 | 2021-07-27 | Abbott Diabetes Care Inc. | Systems, devices and methods for analyte sensor insertion |
US11134868B2 (en) | 2017-03-17 | 2021-10-05 | Medtronic Minimed, Inc. | Metal pillar device structures and methods for making and using them in electrochemical and/or electrocatalytic applications |
WO2018175489A1 (en) | 2017-03-21 | 2018-09-27 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
EP3600493A4 (en) | 2017-03-31 | 2020-08-19 | Capillary Biomedical, Inc. | Helical insertion infusion device |
CN108968976B (en) | 2017-05-31 | 2022-09-13 | 心脏起搏器股份公司 | Implantable medical device with chemical sensor |
US10856784B2 (en) | 2017-06-30 | 2020-12-08 | Medtronic Minimed, Inc. | Sensor initialization methods for faster body sensor response |
CN109381195B (en) | 2017-08-10 | 2023-01-10 | 心脏起搏器股份公司 | Systems and methods including electrolyte sensor fusion |
CN109419515B (en) | 2017-08-23 | 2023-03-24 | 心脏起搏器股份公司 | Implantable chemical sensor with staged activation |
US20190120785A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
JP2021503985A (en) * | 2017-11-21 | 2021-02-15 | サノフイSanofi | Implantable glucose monitor |
CN109864746B (en) | 2017-12-01 | 2023-09-29 | 心脏起搏器股份公司 | Multimode analyte sensor for medical devices |
CN109864747B (en) | 2017-12-05 | 2023-08-25 | 心脏起搏器股份公司 | Multimode analyte sensor optoelectronic interface |
US10089055B1 (en) | 2017-12-27 | 2018-10-02 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
US20190223771A1 (en) | 2018-01-23 | 2019-07-25 | Medtronic Minimed, Inc. | Implantable polymer surfaces exhibiting reduced in vivo inflammatory responses |
US11186859B2 (en) | 2018-02-07 | 2021-11-30 | Medtronic Minimed, Inc. | Multilayer electrochemical analyte sensors and methods for making and using them |
US11220735B2 (en) | 2018-02-08 | 2022-01-11 | Medtronic Minimed, Inc. | Methods for controlling physical vapor deposition metal film adhesion to substrates and surfaces |
US11583213B2 (en) | 2018-02-08 | 2023-02-21 | Medtronic Minimed, Inc. | Glucose sensor electrode design |
EP3776801A4 (en) | 2018-04-10 | 2021-12-22 | Tandem Diabetes Care, Inc. | System and method for inductively charging a medical device |
CA3100384A1 (en) | 2018-05-16 | 2019-11-21 | Medtronic Minimed, Inc. | Thermally stable glucose limiting membrane for glucose sensors |
EP3588026A1 (en) | 2018-06-29 | 2020-01-01 | Spiden AG | Optical system for the spectral component analysis of non-solid media |
CA3106516C (en) | 2018-07-17 | 2023-07-25 | Icu Medical, Inc. | Updating infusion pump drug libraries and operational software in a networked environment |
US11152109B2 (en) | 2018-07-17 | 2021-10-19 | Icu Medical, Inc. | Detecting missing messages from clinical environment |
NZ772135A (en) | 2018-07-17 | 2022-11-25 | Icu Medical Inc | Systems and methods for facilitating clinical messaging in a network environment |
US10861592B2 (en) | 2018-07-17 | 2020-12-08 | Icu Medical, Inc. | Reducing infusion pump network congestion by staggering updates |
US10692595B2 (en) | 2018-07-26 | 2020-06-23 | Icu Medical, Inc. | Drug library dynamic version management |
CA3107315C (en) | 2018-07-26 | 2023-01-03 | Icu Medical, Inc. | Drug library management system |
US11464908B2 (en) | 2019-02-18 | 2022-10-11 | Tandem Diabetes Care, Inc. | Methods and apparatus for monitoring infusion sites for ambulatory infusion pumps |
USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
EP3998936A4 (en) | 2019-07-17 | 2022-08-31 | Nxgenport, L.L.C. | Implantable venous access port with remote physiological monitoring capabilities |
US11718865B2 (en) | 2019-07-26 | 2023-08-08 | Medtronic Minimed, Inc. | Methods to improve oxygen delivery to implantable sensors |
US11523757B2 (en) | 2019-08-01 | 2022-12-13 | Medtronic Minimed, Inc. | Micro-pillar working electrodes design to reduce backflow of hydrogen peroxide in glucose sensor |
US11278671B2 (en) | 2019-12-04 | 2022-03-22 | Icu Medical, Inc. | Infusion pump with safety sequence keypad |
WO2022020184A1 (en) | 2020-07-21 | 2022-01-27 | Icu Medical, Inc. | Fluid transfer devices and methods of use |
US20220031205A1 (en) | 2020-07-31 | 2022-02-03 | Medtronic Minimed, Inc. | Sensor identification and integrity check design |
US20220133190A1 (en) | 2020-10-29 | 2022-05-05 | Medtronic Minimed, Inc. | Glucose biosensors comprising direct electron transfer enzymes and methods of making and using them |
US11135360B1 (en) | 2020-12-07 | 2021-10-05 | Icu Medical, Inc. | Concurrent infusion with common line auto flush |
USD999913S1 (en) | 2020-12-21 | 2023-09-26 | Abbott Diabetes Care Inc | Analyte sensor inserter |
US20220240823A1 (en) | 2021-01-29 | 2022-08-04 | Medtronic Minimed, Inc. | Interference rejection membranes useful with analyte sensors |
US20220338768A1 (en) | 2021-04-09 | 2022-10-27 | Medtronic Minimed, Inc. | Hexamethyldisiloxane membranes for analyte sensors |
US20230053254A1 (en) | 2021-08-13 | 2023-02-16 | Medtronic Minimed, Inc. | Dry electrochemical impedance spectroscopy metrology for conductive chemical layers |
US20230113175A1 (en) | 2021-10-08 | 2023-04-13 | Medtronic Minimed, Inc. | Immunosuppressant releasing coatings |
US20230123613A1 (en) | 2021-10-14 | 2023-04-20 | Medtronic Minimed, Inc. | Sensors for 3-hydroxybutyrate detection |
US20230172497A1 (en) | 2021-12-02 | 2023-06-08 | Medtronic Minimed, Inc. | Ketone limiting membrane and dual layer membrane approach for ketone sensing |
US20240023849A1 (en) | 2022-07-20 | 2024-01-25 | Medtronic Minimed, Inc. | Acrylate hydrogel membrane for dual function of diffusion limiting membrane as well as attenuation to the foreign body response |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3837339A (en) * | 1972-02-03 | 1974-09-24 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US4013074A (en) * | 1974-06-21 | 1977-03-22 | Siposs George G | Implantable medication-dispensing device |
US4073292A (en) * | 1976-10-29 | 1978-02-14 | William Edelman | Control apparatus for the automatic treatment of diabetes |
US4398908A (en) * | 1980-11-28 | 1983-08-16 | Siposs George G | Insulin delivery system |
US4435173A (en) * | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
US4621643A (en) * | 1982-09-02 | 1986-11-11 | Nellcor Incorporated | Calibrated optical oximeter probe |
US4679562A (en) * | 1983-02-16 | 1987-07-14 | Cardiac Pacemakers, Inc. | Glucose sensor |
IT1170375B (en) * | 1983-04-19 | 1987-06-03 | Giuseppe Bombardieri | Implantable device for measuring body fluid parameters |
US4538616A (en) * | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
US4704029A (en) * | 1985-12-26 | 1987-11-03 | Research Corporation | Blood glucose monitor |
DE3767042D1 (en) * | 1986-06-16 | 1991-02-07 | Siemens Ag | MEASURING DEVICE FOR INTRA-CARDIAL DETECTION OF BLOOD OXYGEN SATURATION. |
US4807629A (en) * | 1986-08-15 | 1989-02-28 | Medtronic, Inc. | Oxygen sensing pacemaker |
US4865038A (en) * | 1986-10-09 | 1989-09-12 | Novametrix Medical Systems, Inc. | Sensor appliance for non-invasive monitoring |
US4825879A (en) * | 1987-10-08 | 1989-05-02 | Critkon, Inc. | Pulse oximeter sensor |
US4890621A (en) * | 1988-01-19 | 1990-01-02 | Northstar Research Institute, Ltd. | Continuous glucose monitoring and a system utilized therefor |
US4822336A (en) * | 1988-03-04 | 1989-04-18 | Ditraglia John | Blood glucose level sensing |
CA1327838C (en) * | 1988-06-13 | 1994-03-15 | Fred Zacouto | Implantable device to prevent blood clotting disorders |
JPH02164341A (en) * | 1988-12-19 | 1990-06-25 | Nippon Koden Corp | Hemoglobin concentration measuring device |
US5204532A (en) * | 1989-01-19 | 1993-04-20 | Futrex, Inc. | Method for providing general calibration for near infrared instruments for measurement of blood glucose |
US4979509A (en) * | 1989-07-19 | 1990-12-25 | Northstar Research Institute, Ltd. | Continuous glucose monitoring and a system utilized therefor |
US5101814A (en) * | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5190041A (en) * | 1989-08-11 | 1993-03-02 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5054487A (en) * | 1990-02-02 | 1991-10-08 | Boston Advanced Technologies, Inc. | Laser systems for material analysis based on reflectance ratio detection |
US5115133A (en) * | 1990-04-19 | 1992-05-19 | Inomet, Inc. | Testing of body fluid constituents through measuring light reflected from tympanic membrane |
JPH0415046A (en) * | 1990-05-10 | 1992-01-20 | Kowa Co | Measuring method for blood circulating movement |
US5361759A (en) * | 1990-07-04 | 1994-11-08 | Charing Cross & Westminster Medical School | Meconium monitoring system |
SE9100008D0 (en) * | 1990-12-28 | 1990-12-28 | Aake Oeberg | SET AND SENSOR TO DETECT SPECIFIC PARAMETERS OF CIRCULATING BLOOD INSIDE A LIVE ORGANISM |
AT397458B (en) * | 1992-09-25 | 1994-04-25 | Avl Verbrennungskraft Messtech | SENSOR ARRANGEMENT |
JP3313841B2 (en) * | 1993-09-24 | 2002-08-12 | 興和株式会社 | Blood flow measurement device |
US5474552A (en) * | 1994-06-27 | 1995-12-12 | Cb-Carmel Biotechnology Ltd. | Implantable drug delivery pump |
US5713939A (en) * | 1996-09-16 | 1998-02-03 | Sulzer Intermedics Inc. | Data communication system for control of transcutaneous energy transmission to an implantable medical device |
-
1995
- 1995-07-06 US US08/500,388 patent/US5995860A/en not_active Expired - Lifetime
-
1996
- 1996-07-08 US US08/981,860 patent/US6122536A/en not_active Expired - Lifetime
- 1996-07-08 CA CA002226012A patent/CA2226012A1/en not_active Abandoned
- 1996-07-08 JP JP9505323A patent/JPH11508792A/en active Pending
- 1996-07-08 AU AU64556/96A patent/AU6455696A/en not_active Abandoned
- 1996-07-08 IL IL12274796A patent/IL122747A/en not_active IP Right Cessation
- 1996-07-08 WO PCT/US1996/011435 patent/WO1997001986A1/en not_active Application Discontinuation
- 1996-07-08 EP EP96923706A patent/EP0840567A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0840567A1 (en) | 1998-05-13 |
JPH11508792A (en) | 1999-08-03 |
WO1997001986A1 (en) | 1997-01-23 |
IL122747A0 (en) | 1998-08-16 |
EP0840567A4 (en) | 1998-09-30 |
US6122536A (en) | 2000-09-19 |
IL122747A (en) | 2000-12-06 |
AU6455696A (en) | 1997-02-05 |
US5995860A (en) | 1999-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6122536A (en) | Implantable sensor and system for measurement and control of blood constituent levels | |
US11759131B2 (en) | Marker monitoring via a medical device | |
US11666703B2 (en) | System and method for health monitoring by an ear piece | |
US9980676B2 (en) | System and method for health monitoring using a non-invasive, multi-band biosensor | |
EP0923335B1 (en) | Implantable sensor and system for in vivo measurement and control of fluid constituent levels | |
US20080051764A1 (en) | Physiological Monitoring With Continuous Treatment | |
CN108024727B (en) | Biosensor and method for measuring the same | |
US20220176088A1 (en) | Systems and methods for monitoring health conditions | |
US20120316411A1 (en) | Remote oximetry monitoring system and method | |
WO2005007223A2 (en) | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations | |
EP2063762A1 (en) | Fluid delivery system with optical sensing of analyte concentration levels | |
WO1997015227A1 (en) | Continuous monitoring of diabetes-related blood constituents | |
EP1993637A2 (en) | Systems and methods for sensing analyte and dispensing therapeutic fluid | |
WO2011075711A1 (en) | System and method for maintaining glycemic control based on glucose activity measurements | |
WO2017054006A1 (en) | System and method for a drug delivery and biosensor patch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |